trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12613000198729	CARPETS	Phase 1	NOT_RECRUITING	SA	19/02/2013	1/10/2015	Autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells; Dabrafenib; Dabrafenib + GD2-iCAR-PBT + Trametinib; GD2-iCAR-PBT; Trametinib	autologous_CAR-T-cell_therapy,GD2-targeting; MEK_inhibitor; BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting	Dabrafenib + GD2-iCAR-PBT + Trametinib; Autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells; Dabrafenib + GD2-iCAR-PBT + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting; BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting	Nil known	A phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumours	Refractory solid tumours; Metastatic melanoma	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000198729
ACTRN12613000297729	ENG2	Phase 1 / Phase 2	Stopped early	VIC, NSW	18/03/2013	8/02/2013	Doxorubicin; Doxorubicin + Panitumumab; Ifosfamide; Panitumumab	alkylating_agent; doxorubicin; anti-EGFR_monoclonal_antibody; anthracycline; anthracycline + anti-EGFR_monoclonal_antibody	Doxorubicin + Panitumumab; Doxorubicin + Panitumumab; Ifosfamide	anthracycline + anti-EGFR_monoclonal_antibody; alkylating_agent; anthracycline + anti-EGFR_monoclonal_antibody; doxorubicin	ENG2	A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)	Recurrent Glioblastoma Multiforme		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000297729
ACTRN12613000556741	ACTRN12613000556741		Stopped early	NSW, ACT, QLD, TAS, VIC, NT, WA, SA	17/05/2013	9/09/2013	Napabucasin; Placebo	placebo; cancer_stemness_inhibitor	Napabucasin; Placebo	cancer_stemness_inhibitor; placebo	None	A randomised phase III double-blind study to evaluate the effect of BBI608 or placebo on overall survival in patients with pretreated advanced colorectal carcinoma	Advanced (metastatic or locally advanced) colorectal cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000556741
ACTRN12613000866707	ACTRN12613000866707	Phase 1 / Phase 2	Stopped early	QLD	6/08/2013	16/09/2015					Nil	Phase I/II open-label clinical trial of autologous Epstein-Barr virus-specific T cell therapy as consolidative treatment following chemotherapy for metastatic EBV-associated nasopharyngeal carcinoma.	Metastatic nasopharyngeal carcinoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000866707
ACTRN12613001061729	PMCC-12-79	Phase 1	STATUS_UNKNOWN	VIC	23/09/2013	22/07/2013	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Peter MacCallum Cancer Centre Protocol No. PMCC 12/79	A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies	Any advanced Haematologic Malignancy	3002 - East Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613001061729
ACTRN12614000365662	ACTRN12614000365662	Phase 1	Recruiting	NZ	7/04/2014	28/04/2014	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Paclitaxel; Oraxol + Paclitaxel	taxane	Nil	Patients with cancer for whom IV paclitaxel (at a dose of 80 mg/m2 IV over 1 hour) is indicated will be treated with intravenous paclitaxel and Oraxol (Paclitaxel + HM30181AK-US) to evaluate bioavailability, safety and tolerability of Oraxol.	Cancer	Dunedin	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000365662
ACTRN12614000612617	LL1	Phase 1 / Phase 2	Stopped early	SA	6/06/2014		Monepantel	anthelmintics	Monepantel	anthelmintics	LL1	A Phase I/II Study of the Tolerability, Safety and Pharmacokinetics of Oral Monepantel (MPL) in Individuals with Treatment-Refractory Solid Tumours.	Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000612617
ACTRN12614000789662	ACTRN12614000789662	Phase 2	Not yet recruiting	NSW	24/07/2014		Luminespib	HSP90_inhibitor	Luminespib	HSP90_inhibitor	Nil	A Randomised controlled Phase II trial of the pharmacodynamic effects of the heat shock protein 90 (Hsp90) inhibitor AUY922 in high-risk, localised prostate cancer	Prostate Cancer	2050 - Missenden Road	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000789662
ACTRN12614001181695	BOSTON-II	Phase 1	Recruiting	VIC	11/11/2014	2/11/2015	Pembrolizumab; Radiotherapy	radiotherapy; anti-PD-1_monoclonal_antibody	Pembrolizumab; Radiotherapy	anti-PD-1_monoclonal_antibody; radiotherapy	Nil	A pilot study to assess the safety and feasibility of stereotactic ablative body radiosurgery combined with MK-3475 in patients with oligometastases from breast cancer.	Metastatic Breast Cancer (1-5 metastases)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001181695
ACTRN12614001248651	MesomiR-1	Phase 1	Recruiting	NSW	28/11/2014	29/09/2014	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid; miR-16_miRNA_mimic; glucocorticoid + miR-16_miRNA_mimic	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs; Dexamethasone + TargomiRs	glucocorticoid; glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic; glucocorticoid + miR-16_miRNA_mimic	Nil	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Malignant Pleural Mesothelioma; Advanced Non Small Cell Lung Cancer	2139 - Concord Repatriation Hospital; 2050 - Camperdown; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001248651
ACTRN12614001292662	CLRX301-101	Phase 1 / Phase 2	Stopped early	NSW, VIC	11/12/2014	16/12/2014	CRLX301	docetaxel-loaded_nanopharmaceutical	CRLX301	docetaxel-loaded_nanopharmaceutical	CLRX301-101	Phase 1/2a Dose-Escalation Study of CRLX301 in Patients with Advanced Solid Tumor Malignancies	Solid Tumours; Taxane-naive castration resistant prostate cancer (CRPC)	2109 - Macquarie University; 2170 - Liverpool; 3165 - Bentleigh East	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001292662
ACTRN12615000504516	NAP-CAPABIL	Phase 2	NOT_RECRUITING	NSW	20/05/2015		Capecitabine; Capecitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine + Nab-paclitaxel; Capecitabine + Nab-paclitaxel	fluoropyrimidine + taxane; fluoropyrimidine + taxane	Nil	Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility	advanced biliary cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000504516
ACTRN12615000516583	ACTIVATE-trial	Phase 1	Stopped early	NSW	22/05/2015	3/09/2015	RGSH4K	autologous_anticancer_vaccine	RGSH4K	autologous_anticancer_vaccine	Nil	In patients with advanced solid tumours, is an autologous cancer vaccine (RGSH4K), safe and tolerable, and can a biologically active dose be identified?	Advanced solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000516583
ACTRN12615000571572	ACTRN12615000571572	Phase 1 / Phase 2	Stopped early	QLD	3/06/2015	23/03/2015	Atorvastatin; Atorvastatin + Metformin; Metformin; Placebo	biguanide_antihyperglycaemic_agent; HMG-CoA_reductase_inhibitor; placebo; HMG-CoA_reductase_inhibitor + biguanide_antihyperglycaemic_agent	Atorvastatin; Atorvastatin + Metformin; Metformin; Atorvastatin + Metformin; Placebo	HMG-CoA_reductase_inhibitor; HMG-CoA_reductase_inhibitor + biguanide_antihyperglycaemic_agent; biguanide_antihyperglycaemic_agent; HMG-CoA_reductase_inhibitor + biguanide_antihyperglycaemic_agent; placebo	Nil Known	The effectiveness of a combination of Metformin and Atrovastatin compared with each drug alone and placebo in modulating tumour aggressiveness in men with high risk prostate cancer undergoing radical prostatectomy	Prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000571572
ACTRN12615001072505	ACED	Phase 2	Stopped early	WA, SA, NSW, TAS, VIC, QLD	13/10/2015	19/07/2016	Acetazolamide; Dexamethasone; Placebo	glucocorticoid; placebo; carbonic_anhydrase_inhibitor	Acetazolamide; Dexamethasone; Placebo	carbonic_anhydrase_inhibitor; glucocorticoid; placebo	Nil known	A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone – The ACED trial	Cerebral Oedema in recurrent, progressive and/or persistent High Grade Glioma	2170 - Liverpool; 2050 - Camperdown; 2217 - Kogarah; 5042 - Bedford Park; 3121 - Richmond; 6009 - Nedlands; 2010 - Darlinghurst; 2031 - Randwick; 4029 - Herston; 7000 - Hobart; 3065 - Fitzroy	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001072505
ACTRN12615001088538	TIDAL-Melanoma	Phase 2	Recruiting	QLD	16/10/2015	6/01/2017	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod	topical_immune_response_modifier	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod; Diphencyprone + Imiquimod	topical_immune_response_modifier	Nil known	The effect of topical imiquimod or diphenylcyclopropenone on complete clinical response in patients with cutaneous in-transit melanoma metastases - A Phase II Single Centre Prospective Randomised Pilot Study.	Cutaneous in-transit melanoma metastases	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001088538
ACTRN12615001291572	FRAME	Phase 2	Stopped early	WA	26/11/2015	7/04/2016	AZD4547	FGFR1/2/3_inhibitor	AZD4547	FGFR1/2/3_inhibitor	None	A two stage, open-label, phase II trial assessing the efficacy of a single oral agent AZD4547 in malignant mesothelioma.	Malignant Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001291572
ACTRN12615001328561	DESNET2	Phase 2	Not yet recruiting		4/12/2015		Octreotide; Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Octreotide + Pasireotide; Pasireotide; Octreotide + Pasireotide	somatostatin_analog	Novartis Protocol Number: CSOM230FAU04T	Phase II study evaluating the efficacy of Pasireotide LAR (SOM230) dose escalation in patients with refractory non-functional GEP NETs	Gastro-entero-pancreatic neuroendocrine tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001328561
ACTRN12616000008426	ACTRN12616000008426		Recruiting	NSW	12/01/2016	3/06/2015	RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	None	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.	Advanced or Metastatic Solid Tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000008426
ACTRN12616000228482	ACT001-AU-001	Phase 1	Recruiting	SA, VIC, NSW	19/02/2016	19/09/2016	ACT001	NFKB_inhibitor	ACT001	NFKB_inhibitor	ACT001-AU-001 (Sponsor protocol code)	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors	Solid tumors	3121 - Richmond; 3004 - Melbourne; 2031 - Randwick; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000228482
ACTRN12616000420448	INTEGRATE-IIa	Phase 3	Recruiting	SA, NZ, NT, WA, QLD, TAS, VIC, ACT, NSW	1/04/2016	10/11/2016	Placebo; Regorafenib	placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG  CTC0140	A Randomised Phase III Double-Blind Placebo-Controlled Study to determine if regorafenib improves overall survival in refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Advanced (metastatic or locally recurrent) Gastro-Oesophageal Cancer (AGOC)	4814 - Douglas; 2250 - Gosford; 6008 - Subiaco; 3168 - Clayton; 2444 - Port Macquarie; 2305 - New Lambton Heights; 2139 - Concord; 2217 - Kogarah; 3690 - Wodonga; 4575 - Birtinya; 3165 - East Bentleigh; 5042 - Bedford Park; 2145 - Westmead; 5011 - Woodville; 2065 - St Leonards; 2450 - Coffs Harbour; 6009 - Nedlands; 3355 - Wendouree; 3084 - Heidelberg; 2485 - Tweed Heads; 2010 - Darlinghurst; 2031 - Randwick; 4029 - Herston; 5037 - Kurralta Park; 2605 - Garran; 7000 - Hobart; 0810 - Tiwi	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000420448
ACTRN12616000440426	PRIME001	Phase 1 / Phase 2	NOT_RECRUITING; STATUS_UNKNOWN	NSW	6/04/2016	21/02/2017	Carboplatin; Carboplatin + Decitabine; Decitabine	platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	Carboplatin + Decitabine; Carboplatin + Decitabine	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	None	Pilot Early phase II study of Decitabine and Carboplatin in patients with advanced melanoma	Metastatic melanoma	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000440426
ACTRN12616000958482	NABNEC	Phase 2	Recruiting	NSW, VIC, TAS, QLD, WA, NZ, SA	21/07/2016	17/11/2016	Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane	Carboplatin + Nab-paclitaxel; Carboplatin + Nab-paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	AG0215NET	A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.	Gastrointestinal Neuroendocrine Carcinomas		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000958482
ACTRN12616001019493	MoST-addendum-2	Phase 2	NOT_RECRUITING	NSW, WA	2/08/2016	16/12/2016	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	CTC0141 Addendum 2	Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers.	Cancer	6009 - Nedlands; 2010 - Darlinghurst; 2050 - Camperdown; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001019493
ACTRN12616001187437	MatchMel	Phase 2	Not yet recruiting	NSW	29/08/2016		Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	mTORC1_inhibitor; EGFR_inhibitor,first_generation; SRC_inhibitor; ERBB2_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; VEGFR_inhibitor; PARP_inhibitor; BCR-ABL1_inhibitor,second_generation; YES1_inhibitor; RET_inhibitor; KIT_inhibitor,ATP-competitive; CRAF_inhibitor; ALK/ROS1/IGF1R_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CDK4/6_inhibitor; proteasome_inhibitor; AXL_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation; EGFR_inhibitor,type_II; FLT3_inhibitor; anti-VEGFR2_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor; KIT_inhibitor,first_generation; VEGFR2_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1; PDGFR_inhibitor; ROS1_inhibitor; KIT_inhibitor; HDAC_inhibitor	Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	ALK/ROS1/IGF1R_inhibitor; ALK_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation; FLT3_inhibitor; HDAC_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT_inhibitor; KIT_inhibitor,ATP-competitive; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_2; PARP_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; mTORC1_inhibitor; proteasome_inhibitor	Protocol Number MIA2015/174	Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing.	Metastatic Melanoma	2065 - Wollstonecraft; 2145 - Westmead; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001187437
ACTRN12616001637437	ACTRN12616001637437	Phase 1	NOT_RECRUITING	ACT	25/11/2016	7/10/2016	Complete Freund’s Adjuvant; Pembrolizumab	anti-PD-1_monoclonal_antibody; immunopotentiator	Pembrolizumab; Complete Freund’s Adjuvant	anti-PD-1_monoclonal_antibody; immunopotentiator	Nil known	Phase I Study of the safety of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours	Solid Tumours	2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001637437
ACTRN12617000741381	Protocol-CA209-993ISR	Phase 1	Recruiting	VIC, NSW, SA	22/05/2017	31/08/2017	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	Protocol CA209-993ISR	Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.	Cancer; Renal Transplant	5000 - Adelaide; 3168 - Clayton; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000741381
ACTRN12617000855325	EMBRACE-study	Phase 2	NOT_RECRUITING	WA, SA, NSW, QLD, VIC	9/06/2017	12/09/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	CTC0160	Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study	Triple negative breast cancer; High grade serous ovarian cancer	3355 - Wendouree; 5000 - Adelaide; 2065 - St Leonards; 2450 - Coffs Harbour; 4029 - Herston; 4066 - Auchenflower; 2640 - Albury; 3000 - Melbourne; 4217 - Benowa; 6150 - Murdoch; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000855325
ACTRN12617001000392	MoST-Addendum-3	Phase 2	NOT_RECRUITING	SA, NSW	11/07/2017	21/11/2017	Durvalumab; Durvalumab + Olaparib; Olaparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Durvalumab; Durvalumab + Olaparib; Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	Nil	Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects	Cancer	2050 - Camperdown; 2217 - Kogarah; 5000 - Adelaide; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001000392
ACTRN12617001181392	SP51616	Phase 1	Stopped early	NSW	11/08/2017	9/10/2017	A-337; A-337 + Dexamethasone; Dexamethasone	glucocorticoid; bispecific_T-cell_engager,EpCAM-targeting; bispecific_T-cell_engager,EpCAM-targeting + glucocorticoid	A-337; A-337 + Dexamethasone; Dexamethasone; A-337 + Dexamethasone	bispecific_T-cell_engager,EpCAM-targeting; bispecific_T-cell_engager,EpCAM-targeting + glucocorticoid; glucocorticoid; bispecific_T-cell_engager,EpCAM-targeting + glucocorticoid	SP51616	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid Tumors	Cancer	2170 - Liverpool; 2031 - Randwick; 2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001181392
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	15/08/2017		Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	Trifluridine; thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor; antimetabolite	Irinotecan + Panitumumab; Trifluridine/Tipiracil; Irinotecan + Panitumumab	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5011 - Woodville; 5042 - Bedford Park; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12617001325392	DIAmOND	Phase 2	Recruiting	WA, SA, NSW, VIC, TAS, QLD	15/09/2017	22/11/2018	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	BCT 1703	BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy.	Advanced HER2-positive breast cancer	7000 - Hobart; 3084 - Heidelberg; 4101 - South Brisbane; 3000 - Melbourne; 2145 - Westmead; 6150 - Murdoch; 3550 - Bendigo; 5042 - Bedford Park; 4575 - Birtinya; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001325392
ACTRN12617001573347	ZU545102--CA209-9KJ	Phase 1	NOT_RECRUITING	QLD, VIC, NSW, SA	22/11/2017	24/10/2017	Nivolumab; Nivolumab + Pixatimod; Pixatimod	anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor; angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody	Nivolumab + Pixatimod; Nivolumab + Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody	ZU545102  CA209-9KJ	An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer	Colorectal cancer; Pancreatic Cancer; Advanced solid tumours	3004 - Prahran; 2065 - St Leonards; 5000 - Adelaide; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001573347
ACTRN12618000053224	PRIME002	Phase 2	NOT_RECRUITING	NSW, QLD	16/01/2018	22/03/2018	Avelumab; Azacitidine; Azacitidine + Carboplatin; Carboplatin	anti-PD-L1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	Avelumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Nil known	PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.	Metastatic melanoma; Immunotherapy resistant	4870 - Cairns; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000053224
ACTRN12618000233224	MONARCC	Phase 2	NOT_RECRUITING	QLD, TAS, VIC, NSW, SA, WA	14/02/2018	16/07/2018	Fluorouracil; Panitumumab	anti-EGFR_monoclonal_antibody; fluoropyrimidine	Panitumumab; Fluorouracil	anti-EGFR_monoclonal_antibody; fluoropyrimidine	AG0116CR / CTC 0151	MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.	metastatic colorectal cancer	2747 - Kingswood; 5011 - Woodville; 5042 - Bedford Park; 4575 - Birtinya; 3690 - Wodonga; 3168 - Clayton; 4215 - Southport; 4102 - Woolloongabba; 4032 - Chermside; 7000 - Hobart; 4029 - Herston; 3084 - Heidelberg; 2485 - Tweed Heads; 2010 - Darlinghurst; 3021 - St Albans; 2450 - Coffs Harbour; 2541 - Nowra; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000233224
ACTRN12618000281291	MoST-Addendum-4	Phase 2	Recruiting	SA, NT, WA, QLD, TAS, VIC, ACT, NSW	22/02/2018	7/12/2018	Vismodegib	SMO_inhibitor,first_generation	Vismodegib	SMO_inhibitor,first_generation	CTC0141-addendum 4	Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations	Cancer	6009 - Nedlands; 5000 - Adelaide; 4102 - Woolloongabba; 7000 - Hobart; 0810 - Tiwi; 2605 - Garran; 2010 - Darlinghurst; 2050 - Camperdown; 3000 - Melbourne; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000281291
ACTRN12618000309280	ACTRN12618000309280	Phase 1 / Phase 2	Stopped early	NSW	1/03/2018	9/07/2018	67Cu-SARTATE; 67Cu-SARTATE + Octreotate; Octreotate	radionuclide_therapy; MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy + radionuclide_therapy; MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy	67Cu-SARTATE + Octreotate; 67Cu-SARTATE + Octreotate	MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy + radionuclide_therapy; MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy + radionuclide_therapy	None	Peptide Receptor Radionuclide Therapy administered to Participants with Meningioma with 67Cu-SARTATE™: A single-centre, open-label, nonrandomised, Phase I-IIa Theranostic Clinical Trial	Meningioma	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000309280
ACTRN12618000357257	MoST-Addendum-5	Phase 2	*NOT_RECRUITING	WA, NT, SA, NSW, ACT, TAS, VIC, QLD	9/03/2018	11/04/2019	Eribulin	macrocyclic_ketone_analogue	Eribulin	macrocyclic_ketone_analogue	CTC0141-addendum 5	Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.	Sarcoma; Angiosarcoma; Cancer 306453 0	2605 - Garran; 0810 - Tiwi; 7000 - Hobart; 4102 - Woolloongabba; 2010 - Darlinghurst; 6009 - Nedlands; 5000 - Adelaide; 2217 - Kogarah; 2050 - Camperdown; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000357257
ACTRN12618000686202	SOLACE-2	Phase 2	NOT_RECRUITING	SA, NSW, VIC, TAS, QLD	27/04/2018	8/05/2019	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib	alkylating_agent; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor; PARP_inhibitor + alkylating_agent; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab + Olaparib	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; alkylating_agent; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	CTC 0178 / ANZGOG 1723/2018	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.	Peritoneal cancer; Fallopian tube cancer; Ovarian cancer	5042 - Bedford Park; 2217 - Kogarah; 2305 - New Lambton Heights; 2050 - Camperdown; 3000 - Melbourne; 4101 - South Brisbane; 2250 - Gosford; 7000 - Hobart; 3199 - Frankston; 2485 - Tweed Heads; 2031 - Randwick; 2650 - Wagga Wagga; 3050 - Parkville; 2065 - St Leonards; 5000 - Adelaide; 2450 - Coffs Harbour	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000686202
ACTRN12618000941268	PLA001	Phase 0	Recruiting	NSW	4/06/2018	21/02/2018	PLA2 inhibitor	PLA2_inhibitor	PLA2 inhibitor	PLA2_inhibitor	None	Safety, tolerability, and pharmacokinetics of single and multiple doses of a PLA2 inhibitor (c2) in men with prostate cancer: A Phase 0 and limited dose-escalation trial	Prostate Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000941268
ACTRN12618000954224	ICE-PAC	Phase 2	Recruiting	VIC	6/06/2018	1/12/2017	Avelumab; Avelumab + Radiotherapy; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + radiotherapy	Avelumab + Radiotherapy; Avelumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + radiotherapy	MS100070-0082	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS).	Metastatic castration-resistant prostate cancer (mCRPC).	3168 - Clayton; 3128 - Box Hill	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000954224
ACTRN12618000977279	HLX20-001	Phase 1	Not yet recruiting	SA, NSW, QLD, VIC	12/06/2018		HLX20	anti-PD-1_monoclonal_antibody	HLX20	anti-PD-1_monoclonal_antibody	HLX20-001	A Phase 1 Study on the safety and maximum tolerated dose of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein, in Patients with Advanced Solid Tumors	Metastatic Solid Tumour for patients who have failed/not tolerated/not available standard treatment	4575 - Birtinya; 3144 - Malvern; 4215 - Southport; 2010 - Darlinghurst; 5000 - Adelaide; 2109 - Macquarie Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000977279
ACTRN12618001070224	AM-ATX101-01	Phase 1	Recruiting	SA, WA, NSW	27/06/2018	15/10/2018	ATX-101; Dexamethasone	glucocorticoid; cell_penetrating_peptide,PCNA-targeting	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-01	A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours	Advanced Solid Tumors	5042 - Bedford Park; 2031 - Randwick; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001070224
ACTRN12618001073291	LuPin	Phase 1	Recruiting	NSW	27/06/2018	4/12/2017	Idronoxil; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; idronoxil_suppository	Idronoxil; Lu-177 vipivotide tetraxetan	idronoxil_suppository; radioligand,PSMA-targeting	Nil Known	Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil	Castrate-resistant prostate cancer	2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001073291
ACTRN12618001112257	AM-ATX101-02	Phase 1	Recruiting	NSW, SA, WA	5/07/2018	11/12/2018	ATX-101; Dexamethasone	glucocorticoid; cell_penetrating_peptide,PCNA-targeting	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-02	A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours	Advanced Solid Tumors	2031 - Randwick; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001112257
ACTRN12618001121257	POPCORN	Phase 1 / Phase 2	Recruiting	QLD	6/07/2018	22/05/2019	Denosumab; Denosumab + Nivolumab; Nivolumab	anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	Denosumab + Nivolumab; Nivolumab; Denosumab + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	20177440 Amgen ISS	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	4029 - Herston; 4032 - Chermside; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001121257
ACTRN12618001337268	ACTRN12618001337268	Not Applicable	Not yet recruiting		8/08/2018						None	The safety and efficacy of immunotherapy with the activited T cells from from umbilical cord blood mononuclear cells ex vivo for small cell lung cancer,Kidney cancer and Primary liver cancer treatment	Histopathologically confirmed small cell lung cancer (SCLC); Histopathologically confirmed Liver cancer; Histopathologically confirmed Kidney cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001337268
ACTRN12618001480279	ALT-TRACC	Phase 2	Recruiting	VIC	4/09/2018	6/09/2018	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin	fluoropyrimidine; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; folinic_acid; anti-VEGF_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin; Irinotecan + Oxaliplatin	anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; Fluorouracil; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Nil known	Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial	Metastatic Colorectal Cancer	3000 - Melbourne; 3011 - Footscray; 3128 - Box Hill; 3021 - St Albans; 3280 - Warrnambool; 3076 - Epping; 3084 - Heidelberg; 3844 - Traralgon; 3065 - Fitzroy	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001480279
ACTRN12618001573246	CRIO	Phase 2	Not yet recruiting	QLD	20/09/2018		Carboplatin; Carboplatin + Durvalumab + Radiotherapy; Durvalumab; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Carboplatin + Durvalumab + Radiotherapy; Carboplatin + Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Nil known	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	skin cancer; squamous cell carcinoma	4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001573246
ACTRN12618001742268	ILLUMINATE	Phase 2	Recruiting	NSW, QLD, VIC, TAS, WA, SA	23/10/2018	4/04/2019	Carboplatin; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Cisplatin; Durvalumab; Durvalumab + Pemetrexed; Pemetrexed; Tremelimumab	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite	CTC 0209  ALTG 16/009	A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE).	EGFR mutant advanced non small cell lung cancer.	2217 - Kogarah; 5042 - Bedford Park; 3000 - Melbourne; 2170 - Liverpool; 2250 - Gosford; 3168 - Clayton; 7000 - Hobart; 4032 - Chermside; 3065 - Fitzroy; 4102 - Woolloongabba; 2200 - Bankstown; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001742268
ACTRN12618001825246	2014-000259-99	Phase 2 / Phase 3	Recruiting	WA, SA, NZ, NSW, QLD, VIC	9/11/2018	25/11/2014	Carboplatin; Carboplatin + Etoposide; Cyclophosphamide; Cyclophosphamide + Topotecan; Docetaxel; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Temozolomide; Topotecan	alkylating_agent; gemcitabine; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; taxane; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor	Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Ifosfamide; Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide	alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; gemcitabine; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	RG_13-277  ISRCTN36453794  EudraCT Number: 2014-000259-99	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Ewing Sarcoma	2050 - Camperdown; 3168 - Clayton; 3000 - Melbourne; 2145 - Westmead; 2305 - New Lambton; 6009 - Nedlands; 5006 - North Adelaide; 5000 - Adelaide; 4102 - Woolloongabba; 3052 - Parkville; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001825246
ACTRN12618001955202	FPT155-001	Phase 1	Stopped early	WA, VIC, NSW	4/12/2018	14/11/2018	FPT155	soluble_CD80_fusion_protein	FPT155	soluble_CD80_fusion_protein	FPT155-001	A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors.	Advanced Solid Tumors		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001955202
ACTRN12619000385145	ENG9	Phase 1 / Phase 2	STOPPED_EARLY	NSW, VIC	12/03/2019	4/03/2019	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	Nil known	A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate.	Pancreatic Cancer; Advanced Cancer (Solid Tumours)	2076 - Wahroonga; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000385145
ACTRN12619000566134	OXTOX	Phase 2	Recruiting	NSW	10/04/2019	28/01/2021	Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; PDE4_inhibitor; platinum-based_antineoplastic_agent	Ibudilast + Oxaliplatin; Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	2500 - Wollongong; 2747 - Kingswood; 2139 - Concord; 2800 - Orange; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619000567123	EnzAdapt	Phase 1 / Phase 2	Recruiting	NSW	11/04/2019	29/08/2019	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	EnzAdapt	EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer	Prostate cancer; castrate resistant prostate cancer	2340 - Tamworth; 2298 - Waratah; 2430 - Taree	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000567123
ACTRN12619000640101	ACTRN12619000640101	Phase 2	STATUS_UNKNOWN	ACT, NSW, QLD, VIC	30/04/2019	10/02/2020	PAX-1	sodium_arsenite	PAX-1	sodium_arsenite	None	A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.	Glioblastoma	4120 - Greenslopes; 3168 - Clayton; 2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000640101
ACTRN12619000769189	ATTAC	Phase 1	Recruiting	WA	23/05/2019						None	A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.	Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000769189
ACTRN12619000844145	ALKternate	Phase 1 / Phase 2	Recruiting	VIC, NSW	13/06/2019	14/06/2019	Crizotinib; Crizotinib + Lorlatinib; Lorlatinib	MET_inhibitor,type_1 + ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1; ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor	Crizotinib + Lorlatinib; Lorlatinib; Crizotinib + Lorlatinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor	None	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	2065 - St Leonards; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000844145
ACTRN12619000900112	AtTEnd	Phase 3	Not yet recruiting	TAS, VIC, QLD, NSW, NZ, SA, WA	27/06/2019		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	platinum-based_antineoplastic_agent + taxane; placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	IRFMN-EN-7556  CTC 0246  ANZGOG 1807/2019	Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.	Endometrial Cancer	3199 - Frankston; 4029 - Herston; 2298 - Waratah; 7000 - Hobart; 5000 - Adelaide; Auckland; 5006 - North Adelaide; 3128 - Box Hill; 2217 - Kogarah; 4217 - Benowa; 3083 - Bundoora; 4350 - Toowoomba; 2640 - Albury; 6008 - Subiaco; 4101 - South Brisbane; 2170 - Liverpool; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000900112
ACTRN12619001117101	CAPTURE	Phase 2	Recruiting	NSW, VIC, QLD, WA, NT, SA	12/08/2019	3/08/2020	Alpelisib; Alpelisib + Fulvestrant; Capecitabine; Fulvestrant; Goserelin	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; GnRH_agonist; fluoropyrimidine; PI3K_alpha_inhibitor; GnRH_analogue; selective_estrogen_receptor_degrader	Alpelisib; Alpelisib + Fulvestrant; Goserelin; Alpelisib + Fulvestrant; Capecitabine	GnRH_agonist; GnRH_analogue; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; fluoropyrimidine	BCT 1901	BCT 1901 (CAPTURE): A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.	Advanced Breast Cancer	3280 - Warrnambool; 3121 - Richmond; 0810 - Tiwi; 4102 - Woolloongabba; 3844 - Traralgon; 2298 - Waratah; 3199 - Frankston; 2010 - Darlinghurst; 3135 - Ringwood East; 3168 - Clayton; 2444 - Port Macquarie; 2170 - Liverpool; 3000 - Melbourne; 6008 - Subiaco; 2640 - Albury; 3350 - Ballarat Central; 2747 - Kingswood; 2145 - Westmead; 5011 - Woodville; 5112 - Elizabeth Vale; 2060 - North Sydney	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001117101
ACTRN12619001147178	MoST-Addendum-6	Phase 2	Recruiting	SA, NT, WA, QLD, VIC, TAS, ACT, NSW	16/08/2019	2/11/2020	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	CTC0141-Addendum 6	Single arm, open label, signal seeking, phase IIa trial of the activity of Larotrectinib in patients with advanced NTRK1-3 positive tumours.	Cancer	2050 - Camperdown; 3000 - Melbourne; 2217 - Kogarah; 6009 - Nedlands; 5000 - Adelaide; 7000 - Hobart; 0810 - Tiwi; 2605 - Garran; 4102 - Woolloongabba; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001147178
ACTRN12619001185156	IGNITE	Phase 2	Recruiting	TAS, VIC, QLD, NSW, SA, WA	22/08/2019	26/03/2020	Adavosertib	WEE1_inhibitor	Adavosertib	WEE1_inhibitor	Nil known	A Phase II signal-seeking trial of Adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate.	Cancer of the falllopian tube; Ovarian Cancer; Primary peritoneal cancer	4101 - South Brisbane; 3000 - Melbourne; 2050 - Camperdown; 2145 - Westmead; 5042 - Bedford Park; 2065 - St Leonards; 3021 - St Albans; 6009 - Nedlands; 2031 - Randwick; 7000 - Hobart; 2800 - Orange	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001185156
ACTRN12619001265167	MoST-Addendum-8	Phase 2	Recruiting	ACT, NSW, TAS, VIC, QLD, WA, NT, SA	12/09/2019	25/06/2020	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	CTC0141-addendum 8	Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	Cancer	2217 - Kogarah; 3000 - Melbourne; 2050 - Camperdown; 2010 - Darlinghurst; 4102 - Woolloongabba; 0810 - Tiwi; 7000 - Hobart; 2605 - Garran; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001265167
ACTRN12619001298101	ASN-002-IL	Phase 2	Not yet recruiting	QLD	20/09/2019		Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	Fluorouracil; SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine	Fluorouracil + Gusacitinib; Gusacitinib; Fluorouracil + Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine; Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Carcinoma; Basal Cell Nevus Syndrome (BCNS)	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12619001324101	ANTHEM	Phase 2	Recruiting	WA	27/09/2019	25/02/2020	Anamorelin; Placebo	Growth_hormone_secretagogue_receptor_agonist; placebo	Anamorelin; Placebo	Growth_hormone_secretagogue_receptor_agonist; placebo	Nil known	A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma	Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001324101
ACTRN12619001407189	QB46C-H03--CTRI-2019-11-022032	Phase 1 / Phase 2	Recruiting	QLD, NSW	14/10/2019	29/11/2019	Tigilanol Tiglate	protein_kinase_C_regulator	Tigilanol Tiglate	protein_kinase_C_regulator	QB46C-H03  CTRI/2019/11/022032	Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell Carcinoma	Head and neck squamous cell carcinoma.	4102 - Woolloongabba; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001407189
ACTRN12619001527156	CESTEM-1	Phase 1	Recruiting	QLD	5/11/2019	1/06/2017	Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antihistamine; antihistamine	Cetuximab + Prochlorperazine; Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; anti-EGFR_monoclonal_antibody + antihistamine	None	Open-label Phase I study investigating the safety and efficacy of Cetuximab and prochlorperazine (STEMetil) combination therapy in patients with metastatic Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer (CESTEM study)	Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001527156
ACTRN12619001533189	FP101A	Phase 1	Recruiting	NSW	6/11/2019	9/03/2020	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Fluorouracil; Leucovorin	Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; folinic_acid	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Deflexifol + Fluorouracil + Leucovorin	Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; Fluorouracil + fluoropyrimidine + folinic_acid	TGA CT-2019-CTN-02849-1	A Phase 1 Study of Deflexifol: To determine pharmacokinetic (PK) in patients administered a combined dose of bolus and continuous 46hr infusion of Deflexifol in patients with advanced malignancy after failure of standard treatment	Advanced Malignant Cancer	2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001533189
ACTRN12620000008921	CTIV1708	Phase 1	Recruiting	SA, VIC	8/01/2020	17/09/2020	MVR-T3011	oncolytic_HSV_virus	MVR-T3011	oncolytic_HSV_virus	Theravir Protocol Number: CTIV1708	A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies	Any malignancy with cutaneous and/or subcutaneous tumours	3004 - St Kilda Road Melbourne; 3199 - Frankston; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000008921
ACTRN12620000244909	VG161-A101	Phase 1	Recruiting	NSW, QLD, SA	26/02/2020	27/04/2020	VG-161	oncolytic_virus	VG-161	oncolytic_virus	VG161-A101	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies	Advanced malignant solid tumors	5042 - Bedford Park; 4029 - Herston; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000244909
ACTRN12620000440921	ALMB-0168-AU-101	Phase 1	Recruiting	SA, VIC, NSW	6/04/2020	23/10/2020	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168-AU-101	Phase 1, Multicenter, First-in-Human Dose Escalation Study of ALMB-0168 Administered IV as a Single Agent to Patients with Malignant Bone Disease	Osteosarcoma or any other solid tumor cancer with bone metastases	5042 - Bedford Park; 2031 - Randwick; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000440921
ACTRN12620000568910	MoST-Addendum-10	Phase 2	Recruiting	NSW, ACT, QLD, VIC, TAS, NT, WA, SA	15/05/2020	3/05/2021	Avelumab; Avelumab + Palbociclib; Palbociclib	anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab; Avelumab + Palbociclib; Palbociclib; Avelumab + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141-addendum 10	Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.	Cancer	2050 - Camperdown; 3000 - Melbourne; 4102 - Woolloongabba; 2605 - Garran; 7000 - Hobart; 0810 - Tiwi; 6009 - Nedlands; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000568910
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	Not yet recruiting	VIC	20/05/2020		EO1001	pan-ERBB_inhibitor; ERBB4_inhibitor; EGFR_inhibitor; ERBB2_inhibitor	EO1001	EGFR_inhibitor; ERBB2_inhibitor; ERBB4_inhibitor; pan-ERBB_inhibitor	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ErbB-2(HER2) positive cancer; ERbB-4 (HER4) positive cancer; ErbB-1(EGFR) positive cancer	3168 - Clayton; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620000592943	GQCT001--GQ1001X2101	Phase 1	Recruiting	NSW	21/05/2020	25/06/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQCT001  GQ1001X2101	A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously in Adult Patients with HER2-Positive Advanced Solid Tumors	HER2-Positive Advanced Solid Tumors	2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000592943
ACTRN12620000767909	MoST-Addendum-9	Phase 2	Recruiting	QLD, TAS, VIC, NSW, ACT, SA, NT, WA	27/07/2020		Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation	Trastuzumab; Trastuzumab + Tucatinib; Tucatinib; Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	CTC0141- addendum 9	Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations	Cancer	4102 - Woolloongabba; 0810 - Tiwi; 7000 - Hobart; 2605 - Garran; 2010 - Darlinghurst; 6009 - Nedlands; 5000 - Adelaide; 2217 - Kogarah; 2050 - Camperdown; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000767909
ACTRN12620000849998	ACTRN12620000849998	Phase 1 / Phase 2	OLD_TRIAL	NSW, QLD	27/08/2020	12/05/2020	MG010; MG010 + Sorafenib; Sorafenib	CRAF_inhibitor + KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; VEGFR_inhibitor; CRAF_inhibitor + FLT3_inhibitor; PDGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; FLT3_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; CRAF_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; KIT_inhibitor	MG010 + Sorafenib; MG010 + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor	Nil	A phase I/II, open label, multi-centre study to assess the safety, tolerability, and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments.	Metastatic solid tumours having failed existing treatments.	2031 - Randwick; 2139 - Concord; 4101 - South Brisbane; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000849998
ACTRN12620000861954	MoST-Addendum-12	Phase 2	Recruiting	NSW	28/08/2020		Cobimetinib; Cobimetinib + Vemurafenib; Vemurafenib	MEK_inhibitor; BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Cobimetinib + Vemurafenib; Cobimetinib + Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	CTC 0141 / ALTG 20/002 – addendum 12	Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	non-small cell lung cancer; Cancer	2217 - Kogarah; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000861954
ACTRN12620000918921	MoST-addendum-7	Phase 2	Recruiting	WA, NT, SA, ACT, NSW, VIC, TAS, QLD	17/09/2020	30/11/2020	Tremelimumab	anti-CTLA-4_monoclonal_antibody	Tremelimumab	anti-CTLA-4_monoclonal_antibody	CTC0141 Addendum 7	Single arm, open label, signal seeking, phase IIa trial of the activity of Tremelimumab in patients with advanced rare or neglected cancers	cancer	3000 - Melbourne; 2605 - Garran; 7000 - Hobart; 0810 - Tiwi; 4102 - Woolloongabba; 2010 - Darlinghurst; 6009 - Nedlands; 2065 - St Leonards; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000918921
ACTRN12620000984998	MoST-Addendum-11	Phase 2	Recruiting	SA, NT, WA, QLD, VIC, TAS, ACT, NSW	30/09/2020	9/03/2021	Tildrakizumab	anti-IL-23_monoclonal_antibody	Tildrakizumab	anti-IL-23_monoclonal_antibody	CTC0141-addendum 11	Single arm, open label signal seeking, phase II trial to study the clinical activity of Tildrakizumab in patients with advanced osteosarcoma and soft tissue sarcomas	Soft Tissue Sarcoma; Cancer; Advanced Osteosarcoma	5000 - Adelaide; 6009 - Nedlands; 2605 - Garran; 0810 - Tiwi; 7000 - Hobart; 4102 - Woolloongabba; 3000 - Melbourne; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000984998
ACTRN12620001146987	ACTRN12620001146987	Phase 1	Recruiting	WA, VIC, NSW	2/11/2020		PMR-116	RNA_polymerase_I_transcription_inhibitor	PMR-116	RNA_polymerase_I_transcription_inhibitor	Nil known	Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies	Advanced solid tumours	3000 - Melbourne; 2031 - Randwick; 6009 - Nedlands; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001146987
ACTRN12620001198910	MODERN-LUNG	Phase 2	Recruiting	NSW	10/11/2020	15/04/2021	Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy; Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy; platinum-based_antineoplastic_agent + taxane	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2298 - Waratah; 2148 - Blacktown; 2560 - Campbelltown; 2170 - Liverpool; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000093886	ACT001-AU-004	Phase 2	Not yet recruiting	VIC	1/02/2021		ACT001; ACT001 + Radiotherapy; Radiotherapy	radiotherapy; NFKB_inhibitor + radiotherapy; NFKB_inhibitor	ACT001 + Radiotherapy; ACT001 + Radiotherapy	NFKB_inhibitor + radiotherapy; NFKB_inhibitor + radiotherapy	ACT001-AU-004	A Phase 2, open label, multicentre study assessing the safety and efficacy of ACT001 in combination with whole brain radiation therapy (WBRT) for brain metastases from solid tumours.	Metastatic Brain Cancer; Solid Tumours	3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000093886
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	Not yet recruiting	NSW	15/02/2021		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ACE_inhibitor	Ipilimumab + Nivolumab; Perindopril; Ipilimumab + Nivolumab	ACE_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Unresectable; Melanoma - Metastatic		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000269831	HYNOVA	Not Applicable	Not yet recruiting	NSW, VIC, QLD	11/03/2021		Cisplatin	platinum-based_antineoplastic_agent	Cisplatin	platinum-based_antineoplastic_agent	CTC 0302  ANZGOG 1901 /2020	The safety of hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (HYNOVA).	Ovarian cancer; Fallopian tube cancer; Primary peritoneal cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000269831
ACTRN12621000273886	ADELE	Phase 2	Not yet recruiting	NSW, VIC	11/03/2021		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel + Tislelizumab; Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	3000 - Melbourne; 2031 - Randwick; 3052 - Parkville	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000284864	MoST-Addendum-13	Phase 2	Recruiting	NSW, ACT, TAS, VIC, QLD, WA, NT, SA	16/03/2021		Entrectinib	ROS1_inhibitor; TRK_inhibitor,first_generation; ALK_inhibitor,third_generation	Entrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,first_generation	CTC0141-addendum 13	A single-arm, open-label, phase II trial of the tumour response to entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling	Cancer	2145 - Westmead; 3000 - Melbourne; 4032 - Chermside; 4102 - Woolloongabba; 3065 - Fitzroy; 2605 - Garran; 0810 - Tiwi; 7000 - Hobart; 5000 - Adelaide; 2065 - St Leonards; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000284864
ACTRN12621000312842	MoST-Addendum-14	Phase 2	Recruiting	VIC, TAS, QLD, NSW, ACT, SA, WA	22/03/2021	3/09/2021	Alectinib	ALK_inhibitor,second_generation	Alectinib	ALK_inhibitor,second_generation	CTC 0141 – addendum 14	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	Cancer; ALK gene alterations; Non-small cell lung cancer	2065 - St Leonards; 5000 - Adelaide; 6009 - Nedlands; 7000 - Hobart; 4102 - Woolloongabba; 3000 - Melbourne; 2217 - Kogarah; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000479808	ATTACK-1-trial	Phase 1	Recruiting	NSW, VIC, SA	22/04/2021	16/06/2021	Auceliciclib; Auceliciclib + Temozolomide; Ifosfamide; Temozolomide	alkylating_agent; CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor	Auceliciclib; Auceliciclib + Temozolomide; Auceliciclib + Temozolomide; Ifosfamide	CDK4/6_inhibitor; CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor + alkylating_agent	Nil known	A Phase 1a/b, open-label, dose-exploration, combination/ expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).	Glioblastoma multiforme (GBM); Cancer; Solid tumors; Colorectal cancer; Ovarian cancer	5042 - Bedford Park; 2170 - Liverpool; 3084 - Heidelberg	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000479808
ACTRN12621000507886	MoST-Addendum-15	Phase 2	Recruiting	SA, QLD	30/04/2021	7/09/2021	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab; Acalabrutinib + Durvalumab	BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141- addendum 15	A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	High grade B cell lymphoma; Cancer	5000 - Adelaide; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000507886
ACTRN12621000611820	PICAASO	Phase 2	Not yet recruiting	NSW, VIC	21/05/2021		Dasatinib	YES1_inhibitor; SRC_inhibitor; KIT_inhibitor; BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	3000 - Melbourne; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	Not yet recruiting	WA, VIC, TAS, QLD, NSW	28/05/2021		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor; CDK4/6_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Alpelisib + Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Endometrial cancer; Platinum resistant high-grade epithelial cancers of fallopian tube; Other gynaecological cancers (excluding endometrial cancers); Leiomyosarcomas; Granulosa cell tumours; Endometrial stromal sarcomas; Platinum resistant high-grade epithelial cancers of primary peritoneum; Low grade epithelial cancers of ovary; Platinum resistant high-grade epithelial cancers of ovary	4101 - South Brisbane; 3000 - Melbourne; 2640 - Albury; 2050 - Camperdown; 2305 - New Lambton Heights; 3168 - Clayton; 2217 - Kogarah; 2145 - Westmead; 2065 - St Leonards; 6009 - Nedlands; 2031 - Randwick; 3052 - Parkville; 7000 - Hobart; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000747820	TaxAdapt	Phase 1 / Phase 2	Not yet recruiting	NSW	11/06/2021		Docetaxel	taxane	Docetaxel	taxane	Nil known	TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer	Castration-resistant prostate cancer	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000747820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	Recruiting	QLD	18/06/2021	21/07/2021	Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	alkylating_agent; antimetabolite; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel; Cyclophosphamide + Fludarabine + Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Herston; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	Not yet recruiting	NSW	25/06/2021		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000811808	MoST-Addendum-17	Phase 2	Recruiting	NT, WA, SA, NSW, ACT, QLD, TAS, VIC	28/06/2021	9/11/2021	Tepotinib	MET_inhibitor,type_1	Tepotinib	MET_inhibitor,type_1	CTC0141- addendum 17	A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling	Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations	2217 - Kogarah; 2145 - Westmead; 3000 - Melbourne; 3084 - Heidelberg; 2605 - Garran; 7000 - Hobart; 0810 - Tiwi; 4032 - Chermside; 4102 - Woolloongabba; 3065 - Fitzroy; 2065 - St Leonards; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000811808
ACTRN12621000991819	PDCCiHNC	Not Applicable	Not yet recruiting	NSW	28/07/2021		Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	PI3K/mTOR_inhibitor; vinca_alkaloid; mTORC1/mTORC2_inhibitor; antifolate; EGFR_inhibitor,first_generation; platinum-based_antineoplastic_agent; anthracycline; SRC_inhibitor; topoisomerase_inhibitor; taxane; gemcitabine; fluoropyrimidine; VEGFR_inhibitor; BCR-ABL1_inhibitor,second_generation; YES1_inhibitor; Fluorouracil; CRAF_inhibitor; JAK1/JAK2_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CDK4/6_inhibitor; PDGFRA_inhibitor; FLT3_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1; PDGFR_inhibitor; ROS1_inhibitor; ATR_inhibitor; doxorubicin; SMO_inhibitor; antimetabolite; KIT_inhibitor	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SMO_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; fluoropyrimidine; mTORC1/mTORC2_inhibitor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid; Fluorouracil; doxorubicin; gemcitabine	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001155886	PRIME005	Phase 1 / Phase 2	Recruiting	NSW, QLD	27/08/2021	13/09/2021	Azacitidine; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Carboplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	CA184-602	Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy.	Advanced Melanoma	4870 - Cairns; 2298 - Waratah; 2298 - Waratah West	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001155886
ACTRN12621001172897	ACT001-AU-001	Phase 1	Recruiting	SA, VIC, NSW	31/08/2021	15/04/2021	ACT001; ACT001 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody; NFKB_inhibitor	ACT001 + Pembrolizumab; ACT001 + Pembrolizumab	NFKB_inhibitor + anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001-AU-001 (Sponsor protocol code) - PART B	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).	Glioblastoma Multiforme	3121 - Richmond; 2031 - Randwick; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001172897
ACTRN12621001225808	MoST-Addendum-18	Phase 2	Recruiting	NSW	13/09/2021		Carboplatin; Carboplatin + Cisplatin + Etoposide; Cisplatin; Durvalumab; Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide; Durvalumab; Carboplatin + Cisplatin + Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CTC0141- addendum 18	A single-arm, open-label, signal-seeking, phase II trial of durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma	Extra-pulmonary small cell carcinoma	2050 - Camperdown; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001225808
ACTRN12621001290886	ASCEND	Phase 2	Not yet recruiting	NSW, ACT, QLD, VIC, TAS, WA, SA	24/09/2021		CEND-1; CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine; Nab-paclitaxel; Placebo	gemcitabine; antimetabolite + taxane + tumor-homing_peptide_iRGD; tumor-homing_peptide_iRGD; placebo; antimetabolite; taxane	CEND-1 + Gemcitabine + Nab-paclitaxel; CEND-1 + Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + taxane + tumor-homing_peptide_iRGD; antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine; placebo	CTC0304	A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients on progression-free survival in patients with untreated metastatic pancreatic ductal adenocarcinoma	Metastatic Pancreatic Ductal Adenocarcinoma	6008 - Subiaco; 2170 - Liverpool; 3144 - Malvern; 2640 - Albury; 2305 - New Lambton Heights; 2050 - Camperdown; 3168 - Clayton; 2290 - Gateshead; 2217 - Kogarah; 2500 - Wollongong; 6150 - Murdoch; 5011 - Woodville; 2145 - Westmead; 2747 - Kingswood; 5042 - Bedford Park; 3121 - Richmond; 3076 - Epping; 3021 - St Albans; 2031 - Randwick; 3084 - Heidelberg; 3065 - Fitzroy; 2605 - Garran; 4029 - Herston; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001290886
ACTRN12621001342808	CL001-559	Phase 1	Recruiting	WA, SA, NSW, VIC	7/10/2021	2/08/2021	CCX559	PD-L1_inhibitor,oral	CCX559	PD-L1_inhibitor,oral	CL001_559	A Phase 1 First In Human, Multicenter, Open label Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In Subjects With Solid Tumors	Neoplastic Disorder - Solid Tumors	3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001342808
ACTRN12621001347853	SPEAR	Phase 2	Recruiting	WA, SA, NSW, QLD, VIC	7/10/2021		Sulfasalazine	SLC7A11_inhibitor	Sulfasalazine	SLC7A11_inhibitor	None	A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma	Pancreatic cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001347853
ACTRN12621001403820	IMBO-Pilot-study	Phase 2	Not yet recruiting	VIC, NSW	18/10/2021		Dexamethasone; Placebo	glucocorticoid; placebo	Dexamethasone; Placebo	glucocorticoid; placebo	054/20	A phase II, multi-site, double blind, randomised placebo-controlled feasibility trial of crushed oral famotidine for management of Inoperable Malignant Bowel Obstruction (IMBO)	Malignant Bowel Obstruction; Bowel Obstruction; Bowel cancer	2170 - Liverpool; 2176 - Prairiewood; 2217 - Kogarah; 3084 - Heidelberg; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001403820
ACTRN12621001419853	OP-1250-002	Phase 1	Not yet recruiting	NSW, QLD, VIC, WA	21/10/2021		Fulvestrant; Fulvestrant + Palbociclib; Palazestrant; Palazestrant + Palbociclib; Palbociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	Fulvestrant + Palbociclib; Palazestrant; Palazestrant + Palbociclib; Fulvestrant + Palbociclib; Palazestrant + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	OP-1250-002	A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	3220 - Geelong; 6000 - Perth; 4101 - South Brisbane; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001419853
ACTRN12621001436864	CTB-02-01	Phase 1 / Phase 2	Not yet recruiting	NSW	25/10/2021		Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib	MEK_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib; Cetuximab + Cobimetinib + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	CTB-02-01	A two-part open label Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the combination of cetuximab, cobimetinib and palbociclib in subjects with K-RAS wild-type BRAF V600E mutated, or K-RAS mutated, advanced or metastatic colorectal cancer who have failed all available standard therapies	Colorectal Cancer	2050 - Camperdown; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001436864
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	Recruiting	NSW	10/11/2021	25/10/2021	Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository	Idronoxil; Idronoxil + Nivolumab; Nivolumab; Idronoxil + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository; anti-PD-1_monoclonal_antibody + idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2217 - Kogarah; 2076 - Wahroonga; 2228 - Miranda; 2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12621001690842	MoST-addendum-19	Phase 2	Not yet recruiting	WA, SA, NSW, VIC, TAS	10/12/2021		Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	CTC 0141 – addendum 19	Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation.	Cancer	3000 - Melbourne; 2145 - Westmead; 5000 - Adelaide; 6009 - Nedlands; 2010 - Darlinghurst; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001690842
ACTRN12622000016730	HER2Pro-1B	Phase 1	Not yet recruiting	NSW, QLD	11/01/2022		Dexamethasone; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab; Prochlorperazine; Trastuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; glucocorticoid; anti-ERBB2_monoclonal_antibody; taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Prochlorperazine; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	None	Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study	Metastatic HER2-positive breast cancer	2010 - Darlinghurst; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000016730
ACTRN12622000405718	ONC201-104	Phase 1	Not yet recruiting	NZ	9/03/2022		ONC201	ERK_inhibitor; DRD2_antagonist; AKT_inhibitor	ONC201	AKT_inhibitor; DRD2_antagonist; ERK_inhibitor	ONC201-104	A Phase 1 study to evaluate the effect of renal impairment on the pharmacokinetics of ONC201	Solid Tumours; Renal Impairment; Cancer	Christchurch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000405718
ACTRN12622000513718	GQ1007-101	Phase 1	Not yet recruiting	VIC, QLD, NSW	31/03/2022		Envafolimab; Envafolimab + GQ1007; GQ1007	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody	Envafolimab; Envafolimab + GQ1007; GQ1007; Envafolimab + GQ1007	anti-ERBB2_antibody-immune-agonist-conjugate; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody	GQ1007-101	A Phase I, First-In-Human, Multicenter, Open-Label, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors	Solid Tumors	4217 - Benowa; 3168 - Clayton; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000513718
ACTRN12622000973718	SHERLOCK	Phase 2	Not yet recruiting	NSW, QLD, VIC, TAS	11/07/2022		Bevacizumab; Carboplatin; Pemetrexed; Sotorasib	platinum-based_antineoplastic_agent; antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; anti-VEGF_monoclonal_antibody	Carboplatin; Pemetrexed; Sotorasib; Bevacizumab	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; antimetabolite; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody	TOGA 21/011  CTC 0377	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	advanced non-squamous non-small cell lung cancer with KRAS G12C mutation 326412 0		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000973718
ACTRN12622000993796	ACTRN12622000993796	Phase 1	Not yet recruiting	WA, NSW, VIC	14/07/2022		AXA-042	TLR2/6_agonist	AXA-042	TLR2/6_agonist	None	A Phase 1, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy in subjects with advanced solid tumors.	Advanced solid tumors	6009 - Nedlands; 2031 - Randwick; 3000 - Melbourne; 3175 - Dandenong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000993796
ACTRN12622001003763	X22-0072	Phase 2	Not yet recruiting	NSW	18/07/2022		Evolocumab	anti-PCSK9_monoclonal_antibody	Evolocumab	anti-PCSK9_monoclonal_antibody	Protocol Number: X22-0072	A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer	Metastatic Castrate Resistant Prostate Cancer	2050 - Camperdown; 2139 - Concord; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001003763
ACTRN12622001201763	TRAS-GB	Phase 2	Not yet recruiting	NZ	7/09/2022		Celecoxib; Metformin; Propranolol; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	alkylating_agent; biguanide_antihyperglycaemic_agent; alkylating_agent + radiotherapy; beta-adrenergic_blocker; radiotherapy; COX2_inhibitor	Celecoxib; Metformin; Propranolol; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide	COX2_inhibitor; alkylating_agent + radiotherapy; beta-adrenergic_blocker; biguanide_antihyperglycaemic_agent; alkylating_agent + radiotherapy	none	Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial	Glioblastoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001201763
ACTRN12622001339741	HH3806-A101	Phase 1	Not yet recruiting	VIC	18/10/2022		HH3806	BET_inhibitor	HH3806	BET_inhibitor	HH3806-A101	A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies	relapsed/refractory Non-Hodgkin’s lymphomas (NHL); Solid Tumors	3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001339741
ACTRN12622001514796	KARPOS	Not Applicable	Not yet recruiting	SA	6/12/2022		Bevacizumab; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; GD2-iCAR-PBT; Ifosfamide	alkylating_agent; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; anti-VEGF_monoclonal_antibody; autologous_CAR-T-cell_therapy,GD2-targeting; antimetabolite; alkylating_agent + antimetabolite	Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; GD2-iCAR-PBT; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; Ifosfamide	alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting	Nil Known	KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme	Glioblastoma Multiforme	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001514796
ACTRN12622001542785	Lewis-Y-Nivo-CAR-T	Phase 1	Not yet recruiting	VIC	13/12/2022		Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; alkylating_agent; autologous_CAR-T-cell_therapy,LeY-targeting; anti-PD-1_monoclonal_antibody; antimetabolite; alkylating_agent + antimetabolite	Cyclophosphamide + Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab; Cyclophosphamide + Fludarabine; LeY-CAR-T + Nivolumab	alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; autologous_CAR-T-cell_therapy,LeY-targeting; alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting	Nil known	A Pilot Study Assessing Safety and Tolerability of Lewis Y (LeY) targeting Chimeric Antigen Receptor (CAR) T cells in combination with Nivolumab in Patients With LeY Expressing Solid Tumours	LeY Expressing Advanced Solid Tumours	3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001542785
ACTRN12623000073606	SLAP-trial	Phase 0	Not yet recruiting	NSW	23/01/2023		Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	None	A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer	Prostate cancer 328693 0	2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000073606
ACTRN12623000096651	LUMOS2	Phase 2	Not yet recruiting	VIC, TAS, QLD, NSW	27/01/2023		AK104; Paxalisib; Selinexor	selective_inhibitor_of_nuclear_export; bispecific_PD-1/CTLA-4_antibody; dual_PI3K/mTOR_inhibitor	AK104; Paxalisib; Selinexor	bispecific_PD-1/CTLA-4_antibody; dual_PI3K/mTOR_inhibitor; selective_inhibitor_of_nuclear_export	CTC0837  COGNO2201	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	Grade 3 Glioma; Grade 2 Glioma	4029 - Herston; 7000 - Hobart; 3065 - Fitzroy; 2010 - Darlinghurst; 3084 - Heidelberg; 2065 - St Leonards; 3168 - Clayton; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000096651
ACTRN12623000108617	EMITT-1	Phase 1	Not yet recruiting	SA, VIC, NSW	31/01/2023		GRWD5769	ERAP1_inhibitor	GRWD5769	ERAP1_inhibitor	GRWD5769-ST-01	A modular, multi-part, multi-arm, open-label, Phase I/II Study to evaluate the safety and tolerability of GRWD5769 in patients with solid malignancies - Module 1.	Advanced solid malignancies		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000108617
ACTRN12623000174684	APG2449OG101	Phase 1	Not yet recruiting	NSW	21/02/2023		Doxorubicin	doxorubicin; anthracycline	Doxorubicin	anthracycline; doxorubicin	APG2449OG101	Safety, tolerability, and efficacy of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in treating Patients with Platinum-resistant Ovarian Cancer	Ovarian Cancer	2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000174684
ACTRN12623000185662	SSO110-01	Phase 1	Not yet recruiting	WA, QLD, VIC, NSW	22/02/2023		Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Satoreotide Tetraxetan	anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate	Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Atezolizumab + Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody	SSO110-01	A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with atezolizumab	Extensive Stage Small Cell Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000185662
ACTRN12623000202662	SON-DP-A002-ST	Phase 1	Not yet recruiting	SA	24/02/2023		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	SON-DP-A002-ST	A First-in-Human (FIH), Open-Label, Phase Ia Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced/Metastatic Solid Tumours that have relapsed or are refractory/intolerant to standard of care therapies	Solid tumor malignancies	5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000202662
ACTRN12623000216617	RESCUE	Phase 1	Not yet recruiting	NZ	28/02/2023		177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radiotherapy; radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioligand,PSMA-targeting; radiotherapy	Nil Known	A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands	Metastatic Prostate Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000216617
ACTRN12623000223639	iLSTA	Phase 1	Not yet recruiting	WA	2/03/2023		Durvalumab; Durvalumab + Gemcitabine + Nab-paclitaxel; Gemcitabine; Nab-paclitaxel	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; taxane; gemcitabine; antimetabolite	Durvalumab; Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab + Gemcitabine + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	Nil known	A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)	Cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000223639
ACTRN12623000307606	NP-105	Phase 1	Not yet recruiting	NSW	21/03/2023		RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	NP-105	A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000307606
ACTRN12623000686606	IMRARP	Not Applicable	Not yet recruiting	VIC	26/06/2023						None	The effect of intrathecal morphine compared to standard care with oral and IV opioids on the quality of recovery after robotic-assisted radical prostatectomy	Bladder Spasms; Prostate Cancer 329956 0; Post-operative Pain	3121 - Richmond; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000686606
ACTRN12623000739617	ACTRN12623000739617	Not Applicable	Not yet recruiting	NSW, ACT, VIC, TAS, QLD, WA, NT, SA	7/07/2023						Nil known	Comparing the effectiveness of two body image writing interventions against a neutral writing control in targeting positive body image in female cancer populations: A Randomised Controlled Trial	cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000739617
ACTRN12623000798662	HCC	Phase 1 / Phase 2	Not yet recruiting	SA, NSW	26/07/2023		BOS-342	bispecific_4-1BB/GPC3_antibody	BOS-342	bispecific_4-1BB/GPC3_antibody	Nil Known	A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other GPC3-expressing Tumors	Hepatocellular Carcinoma (HCC); Other GPC3-expressing Tumors	5042 - Bedford Park; 2050 - Camperdown; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000798662
ACTRN12623000874617	Biomarcer-2	Phase 2	Not yet recruiting	NSW, QLD, VIC, TAS, WA	15/08/2023		Cetuximab; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Fluorouracil; Irinotecan; Leucovorin	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; folinic_acid; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor	Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression	Advanced RAS Wild type right sided Colorectal cancer	3084 - Heidelberg; 3844 - Traralgon; 2298 - Waratah; 7000 - Hobart; 3011 - Footscray; 3280 - Warrnambool; 3076 - Epping; 6150 - Murdoch; 3000 - Melbourne; 2305 - New Lambton Heights	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000874617
ACTRN12623000956606	Australia	Unknown	Not yet recruiting	VIC, QLD, NSW, SA	4/09/2023		AT-0174	dual_IDO/TDO_inhibitor	AT-0174	dual_IDO/TDO_inhibitor	Antido Therapeutics (Australia) Protocol No. AT-0174-001	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	Locally Advanced Solid Tumours	4575 - Birtinya; 3350 - Ballarat Central; 3065 - Fitzroy; 5000 - Adelaide; 2228 - Miranda	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000956606
ACTRN12623001072606	LuCape	Unknown	Not yet recruiting	WA	6/10/2023		Capecitabine	fluoropyrimidine	Capecitabine	fluoropyrimidine	Nil known	A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)	metastatic castration-resistant prostate cancer 331258 0	6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001072606
ACTRN12623001077651	EMITT-1	Unknown	Not yet recruiting	NSW, VIC, SA	10/10/2023		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	anti-PD-1_monoclonal_antibody; ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + GRWD5769; GRWD5769; Cemiplimab + GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01 Module 2	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2.	Advanced solid malignancies	5042 - Bedford Park; 3084 - Heidelberg; 2010 - Darlinghurst; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001077651
ACTRN12623001126606	TCaP	Unknown	Not yet recruiting	VIC, QLD	1/11/2023		Cytarabine; Cytarabine + Pembrolizumab; Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody; alkylating_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Cytarabine + Pembrolizumab; Pembrolizumab; Cytarabine + Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite	Nil known	Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme	Glioblastoma multiforme/astrocytoma grade 4	4029 - Royal Brisbane Hospital; 4102 - Woolloongabba; 3084 - Heidelberg; 4006 - Bowen Hills	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001126606
ACTRN12623001164684	ACTRN12623001164684	Unknown	Not yet recruiting	QLD	9/11/2023		Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	biguanide_antihyperglycaemic_agent; HMG-CoA_reductase_inhibitor; anti-malarial_agent; melatonin	Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Nil	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for adult cancer by Circulating Tumour Cell (CTC) analysis: A case-series	Cancer	4209 - Willow Vale	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001164684
ACTRN12623001216606	MEHDSAM	Unknown	Not yet recruiting	NSW	27/11/2023		Sonidegib	SMO_inhibitor,first_generation	Sonidegib	SMO_inhibitor,first_generation	CT-2023-CTN-04330-1	Single-institution, single-arm, open-label phase II basket study investigating the effect of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001216606
ACTRN12623001217695	ACTRN12623001217695	Unknown	Not yet recruiting	NSW	27/11/2023						AFB-105	An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours.	Advanced malignant solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001217695
ACTRN12623001219673	EN002-CN-001	Unknown	Recruiting	QLD, NSW	27/11/2023	22/08/2022					EN002-CN-001	A phase I-II clinical trial to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of EN002-gel in patients with non-melanoma skin cancer and precancerous lesions	Bowen’s disease; Basal cell carcinoma; Squamous cell carcinoma of the skin; Actinic keratosis	2289 - Kotara; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001219673
ACTRN12623001333606	CCaLM	Unknown	Not yet recruiting	NSW	19/12/2023		Placebo	placebo	Placebo	placebo	Nil known	The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)	Colon cancer	2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001333606
ACTRN12624000110583	SOCRATES-PILOT	Unknown	Not yet recruiting	NSW	8/02/2024		Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	alkylating_agent; HMG-CoA_reductase_inhibitor; antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor; aromatase_inhibitor; PARP_inhibitor; anti-VEGF_monoclonal_antibody	Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; HMG-CoA_reductase_inhibitor; PARP_inhibitor; alkylating_agent; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; taxane	CTC 0393	SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies	Cardio Vascular Disease; Cancer	2139 - Concord; 2050 - Camperdown; 2050 - Missenden Road; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000110583
ACTRN12624000268549	LEPO	Unknown	Not yet recruiting	NSW	15/03/2024						ADRI002	LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma	Mesothelioma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000268549
ACTRN12624000288527	REZOLV3R	Unknown	Not yet recruiting	VIC, QLD, NSW	20/03/2024		Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	CTC 0398	Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (REZOLV3R)	Chemotherapy resistant solid tumours; Recurrent malignant ascites		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000288527
NCT01728155	LINES	Phase 3	Recruiting		13/11/2012	1/12/2011	Isotretinoin; Isotretinoin + Radiotherapy; Radiotherapy	radiotherapy; 13-cis-retinoic_acid + radiotherapy; 13-cis-retinoic_acid	Isotretinoin + Radiotherapy; Isotretinoin + Radiotherapy	13-cis-retinoic_acid + radiotherapy; 13-cis-retinoic_acid + radiotherapy	LINES	European Low and Intermediate Risk Neuroblastoma Protocol	LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES		https://clinicaltrials.gov/ct2/show/NCT01728155
NCT01791387	DILIGENCE-1	Phase 2	Unknown status	NZ	15/02/2013	1/03/2012	Dovitinib	FGFR1/2/3_inhibitor; VEGFR_inhibitor; PDGFRB_inhibitor	Dovitinib	FGFR1/2/3_inhibitor; PDGFRB_inhibitor; VEGFR_inhibitor	ACTRN12612000140853  CTKI258AAU02T	Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study	Clear Cell Renal Cell Carcinoma	Auckland	https://clinicaltrials.gov/ct2/show/NCT01791387
NCT02132754	4166-001	Phase 1	NOT_RECRUITING	NSW	5/05/2014	27/06/2014	MK-4166; MK-4166 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody	MK-4166; MK-4166 + Pembrolizumab; MK-4166 + Pembrolizumab	anti-GITR_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4166-001	Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies	Solid Tumor	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02132754
NCT02233049	BIOMEDE	Phase 2	Recruiting		5/09/2014	1/10/2014	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus; Erlotinib; Everolimus	YES1_inhibitor + mTORC1_inhibitor; mTORC1_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; PDGFRA_inhibitor; EGFR_inhibitor,first_generation; SRC_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; YES1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; KIT_inhibitor + mTORC1_inhibitor; KIT_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus	BCR-ABL1_inhibitor,second_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor; KIT_inhibitor; KIT_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; SRC_inhibitor; SRC_inhibitor + mTORC1_inhibitor; YES1_inhibitor; YES1_inhibitor + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor; KIT_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; SRC_inhibitor + mTORC1_inhibitor; YES1_inhibitor + mTORC1_inhibitor	2014/2126  2014-001929-32	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	Diffuse Intrinsic Pontine Glioma		https://clinicaltrials.gov/ct2/show/NCT02233049
NCT02516553	2015-001111-12--1367.1	Phase 1	NOT_RECRUITING	NSW	6/08/2015	8/07/2015	BI 894999	BET_inhibitor	BI 894999	BET_inhibitor	2015-001111-12  1367.1	An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit	Neoplasms; NUT Carcinoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02516553
NCT02576431	NAVIGATE	Phase 2	Recruiting	NT, WA, NSW	15/10/2015	30/09/2015	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	LOXO-TRK-15002  20289	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Solid Tumors Harboring NTRK Fusion	6008 - Subiaco; 6009 - Nedlands; 2109 - Macquarie University; 0810 - Tiwi	https://clinicaltrials.gov/ct2/show/NCT02576431
NCT02611960	Keynote-122	Phase 3	NOT_RECRUITING	NSW	19/11/2015	18/04/2016	Capecitabine; Capecitabine + Docetaxel + Gemcitabine; Docetaxel; Gemcitabine; Pembrolizumab	gemcitabine; fluoropyrimidine; antimetabolite + fluoropyrimidine + taxane; anti-PD-1_monoclonal_antibody; antimetabolite; taxane	Capecitabine + Docetaxel + Gemcitabine; Pembrolizumab; Capecitabine + Docetaxel + Gemcitabine	anti-PD-1_monoclonal_antibody; antimetabolite + fluoropyrimidine + taxane; antimetabolite + fluoropyrimidine + taxane; gemcitabine	MK-3475-122  3475-122	A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)	Nasopharyngeal Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02611960
NCT02702414	KEYNOTE-224	Phase 2	NOT_RECRUITING	NSW, VIC	3/03/2016	31/05/2016	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-004566-28  3475-224	A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Hepatocellular Carcinoma	3168 - Melbourne; 2050 - Camperdown; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02702414
NCT02705482	D6060C00002	Phase 1	NOT_RECRUITING	VIC, QLD, NSW	4/03/2016	30/03/2016	Durvalumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab; Tavolimab + Tremelimumab; Tremelimumab	anti-OX40_agonistic_antibody; immune_checkpoint_blockade; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Tavolimab; Tavolimab + Tremelimumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; immune_checkpoint_blockade	D6060C00002	A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	Select Advanced Solid Tumors	4068 - Woolloongabba; 3168 - Clayton; 2217 - Kogarah; 2109 - Macquarie University; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02705482
NCT02775435	KEYNOTE-407	Phase 3	NOT_RECRUITING	NSW	15/05/2016	9/06/2016	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Placebo	platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; glucocorticoid; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; glucocorticoid; placebo; platinum-based_antineoplastic_agent + taxane	2016-000229-38  3475-407	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT02787005	KEYNOTE-199	Phase 2	NOT_RECRUITING	NSW	26/05/2016	1/07/2016	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	Enzalutamide + Pembrolizumab; Pembrolizumab; Enzalutamide + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	2015-003644-40  3475-199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)	Metastatic Castration-resistant Prostate Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02787005
NCT02829099	64457107CAN1001--CR108186	Phase 1	Recruiting	NSW, QLD, VIC	7/07/2016	21/09/2016	Mitazalimab	anti-CD40_agonistic_antibody	Mitazalimab	anti-CD40_agonistic_antibody	64457107CAN1001  CR108186	A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors	Advanced Solid Neoplasms	2050 - Camperdown; 3168 - Clayton; 4102 - Woolloongabba; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT02829099
NCT02964013	MK-7684-001--7684-001	Phase 1	NOT_RECRUITING	NSW	15/11/2016	13/12/2016	Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Cisplatin; Etoposide; Pembrolizumab; Pembrolizumab + Vibostolimab; Pemetrexed; Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab; Vibostolimab; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	MK-7684-001  7684-001	A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02964013
NCT03286842	D0816C00018	Phase 3	NOT_RECRUITING	NSW	14/09/2017	17/01/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	D0816C00018	A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.	HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 Mutations	NSW 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03286842
NCT03319628	XMT-1536-1	Phase 1/Phase 2	Recruiting	NSW, VIC, SA	24/10/2017	12/12/2017	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	XMT-1536-1	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Non Small Cell Lung Cancer Metastatic; Platinum Resistant Ovarian Cancer	- Heidelberg; 2148 - Blacktown; - Melbourne; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03358875	2018-000245-39--BGB-A317-303	Phase 3	NOT_RECRUITING	NZ	2/12/2017	30/11/2017	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	2018-000245-39  BGB-A317-303	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer	Hamilton; Tauranga; Wellington	https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03363776	2017-002199-24--CA034-001	Phase 1/Phase 2	NOT_RECRUITING	QLD, VIC, NSW	6/12/2017	24/11/2017	BMS-986277; BMS-986277 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus	BMS-986277; BMS-986277 + Nivolumab; BMS-986277 + Nivolumab	anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus	2017-002199-24  CA034-001	Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors	Cancer	4029 - Herston; 3050 - Parkville; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03363776
NCT03386721	2017-003182-94--BP40234	Phase 2	Recruiting	NZ	29/12/2017	19/02/2018	Atezolizumab; Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Gemcitabine; RO-6874281; Vinorelbine	gemcitabine; vinca_alkaloid; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; taxane; antimetabolite; anti-FAP/interleukin-2_fusion_protein	Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel + Gemcitabine + Vinorelbine	anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; taxane; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; gemcitabine	2017-003182-94  BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT03386721
NCT03430063	2017-003684-35--R2810-ONC-1763	Phase 2	NOT_RECRUITING	NSW	9/02/2018	29/05/2018	Cemiplimab; Ipilimumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2017-003684-35  R2810-ONC-1763	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	- Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03656718	2018-001585-42--CA209-8KX	Phase 1/Phase 2	NOT_RECRUITING	NZ	4/09/2018	24/09/2018	Nivolumab; Nivolumab + rHuPH20; rHuPH20	anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	Nivolumab; Nivolumab + rHuPH20; Nivolumab + rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	2018-001585-42  CA209-8KX	Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy	Neoplasms by Site	Wellington; Tauranga; Dunedin	https://clinicaltrials.gov/ct2/show/NCT03656718
NCT03708328	2018-000982-35--NP40435	Phase 1	Recruiting	NZ	17/10/2018	15/10/2018	RO7121661	bispecific_PD-1/TIM-3_antibody	RO7121661	bispecific_PD-1/TIM-3_antibody	2018-000982-35  NP40435	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Non-small Cell Lung Cancer (NSCLC); Solid Tumors; Metastatic Melanoma; Small Cell Lung Cancer (SCLC)	Auckland	https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03735121	BP40657	Phase 1/Phase 2	Recruiting	NZ	8/11/2018	27/12/2018	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Bevacizumab; Carboplatin; Paclitaxel; rHuPH20	anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; taxane	Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Carboplatin; Paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; platinum-based_antineoplastic_agent; taxane	BP40657	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT03735121
NCT03787602	KRT-232-103	Phase 1/Phase 2	Recruiting	QLD	26/12/2018	19/03/2019	Avelumab; Avelumab + Navtemadlin; Navtemadlin	anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab + Navtemadlin; Navtemadlin; Avelumab + Navtemadlin	MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	Merkel Cell Carcinoma	- Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03787602
NCT03811652	D8540C00002	Phase 1	NOT_RECRUITING	VIC	21/01/2019	20/12/2018	Abiraterone; Abiraterone + Enzalutamide; Capecitabine; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Enzalutamide; Fluorouracil; Irinotecan; MEDI7247; Oxaliplatin; Raltitrexed; Tegafur	anti-ASCT2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; topoisomerase_inhibitor; CYP17A1_inhibitor; fluoropyrimidine; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; antimetabolite	Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; MEDI7247	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; Fluorouracil; anti-ASCT2_antibody-drug_conjugate; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	D8540C00002	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Metastatic Castration-resistant Prostate Cancer (mCRPC); Small Cell Lung Cancer (SCLC); Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Non Small Cell Lung Cancer Squamous (NSCLC-Sq)	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03875079	2018-003872-11--BP41054	Phase 1	NOT_RECRUITING	NSW, VIC	14/03/2019	24/06/2019	Pembrolizumab; Pembrolizumab + RO-6874281; RO-6874281	anti-PD-1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein; anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	Pembrolizumab + RO-6874281; Pembrolizumab + RO-6874281	anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	2018-003872-11  BP41054	An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma	Metastatic Melanoma	3000 - Melbourne; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03875079
NCT03878719	C4221011--ARRAY-162-115	Phase 1	NOT_RECRUITING	VIC, NSW, NZ	18/03/2019	13/08/2020	Binimetinib; Binimetinib + Encorafenib; Encorafenib	MEK_inhibitor; BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Binimetinib + Encorafenib; Binimetinib + Encorafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	C4221011  ARRAY-162-115	A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Melanoma	2031 - Sydney; 2145 - Westmead; 3168 - Clayton; Wellington	https://clinicaltrials.gov/ct2/show/NCT03878719
NCT04049617	GS-US-494-5484	Phase 1/Phase 2	NOT_RECRUITING	NZ	8/08/2019	26/08/2019	GS-4224	anti-PD-L1_monoclonal_antibody	GS-4224	anti-PD-L1_monoclonal_antibody	GS-US-494-5484	A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT04049617
NCT04077463	Chrysalis-2	Unknown	Recruiting		4/09/2019	4/09/2019	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Lazertinib; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	73841937NSC1001  CR108656	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT04077463
NCT04109456	IN10018-004-01	Phase 1	Recruiting	SA, WA, VIC, NSW	30/09/2019	16/03/2020	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Cobimetinib; Atezolizumab + Cobimetinib	MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	IN10018-004-01	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma	Metastatic Melanoma	- Melbourne; - Nedlands; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04109456
NCT04164199	2019-002554-23--BGB-A317-290-LTE1	Phase 3	Recruiting	QLD, VIC, NSW, SA, NZ	15/11/2019	19/12/2019	Capecitabine; Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed; Pemetrexed + Tislelizumab; Temozolomide; Tislelizumab	alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; fluoropyrimidine; PARP_inhibitor; PARP_inhibitor + alkylating_agent; anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-PD-1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab; Tislelizumab; Capecitabine + Tislelizumab; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine	2019-002554-23  BGB-A317-290-LTE1	An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies	Advanced Malignancies	4101 - Brisbane; Auckland; 2031 - Randwick; 5011 - Woodville; - East Melbourne; 3168 - Clayton; 2065 - Saint Leonards; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04251117	GT-30	Phase 1/Phase 2	NOT_RECRUITING	NZ	31/01/2020		GNOS-PV02; GNOS-PV02 + INO-9012 + Pembrolizumab; INO-9012; Pembrolizumab	anti-PD-1_monoclonal_antibody; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12; personalized_neoantigen_vaccine	GNOS-PV02 + INO-9012 + Pembrolizumab; GNOS-PV02 + INO-9012 + Pembrolizumab	DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GT-30	An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma	HCC	Auckland	https://clinicaltrials.gov/ct2/show/NCT04251117
NCT04262466	IMC-F106C-101	Unknown	Recruiting	NZ	10/02/2020	25/02/2020	Atezolizumab; Pembrolizumab; Tebentafusp	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting	Atezolizumab; Pembrolizumab; Tebentafusp	anti-CD3/scFv_fusion_protein,gp100-targeting; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	IMC-F106C-101	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers	Select Advanced Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT04262466
NCT04311710	CheckMate-76U	Phase 1/Phase 2	NOT_RECRUITING	VIC, NZ	17/03/2020	22/06/2020	Ipilimumab; Nivolumab; rHuPH20	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; recombinant_human_hyaluronidase	Ipilimumab; Nivolumab; rHuPH20	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	CA209-76U	A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab	Tumor	3144 - Malvern; Auckland	https://clinicaltrials.gov/ct2/show/NCT04311710
NCT04390763	daNIS-1	Phase 2	NOT_RECRUITING	VIC, NSW	18/05/2020	16/10/2020	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Spartalizumab	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-PD-1_monoclonal_antibody; antimetabolite + taxane; taxane; antimetabolite; anti-TGF-beta_monoclonal_antibody	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	2020-000349-14  CNIS793B12201	A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	3000 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04390763
NCT04417621	2020-000873-26--CLXH254C12201	Phase 2	Recruiting	WA, QLD, NSW	4/06/2020	30/10/2020	LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	ERK_inhibitor; MEK_inhibitor; CDK4/6_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2020-000873-26  CLXH254C12201	A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma	Melanoma	6008 - Subiaco; 2060 - North Sydney; 4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT04417621
NCT04427072	GeoMETry-III	Phase 3	NOT_RECRUITING	VIC	11/06/2020	25/09/2020	Capmatinib; Docetaxel	taxane; MET_inhibitor,type_1	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	CINC280A2301	A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14).	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04427072
NCT04438083	CRSP-ONC-003	Phase 1	Recruiting	VIC	18/06/2020	16/06/2020	CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CRSP-ONC-003	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation	Renal Cell Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04438083
NCT04499352	2019-004749-33--1381-0011	Phase 2	Recruiting	NSW	5/08/2020	14/09/2020	BI836880; Ezabenlimab	anti-PD-1_monoclonal_antibody; VEGF/Ang2-blocking_nanobody	BI836880; Ezabenlimab	VEGF/Ang2-blocking_nanobody; anti-PD-1_monoclonal_antibody	2019-004749-33  1381-0011	An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal	Anal Canal Squamous Cell Carcinoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04499352
NCT04524689	CARMEN-LC05	Phase 2	Recruiting	VIC, NSW	24/08/2020	26/10/2020	Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab; Pembrolizumab + Tusamitamab ravtansine; Pemetrexed; Tusamitamab ravtansine	anti-CEACAM5_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab + Tusamitamab ravtansine	anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	U1111-1233-9798  ACT16146	Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	3081 - Heidelberg West; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04524689
NCT04524871	GO42216	Unknown	Recruiting	NZ	24/08/2020	2/11/2020	ADG126; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab; Bevacizumab + RO7247669; RO7247669; TPST-1120; Tiragolumab; Tocilizumab	bispecific_PD-1/LAG3_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor; anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + RO7247669; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + RO7247669	PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	GO42216	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT04524871
NCT04567615	2018-003151-38--CA224-073	Phase 2	Recruiting	NSW, NZ	28/09/2020	4/02/2021	Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-003151-38  CA224-073	A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)	Liver Cancer, Adult; Hepatoma; Liver Cell Carcinoma, Adult; Liver Cell Carcinoma; Hepatocellular Carcinoma	Auckland; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04567615
NCT04612751	2021-000274-28--DS1062-A-U104	Phase 1	Recruiting	SA, NSW	3/11/2020	6/11/2020	Carboplatin; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Durvalumab; Carboplatin; Cisplatin; Datopotamab deruxtecan + Durvalumab	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	2021-000274-28  DS1062-A-U104	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Data-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Advanced or Metastatic NSCLC	2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04619797	SKYSCRAPER-06	Unknown	Recruiting	NZ	6/11/2020	14/12/2020	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Placebo; Tiragolumab	anti-TIGIT_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	2020-002851-39  BO42592	A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Auckland; Palmerston North; Hamilton; Tauranga	https://clinicaltrials.gov/ct2/show/NCT04619797
NCT04626479	2019-003609-84--3475-03A	Phase 1/Phase 2	Recruiting	NZ, NSW, VIC, QLD	12/11/2020	16/12/2020	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2019-003609-84  3475-03A	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A	Carcinoma, Renal Cell	4029 - Herston; Auckland; 3084 - Heidelberg; 2148 - Blacktown; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04626479
NCT04626518	2019-003610-13--3475-03B	Phase 1/Phase 2	Recruiting	QLD, VIC, NSW, NZ	12/11/2020	17/12/2020	Belzutifan; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; MK-4830; MK-4830 + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; anti-ILT4_monoclonal_antibody; VEGF_inhibitor; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor	Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; MK-4830 + Pembrolizumab; Pembrolizumab + Quavonlimab; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; MK-4830 + Pembrolizumab; Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2019-003610-13  3475-03B	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B	Carcinoma, Renal Cell	Auckland; 2217 - Kogarah; 2148 - Blacktown; 3084 - Melbourne; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT04626518
NCT04657991	STARBOARD--C4221016	Unknown	Recruiting	VIC, NZ	8/12/2020	15/01/2021	Binimetinib; Binimetinib + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor; placebo; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody	Binimetinib + Encorafenib + Pembrolizumab; Pembrolizumab; Binimetinib + Encorafenib + Pembrolizumab; Placebo	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; placebo	STARBOARD  C4221016	A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA	Melanoma	Auckland; Manawatu; Canterbury	https://clinicaltrials.gov/ct2/show/NCT04657991
NCT04730869	U1111-1262-0203--RD020132	Unknown	Recruiting	NZ	29/01/2021	26/05/2021	Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	U1111-1262-0203  RD020132	Feasibility, Safety, and Efficacy of a Metabolic Therapy Program in Conjunction With Standard Treatment for Glioblastoma	Glioblastoma	Waikato	https://clinicaltrials.gov/ct2/show/NCT04730869
NCT04745689	TAZMAN	Phase 2	Recruiting	NSW	9/02/2021	23/02/2021	Barasertib; Barasertib + Durvalumab; Carboplatin; Cisplatin; Durvalumab; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; AURKB_inhibitor	Barasertib + Durvalumab; Barasertib + Durvalumab; Carboplatin; Cisplatin; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	D6132C00001	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer	2500 - Wollongong; 2250 - North Gosford	https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04746924	BGB-A317-A1217-302--AdvanTIG-302	Phase 3	Recruiting	SA, WA, QLD, VIC, NSW	10/02/2021	8/06/2021	Ociperlimab; Ociperlimab + Tislelizumab; Pembrolizumab; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Ociperlimab + Tislelizumab; Pembrolizumab; Tislelizumab; Ociperlimab + Tislelizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	BGB-A317-A1217-302  AdvanTIG-302	A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; NSCLC	4224 - Tugun; 3168 - Clayton; 3350 - Ballarat; 2065 - Saint Leonards; 2298 - Waratah; 3021 - St Albans; 4032 - Chermside; 6150 - Murdoch; 2139 - Concord; 5112 - Elizabeth Vale; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04746924
NCT04760288	AcceleRET-MTC	Phase 3	Not yet recruiting	VIC, NSW, SA	18/02/2021		Cabozantinib; Cabozantinib + Vandetanib; Pralsetinib; Vandetanib	MET_inhibitor,type_2 + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; RET_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; MET_inhibitor,type_2 + VEGFR2_inhibitor; AXL_inhibitor + RET_inhibitor; AXL_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; KIT_inhibitor + RET_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; VEGFR2_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor; RET_inhibitor + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; KIT_inhibitor	Cabozantinib + Vandetanib; Pralsetinib; Cabozantinib + Vandetanib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor	2020-005269-15  CO42865	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.	Thyroid Cancer	2109 - Macquarie Park; 5037 - Kurralta Park; 2065 - St. Leonards; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04760288
NCT04784715	D967UC00001	Phase 3	NOT_RECRUITING	QLD, NSW	5/03/2021	26/04/2021	Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	Pertuzumab + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	D967UC00001	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	Metastatic; Breast Cancer; HER2-positive	4066 - Auchenflower; 2065 - St Leonards; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04784715
NCT04811027	TACTI-003	Phase 2	Recruiting	NSW	23/03/2021	27/08/2021	Eftilagimod Alpha; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote- PNC-34  TACTI-003	TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)	HNSCC	2109 - Macquarie Park; 2640 - East Albury	https://clinicaltrials.gov/ct2/show/NCT04811027
NCT04814108	ZN-c3-004	Phase 2	Recruiting	VIC, NSW	24/03/2021	1/06/2021	ZN-C3	WEE1_inhibitor	ZN-C3	WEE1_inhibitor	ZN-c3-004	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma	Uterine Serous Carcinoma	3144 - Malvern; 2065 - St Leonards; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04814108
NCT04875975	2019-004778-25--AIE001	Phase 2	Recruiting	SA	6/05/2021	27/09/2021	Placebo	placebo	Placebo	placebo	2019-004778-25  AIE001	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis	Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT04875975
NCT04876651	PROSTACT	Phase 3	Not yet recruiting	WA	6/05/2021		177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	6009 - Perth; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04985825	I-PACE	Phase 2	Recruiting	WA, NSW, VIC	2/08/2021	16/12/2021	Imgatuzumab	anti-EGFR_monoclonal_antibody	Imgatuzumab	anti-EGFR_monoclonal_antibody	2021-003262-12  PO-001	Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)	Cutaneous Squamous Cell Carcinoma	3000 - Melbourne; 2298 - Waratah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04985825
NCT05155254	KEYNOTE-D18	Phase 3	Recruiting	NSW	13/12/2021	21/12/2021	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2021-004594-32  IO102-IO103-013 / KEYNOTE-D18	An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)	Metastatic Melanoma; Unresectable Melanoma	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05155254
NCT05169684	2021-003990-74--CA022-009	Phase 2	Recruiting	SA, VIC, NSW	27/12/2021	14/02/2022	BMS-986218; BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; taxane; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane	BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab; Docetaxel; BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + taxane; taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + taxane	2021-003990-74  CA022-009	A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	5112 - Elizabeth Vale; 3084 - Heidleberg; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05169684
NCT05309421	KEYNOTE-KN-D36--EVX-01-001	Phase 2	Not yet recruiting	NSW, WA	4/04/2022		EVX-01; EVX-01 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody; autologous_anticancer_vaccine	EVX-01 + Pembrolizumab; EVX-01 + Pembrolizumab	anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	KEYNOTE KN-D36  EVX-01-001	An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma	Melanoma Stage III; Melanoma Stage IV	2065 - Wollstonecraft; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05309421
NCT05440864	NEOTOMA	Unknown	Not yet recruiting		1/07/2022		Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	22-5353	Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)	Hepatocellular Carcinoma		https://clinicaltrials.gov/ct2/show/NCT05440864
NCT05498428	PALOMA-2	Phase 2	Recruiting	WA, VIC	12/08/2022	11/11/2022	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib	EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent	2022-000526-21  CR109264	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer	Carcinoma, Non-small-Cell Lung	6009 - Nedlands; VIC 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05498428
NCT05562830	MK-3475-04A--3475-04A	Phase 1/Phase 2	Recruiting	QLD	3/10/2022	16/11/2022	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-04A  3475-04A	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A	Urothelial Carcinoma	4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05562830
NCT05650203	JS009-002-I	Phase 1	Not yet recruiting	WA, QLD, NSW	14/12/2022		JS-006; JS-006 + JS-009 + Toripalimab; JS-009; Toripalimab	anti-PD-1_monoclonal_antibody; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-CD112R_monoclonal_antibody	JS-006 + JS-009 + Toripalimab; JS-006 + JS-009 + Toripalimab	anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	JS009-002-I	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Combination With Toripalimab and JS006 in Patients With Advanced Malignancies	Primary Condition: Advanced Tumors	4101 - South Brisbane; 6009 - Perth; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05650203
NCT05712356	BOLSTER	Unknown	Recruiting	SA	3/02/2023	24/08/2023	Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	gemcitabine; placebo; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite	Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent; taxane	2023-503740-14  LSTA1-P02	A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors	Oral Cavity Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Hypopharynx; Advanced Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer; Hypopharynx Cancer; Intrahepatic Cholangiocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Larynx Cancer; Bile Duct Cancer; Cancer of the Head and Neck; Oral Cavity Cancer; Squamous Cell Carcinoma of Head and Neck; Extrahepatic Cholangiocarcinoma; Gallbladder Cancer; Head and Neck Squamous Cell Carcinoma; Hypopharynx Squamous Cell Carcinoma; HNSCC; Gallbladder Carcinoma; Squamous Cell Carcinoma of the Oropharynx; Gall Bladder Cancer; Gall Bladder Carcinoma; Oropharynx Cancer; Squamous Cell Carcinoma of the Oral Cavity; Cholangiocarcinoma; Squamous Cell Carcinoma of the Larynx; Oropharynx Squamous Cell Carcinoma	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05712356
NCT05805501	BO43936	Phase 2	Recruiting	SA, QLD	10/04/2023	21/04/2023	Axitinib; Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab; Pembrolizumab; RO7247669; Tiragolumab	KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; VEGFR/PDGFR_inhibitor; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab; Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	BO43936	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	5037 - Kurralta Park; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05805501
NCT05830084	REGO-EWING	Unknown	Recruiting		13/04/2023	27/03/2023	Radiotherapy; Regorafenib	radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Radiotherapy; Regorafenib	radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	2022/3545  2022-002874-10	Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing Sarcoma	Bone Cancer		https://clinicaltrials.gov/ct2/show/NCT05830084
NCT05879822	2022-502716-37-00--INCB-99280-211	Unknown	Recruiting	NZ	30/05/2023		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	2022-502716-37-00  INCB 99280-211	A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Advanced Solid Tumor	Dunedin	https://clinicaltrials.gov/ct2/show/NCT05879822
NCT05904886	SKYSCRAPER-14	Unknown	Recruiting	NZ	15/06/2023	14/09/2023	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Bevacizumab; Placebo; Tiragolumab	anti-TIGIT_monoclonal_antibody; placebo; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2023-503422-39-00  CO44668	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	Wellington; Auckland	https://clinicaltrials.gov/ct2/show/NCT05904886
NCT06117774	DeLLphi-306	Unknown	Not yet recruiting	NSW, VIC, WA	7/11/2023		Placebo; Radiotherapy; Tarlatamab	radiotherapy; placebo; bispecific_T-cell_engager,DLL3-targeting	Tarlatamab; Placebo; Radiotherapy	bispecific_T-cell_engager,DLL3-targeting; placebo; radiotherapy	2023-506235-15  20230016	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer	3168 - Clayton; 2444 - Port Macquarie; 2145 - Westmead; 6150 - Murdoch; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06117774
NCT02051868	InterAACT	Phase 2	Unknown status	NSW	30/01/2014	01/12/2013	Carboplatin; Carboplatin + Paclitaxel; Cisplatin; Cisplatin + Fluorouracil; Fluorouracil; Paclitaxel	platinum-based_antineoplastic_agent + taxane; fluoropyrimidine; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; platinum-based_antineoplastic_agent; taxane	Carboplatin + Paclitaxel; Cisplatin + Fluorouracil; Carboplatin + Paclitaxel; Cisplatin + Fluorouracil	fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; Fluorouracil; fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	2013-001949-13	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Squamous Cell Carcinoma of the Anus	NSW 1450 - Sydney - Margot Gorzeman - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT02051868
NCT02215447	NABNEC	Phase 2	Unknown status	VIC, NSW	11/08/2014		Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane		A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas	Gastrointestinal Neuroendocrine Carcinomas	2065 - St Leonards - Royal North Shore Hospital; 3050 - Parkville - Royal Melbourne Hospital; 3220 - Geelong - Barwon Health	https://clinicaltrials.gov/ct2/show/NCT02215447
NCT02216487	Chime	Phase 2	Unknown status	NSW, VIC	12/08/2014	01/06/2014	Cetuximab; Cetuximab + Irinotecan; Irinotecan	anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor	Cetuximab + Irinotecan; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor		Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	1871 - Sydney - Liverpool Hospital - (Not yet recruiting); 2500 - Wollongong - Southern Medical Day Care Centre - (Not yet recruiting); 3021 - Melbourne - Western General Hospital	https://clinicaltrials.gov/ct2/show/NCT02216487
NCT02254785	NCT02254785	Phase 2	Unknown status	VIC	01/10/2014	01/10/2014	Abiraterone; Abiraterone + Enzalutamide; Cabazitaxel; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Cabazitaxel; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation		A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer	Metastatic Castration-Resistant Prostatic Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Health-Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT02254785
NCT02264678	2014-002233-66	Phase 1/Phase 2	Recruiting	WA	10/10/2014		AZD5305; AZD5305 + Ceralasertib; Carboplatin; Carboplatin + Ceralasertib; Ceralasertib; Ceralasertib + Durvalumab; Ceralasertib + Durvalumab + Olaparib; Ceralasertib + Olaparib; Durvalumab; Olaparib	ATR_inhibitor + PARP_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + PARP_inhibitor; PARP_inhibitor; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ATR_inhibitor + platinum-based_antineoplastic_agent; ATR_inhibitor; platinum-based_antineoplastic_agent	AZD5305 + Ceralasertib; Carboplatin + Ceralasertib; Ceralasertib; Ceralasertib + Durvalumab; Ceralasertib + Durvalumab + Olaparib; Ceralasertib + Olaparib; AZD5305 + Ceralasertib; Carboplatin + Ceralasertib; Ceralasertib + Durvalumab; Ceralasertib + Durvalumab + Olaparib; Ceralasertib + Olaparib	ATR_inhibitor; ATR_inhibitor + PARP_inhibitor; ATR_inhibitor + PARP_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + platinum-based_antineoplastic_agent; ATR_inhibitor + PARP_inhibitor; ATR_inhibitor + PARP_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + platinum-based_antineoplastic_agent	2014-002233-66	A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.	Adv Solid Malig - H&amp;N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	6009 - Nedlands - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT02264678
NCT02408861	AMC-095	Phase 1	Recruiting	NSW	03/04/2015		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461; PAMC-095_R03PAPP01; AMC-095; AMC-095; AMC-095; U01CA121947; UM1CA121947	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Advanced Malignant Solid Neoplasm; Anal Carcinoma; HIV Infection; Kaposi Sarcoma; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma; Unresectable Solid Neoplasm	2010 - Darlinghurst - Saint Vincent's Hospital - (Suspended); 2052 - Sydney - University of New South Wales	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02503033	NCT02503033	Phase 1	Unknown status	QLD, VIC, ACT, NSW, Australian Capital Territory, SA, WA	16/07/2015		HMPL-523	SYK_inhibitor	HMPL-523	SYK_inhibitor		A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies	Hematologic Malignancies	2640 - Albury - Border Medical Oncology Research Unit; 3144 - Melbourne - Cabrini Health; 3220 - Geelong - Barwon Health; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre; 4814 - Townsville - Townsville Hospital; 6000 - Perth - Royal Perth Hospital; Adelaide - Royal Adelaide Hospital; Canberra - Canberra Hospital; Fitzroy - St Vincent's Hospital; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; Heidelberg - Austin Hospital; Liverpool - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT02503033
NCT02513849	NCT02513849	Phase 1	Unknown status		30/07/2015	01/12/2015	Tamoxifen	selective_estrogen_receptor_modulator	Tamoxifen	selective_estrogen_receptor_modulator	163909	A Pilot Study of Tamoxifen in Oesophageal Cancer	Cancer; Gastrointestinal Neoplasms		https://clinicaltrials.gov/ct2/show/NCT02513849
NCT02582697	P3BEP	Phase 3	Unknown status	NSW, QLD, Auckland, VIC, TAS, Palmerston North, WA, SA, NZ	19/10/2015		Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	platinum-based_antineoplastic_agent; granulocyte_colony_stimulating_factor; topoisomerase_inhibitor; antineoplastic_antibiotic	Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	antineoplastic_antibiotic; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	ACTRN12613000496718	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	1023 - Grafton - Starship Children's Hospital; 1142 - Grafton - Auckland Hospital; 2031 - Sydney - Prince of Wales Hospital; 2050 - Sydney - Chris O'Brien Lifehouse; 2065 - St Leonards - Royal North Shore Hospital; 2076 - Wahroonga - SAN Clinical Trials Unit; 2109 - Sydney - Macquarie Cancer Clinical Trials; 2139 - Sydney - Concord Repatriation General Hospital; 2145 - Sydney - Westmead Hospital - (Withdrawn); 2298 - Newcastle - Calvary Mater Newcastle; 2485 - Tweed Heads - Tweed Hospital; 2751 - Sydney - Nepean Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital - (Withdrawn); 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3690 - Wodonga - Border Medical Oncology; 4029 - Brisbane - Royal Brisbane &amp; Women's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 4102 - Woolloongabba - Princess Alexandra; 4442 - Roslyn - Palmerston North Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford Park - Flinders Medical Centre - (Active, not recruiting); 6847 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital; 8011 - Christchurch - Christchurch Hospital; 9054 - Dunedin - Dunedin Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02628067	KEYNOTE-158	Phase 2	Recruiting	NSW	09/12/2015		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	163196; MK-3475-158; KEYNOTE-158; 2022-500397-34-00; 2015-002067-41	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma	North Ryde - MSD Australia	https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2	Recruiting	NSW	30/12/2015		Ribociclib; Ribociclib + Trametinib; Trametinib	MEK_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	Ribociclib + Trametinib; Trametinib; Ribociclib + Trametinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor		Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2145 - Westmead - Westmead Hospital - (Not yet recruiting); 2260 - Wollstonecraft - Melanoma Institute Australia	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02773524	INTEGRATEIIa	Phase 3	Unknown status	Australian Capital Territory, SA, NZ, NT, WA, QLD, TAS, VIC, NSW, ACT	12/05/2016		Placebo; Regorafenib	placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo		A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	0810 - Tiwi - Royal Darwin Hospital; 1023 - Auckland - Auckland Hospital; 2010 - Darlinghurst - St Vincent's Public Hospital; 2031 - Randwick - Prince of Wales Hospital; 2035 - New Lambton Heights - Newcastle Private Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2250 - Gosford - Gosford Hospital; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - The Tweed Hospital; 2640 - Albury - Border Medical Oncology; 3084 - Heidelberg - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 3355 - Wendouree - Ballarat Oncology and Haematology Services; 4029 - Herston - Royal Brisbane and Womens Hospital; 4560 - Sunshine Coast - Sunshine Coast University Hospital; 4814 - Douglas - The Townsville Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 5035 - Ashford - Ashford Cancer Centre Research; 5042 - Bedford Park - Flinders Medical Centre; 6008 - Subiaco - St John of God Hospital Subiaco; 6009 - Nedlands - Sir Charles Gairdner Hospital; 700 - Hobart - Royal Hobart Hospital; Canberra - Canberra Hospital; Saint Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT02773524
NCT02821013	STOP-GAP	Phase 3	Recruiting	South A., SA, Mildura, VIC, QLD, NSW	29/06/2016						UQ-QMP-0001	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Unresectable/Metastatic Melanoma	2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 2450 - Coffs Harbour - Coffs Habour Health Campus - NCCI; 2650 - Wagga Wagga - Riverina Cancer Care Centre Wagga Wagga - (Not yet recruiting); 3004 - Melbourne - Alfred Hospital; 3168 - Clayton - Monash Medical Centre; 3500 - VIC - Mildura Base Public Hospital; 4029 - Herston - Royal Brisbane and Womens Hospital; 4102 - Brisbane - Princess Alexandra Hospital; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 4870 - Cairns - Cairns Hospital; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT02821013
NCT02824965	NCT02824965	Phase 1	Unknown status	VIC	06/07/2016		CAVATAK; Coxsackievirus A21; Coxsackievirus A21 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; virus-based_therapy; oncolytic_Coxsackie_virus,ICAM_overexpressing	Coxsackievirus A21 + Pembrolizumab; CAVATAK; Coxsackievirus A21 + Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; virus-based_therapy		A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC	Non-Small Cell Lung Cancer	3078 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT02824965
NCT02861573	KEYNOTE-365	Phase 1/Phase 2	Recruiting	NSW, NZ	05/08/2016		Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Belzutifan; Belzutifan + Pembrolizumab; Carboplatin; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone; Docetaxel; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide; Enzalutamide + Pembrolizumab; Etoposide; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Prednisone; Vibostolimab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; glucocorticoid; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation; topoisomerase_inhibitor; taxane; CYP17A1_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; PARP_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; HIF2a_inhibitor; VEGF_inhibitor; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab; Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	KEYNOTE-365; MK-3475-365; 2016-002312-41	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland - Merck Sharp &amp; Dohme (New Zealand) Ltd.,; North Ryde - MSD Australia	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02960022	jRCT2031220674	Phase 2	Recruiting	WA, NZ, NSW, VIC	07/11/2016		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Prednisone	glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	2016-001694-32; jRCT2031220674; 2023-510298-33-00	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	2076 - Wahroonga - Site AU61017; 2145 - Westmead - Site AU61004; 2485 - Tweed Heads - Site AU61001 - (Completed); 2640 - Albury - Site AU61014; 3021 - St Albans - Site AU61016; 3165 - East Bentleigh - Site AU61007; 3350 - Ballarat - Site AU61019; 9016 - Dunedin - Site NZ64005; Ashford - Site AU61006 - (Active, not recruiting); Hamilton - Site NZ64001 - (Active, not recruiting); Malvern - Site AU61009 - (Completed); Parkville - Site AU61021; South Brisbane - Site AU61008 - (Completed); V2S 3N5 - Auckland - Site NZ64002; Westmead - Site AU61004 - (Completed)	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT03093116	TRIDENT-1	Phase 1/Phase 2	Recruiting	SA, VIC, NSW	21/03/2017		Repotrectinib	ROS1_inhibitor; TRK_inhibitor,second_generation; ALK_inhibitor,third_generation	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	CA127-1024; TPX-0005-01	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Locally Advanced Solid Tumors; Metastatic Solid Tumors	2050 - Camperdown - Local Institution - 6102; 3000 - Melbourne - Local Institution - 6101; 5042 - Adelaide - Local Institution - 6103	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03127631	RADICALPC	N/A	Recruiting	NSW, SA	20/04/2017		Atorvastatin; Lomustine; Simvastatin	alkylating_agent; HMG-CoA_reductase_inhibitor	Atorvastatin; Lomustine; Simvastatin	HMG-CoA_reductase_inhibitor; alkylating_agent		The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) &amp; A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)	Prostate Cancer; Cardiovascular Disease	2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle - (Not yet recruiting); 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Adelaide - Flinders Medical Center	https://clinicaltrials.gov/ct2/show/NCT03127631
NCT03146468	NIVALLO	Phase 2	Unknown status	VIC	07/05/2017		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody		Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation	Haematological Malignancy	3050 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT03146468
NCT03157128	LIBRETTO-001	Phase 1/Phase 2	Recruiting	VIC, NSW	15/05/2017		Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	J2G-OX-JZJA; LOXO-RET-17001; 2017-000800-59	A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor	2065 - St. Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03175224	SPARTA	Phase 2	Recruiting	VIC, NSW, SA, WA	01/06/2017		Vebreltinib	MET_inhibitor,type_1	Vebreltinib	MET_inhibitor,type_1		Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Solid Tumors; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; NSCLC; Lung Cancer; Brain Tumor; Glioblastoma Multiforme; EGFR Gene Mutation; MET Amplification; HGF; Thyroid Cancer; Pancreatic Cancer; Colon Cancer; MET Alteration; MET Fusion; Exon 14 Skipping	Albury - Border Medical Oncology; Bedford Park - Flinders Medical Centre; Frankston - Peninsula and Southeast Oncology; Melbourne - St Vincents Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary Central Districts Hospita - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03177239	UNISoN	Phase 2	Unknown status	SA, WA, QLD, VIC, NSW	04/06/2017		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody		A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).	Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11 Translocation Carcinoma	2010 - Darlinghurst - St Vincents Hospital; 2031 - Randwick - Prince of Wales Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2086 - Frenchs Forest - Northern Cancer Institute; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St. George Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 2340 - Tamworth - Tamworth Hospital - North West Cancer Centre; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2460 - Albury - Border Medical Oncology; 2560 - Campbelltown - Campbelltown Hospital; 3128 - Box Hill - Box Hill Hospital - Eastern Health; 3168 - Clayton - Monash Medical Centre; 3355 - Ballarat - Ballarat Oncology &amp; Haematology Services; 4000 - Brisbane - Royal Brisbane &amp; Women's Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 5000 - Adelaide - Flinders Medical Centre; 5037 - Adelaide - Ashford Cancer Centre; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03177239
NCT03178552	B-FAST	Phase 2/Phase 3	Recruiting	SA, NZ, WA, QLD, VIC, NSW	05/06/2017		Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cobimetinib; Divarasib; Divarasib + Docetaxel; Docetaxel; Entrectinib; Gemcitabine; Pemetrexed; Vemurafenib	ALK_inhibitor,second_generation; anti-PD-L1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; taxane; MEK_inhibitor; TRK_inhibitor,first_generation; KRAS_G12C_inhibitor; gemcitabine; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor; anti-VEGF_monoclonal_antibody; ALK_inhibitor,third_generation; KRAS_G12C_inhibitor + taxane; ROS1_inhibitor; antimetabolite	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Divarasib + Docetaxel; Entrectinib; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Divarasib + Docetaxel	ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + taxane; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2017-000076-28	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital; 2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology - (Active, not recruiting); 3084 - Heidelberg - Austin Hospital; Medical Oncology; 4032 - Chermside - The Prince Charles Hospital; Oncology Dept. - (Completed); 5037 - Kurralta Park - Ashford Cancer Center Research - (Terminated); 6009 - Nedlands - Sir Charles Gairdner Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT03188159	NCT03188159	Phase 2	Unknown status	SA	14/06/2017		Vinorelbine	vinca_alkaloid	Vinorelbine	vinca_alkaloid		Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)	Ovarian Cancer; Fallopian Tube Cancer	Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03188159
NCT03212404	NCT03212404	Phase 1	Recruiting	VIC, QLD, NSW, NZ	06/07/2017		Cosibelimab	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody		A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Malignant Mesothelioma, Advanced; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Classical Hodgkin Lymphoma; Cutaneous Squamous Cell Carcinoma; Non Hodgkin Lymphoma; Endometrial Cancer	2500 - Wollongong - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site; 4101 - South Brisbane - Research Site; 4102 - Woolloongabba - Research Site; 4120 - Greenslopes - Research Site; 4217 - Benowa - Research Site; 4556 - Buderim - Research Site; 8140 - Christchurch - Research Site	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03261011	NCT03261011	Phase 1	Unknown status	WA, VIC	22/08/2017		AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody		A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Advanced Cancer	3002 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research/Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT03261011
NCT03278717	ICON9	Phase 3	Recruiting	VIC, TAS, QLD, NSW, ACT, NZ, SA	07/09/2017		Cediranib; Cediranib + Olaparib; Olaparib	VEGF_inhibitor; PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor	Cediranib + Olaparib; Olaparib; Cediranib + Olaparib	PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor; PARP_inhibitor + VEGF_inhibitor		International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy	Ovarian Cancer	Albury - Border Medical Oncology; Auckland - Auckland City Hospital; Bedford Park - Flinders Medical Centre; Benowa - Pindara Private Hospital; Camperdown - Chris O'Brien Lifehouse; Canberra - Canberra Hospital; Christchurch - Christchurch Hospital; Clayton - Monash Health; Gosford - Gosford Hospital; Hobart - Royal Hobart Hospital; Melbourne - Peter MacCallum Cancer Centre; South Brisbane - ICON Cancer Centre; South Brisbane - Mater Cancer Centre; Sydney - Calvary Mater Hospital; Sydney - Campbelltown Hospital; Sydney - Prince of Wales Hospital; Townsville - Townsville Hospital; Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03278717
NCT03319940	NCT03319940	Phase 1	Recruiting	NSW	19/10/2017		Pembrolizumab; Pembrolizumab + Tarlatamab; Tarlatamab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; bispecific_T-cell_engager,DLL3-targeting	Pembrolizumab + Tarlatamab; Tarlatamab; Pembrolizumab + Tarlatamab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting		A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)	Small Cell Lung Carcinoma	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03337698	Morpheus-Lung	Phase 1/Phase 2	Recruiting	NSW, VIC	07/11/2017		Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Camonsertib; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Camonsertib; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab + Zanzalintinib; Bevacizumab; Camonsertib; Carboplatin; Cibisatamab; Ciforadenant; Cobimetinib; Docetaxel; Evolocumab; Gemcitabine; Ipatasertib; Linagliptin; Pemetrexed; Radiotherapy; Sacituzumab Govitecan; Tiragolumab; Tocilizumab; Zanzalintinib	anti-TIGIT_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; gemcitabine; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-Trop2_antibody-drug_conjugate; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PCSK9_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; radiotherapy; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; pan-AKT_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; ATR_inhibitor; antimetabolite; anti-IL-6_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Camonsertib; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Camonsertib; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab + Zanzalintinib; Docetaxel; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Camonsertib; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Camonsertib; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab + Zanzalintinib; Tocilizumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; taxane; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; gemcitabine	2017-001267-21	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown - Blacktown Hospital; 3002 - East Melbourne - Peter Mac Callum Cancer Center - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03337698
NCT03391778	ADP-0000-002	Phase 1	Recruiting	VIC	02/01/2018						ADP-0000-002	Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies	Neoplasms	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT03391778
NCT03424005	Morpheus-panBC	Phase 1/Phase 2	Recruiting	WA, VIC	05/02/2018		Abemaciclib; Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Fulvestrant; Fulvestrant + Inavolisib + Ribociclib; Gemcitabine; Inavolisib; Inavolisib + Trastuzumab Deruxtecan; Ipatasertib; Ladiratuzumab Vedotin; Nab-paclitaxel; Ribociclib; Sacituzumab Govitecan; Selicrelumab; Tocilizumab; Trastuzumab Deruxtecan	anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-LIV1_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; gemcitabine; fluoropyrimidine; anti-Trop2_antibody-drug_conjugate; macrocyclic_ketone_analogue; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-CD40_agonistic_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; PI3K_alpha_inhibitor; CDK4/6_inhibitor; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; antimetabolite; anti-IL-6_monoclonal_antibody	Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Trastuzumab Deruxtecan; Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Trastuzumab Deruxtecan	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; fluoropyrimidine; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; gemcitabine	2017-002038-21	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)	Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne; 6150 - Murdoch - Fiona Stanley Hospital - Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03448042	NCT03448042	Phase 1	Recruiting	VIC	26/02/2018		Runimotamab; Tocilizumab; Trastuzumab	anti-ERBB2_monoclonal_antibody; anti-IL-6_monoclonal_antibody; bispecific_T-cell_engager,ERBB2-targeting	Runimotamab; Tocilizumab; Trastuzumab	bispecific_T-cell_engager,ERBB2-targeting; anti-ERBB2_monoclonal_antibody; anti-IL-6_monoclonal_antibody		A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03448042
NCT03486873	KEYNOTE-587	Phase 3	Recruiting	QLD, VIC, Canterbury, NSW, SA, NZ, Waikato, WA	29/03/2018		Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-3475-587; KEYNOTE-587; 195006; PHRR210209-002881; 2022-500255-24-00; jRCT2080224921; 2017-004417-42	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Solid Tumors; Hematologic Malignancies	1023 - Auckland - Auckland City Hospital ( Site 1503); 2050 - Camperdown - Chris OBrien Lifehouse ( Site 3003); 2050 - Camperdown - Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016); 2060 - North Sydney - Mater Hospital Sydney ( Site 3007); 2065 - St Leonards - Royal North Shore Hospital-Medical Oncology Clinical Trials ( Site 3025); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 3001); 2109 - Macquarie University - Macquarie University ( Site 3010); 2145 - Westmead - Westmead Hospital ( Site 3000); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 3021); 2298 - Waratah - Calvary Mater Newcastle ( Site 3005); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3020); 2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 3027); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3008); 3021 - St Albans - Western Health-Sunshine &amp; Footscray Hospitals ( Site 3023); 3065 - Melbourne - St Vincent's Hospital-Oncology Clinical Trials ( Site 3018); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3004); 3168 - Clayton - Monash Health ( Site 3015); 3204 - Hamilton - Waikato Hospital ( Site 1502); 3355 - Wendouree - Ballarat Oncology &amp; Haematology Services ( Site 3022); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 3009); 4101 - Brisbane - Mater Misericordiae Limited-Medical Oncology ( Site 3019); 4102 - Woolloongabba - Princess Alexandra Hospital ( Site 3002); 4120 - Brisbane - Gallipoli Medical Research Foundation ( Site 3011); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 3012); 4814 - Townsville - The Townsville Hospital ( Site 3017); 5000 - Adelaide - Royal Adelaide Hospital ( Site 3014); 5011 - Woodville - The Queen Elizabeth Hospital ( Site 3026); 6008 - Subiaco - St John of God Subiaco Hospital ( Site 3013); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 3006); 6021 - Wellington - Capital &amp; Coast District Health Board - Wellington Hospital ( Site 1501); 8011 - Christchurch - Canterbury Regional Cancer &amp; Blood Service ( Site 1500)	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03497767	OUTRUN	Phase 2	Recruiting	SA, WA, VIC, QLD, NSW	12/04/2018		Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation		A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	2002 - Sydney - Liverpool Hospital; 2010 - Sydney - St. Vincents Hospital - (Not yet recruiting); 2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Hospital; 2217 - Sydney - St George Hospital; 2298 - Newcastle - Calvary Mater; 3002 - Melbourne - Peter MacCallum Cancer Center; 3175 - Melbourne - Monash Health; 4102 - Brisbane - Princess Alexandra Hospital; 4120 - Brisbane - ICON Cancer Centre Greenslopes; Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Perth - Sir Charles Gairdner - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03497767
NCT03522064	HiTeCH	Phase 2	Recruiting	NSW	10/05/2018		Carboplatin; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone	Carboplatin; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone		High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Castration-resistant Prostate Cancer; Homologous Recombination Deficiency	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03529526	NCT03529526	Phase 1	Unknown status	QLD	17/05/2018		KN046	bispecific_PD-L1/CTLA-4_antibody	KN046	bispecific_PD-L1/CTLA-4_antibody		An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4125 - Southport - ICON Cancer Care	https://clinicaltrials.gov/ct2/show/NCT03529526
NCT03537482	NCT03537482	Early Phase 1	Recruiting	VIC	15/05/2018		Lisaftoclax	Bcl2_inhibitor	Lisaftoclax	Bcl2_inhibitor		A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	3065 - Fitzroy - St. Vincent Hospital; 3121 - Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03557619	NCT03557619	Phase 1	Recruiting	VIC	14/06/2018		Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor		A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	3002 - East Melbourne - Peter MacCallum Cancer Centre-East Melbourne /ID# 225247	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03564340	2019-003298-24	Phase 1/Phase 2	Recruiting	VIC, NSW	08/06/2018		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2019-003298-24	A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers	Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer	3000 - Melbourne - Peter MacCallum Cancer Center; NSW 2031 - Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT03564340
NCT03611868	Keynote-MK-3475-B66	Phase 1/Phase 2	Recruiting	SA, NSW, VIC, QLD	27/07/2018		Alrizomadlin; Alrizomadlin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; MDM2_inhibitor; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; p53-HDM2_interaction_inhibitor	Alrizomadlin + Pembrolizumab; Alrizomadlin + Pembrolizumab	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	Keynote MK-3475-B66	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutation; MDM2 Gene Mutation; MPNST; Cutaneous Melanoma; Mucosal Melanoma; Malignant Peripheral Nerve Sheath Tumors	4101 - South Brisbane - Queensland Children's Hospital; 5042 - Bedford Park - Flinders Medical Centre; Brisbane - Metro South Hospital and Health Services via Princess Alexandra Hospital; Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT03611868
NCT03674567	KEYNOTE-877	Phase 1/Phase 2	Recruiting	VIC, WA	14/09/2018		FLX475; FLX475 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; CCR4_inhibitor; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	FLX475; FLX475 + Pembrolizumab; FLX475 + Pembrolizumab	CCR4_inhibitor; CCR4_inhibitor + anti-PD-1_monoclonal_antibody; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	KEYNOTE-877	Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	Advanced Cancer	3084 - Heidelberg - Austin Hospital - (Completed); 6009 - Nedlands - Linear Clinical Research Limited - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03674567
NCT03685448	UNICAB	Phase 2	Recruiting	NSW, VIC, QLD, SA	25/09/2018		Cabozantinib	MET_inhibitor,type_2; VEGFR2_inhibitor; AXL_inhibitor; ROS1_inhibitor; RET_inhibitor; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor	Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor		A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)	Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma	2109 - Macquarie Park - Macquarie University Hospital; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2560 - Campbelltown - Campbelltown Hospital; 3128 - Box Hill - Box Hill Hospital - Eastern Health; 3630 - Shepparton - Goulburn Valley Health, as a satellite site under the supervision of Border Medical Oncology Research Unit, via the Tele-trial model; 5037 - Kurralta Park - Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA; 5042 - Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre; Herston - Royal Brisbane &amp; Women's Hospital; Kogarah - St George Hospital; Newcastle - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT03685448
NCT03742895	LYNK-002	Phase 2	Recruiting	WA, NSW	14/11/2018		Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	MK-7339-002; LYNK-002; 194694; 2018-003007-19	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	Advanced Solid Neoplasms	2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 2200); 2444 - Port Macquarie - MNCCI Port Macquarie Base Hospital ( Site 2201) - (Completed); 6009 - Nedlands - Linear Clinical Research Ltd ( Site 2202) - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03742895
NCT03744468	U1111-1278-0027	Phase 1/Phase 2	Recruiting	NSW, QLD, VIC, WA, SA	15/11/2018		BGB-A425; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody	BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	U1111-1278-0027; 2022-500694-14	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2	2170 - Liverpool - Sydney Southwest Private Hospital; 3021 - St Albans - Western Health Sunshine Hospital; 3128 - Box Hill - Box Hill Hospital; 3144 - Malvern - Cabrini Research and Education Institute; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast Hospital and Health Service; 5006 - North Adelaide - Calvary North Adelaide Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT03744468
NCT03746431	NCT03746431	Phase 1/Phase 2	Recruiting	SA, VIC	15/11/2018		FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate		A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours	Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma	3084 - Heidelberg - Austin Hospital; 5000 - Adelaide - Royal Adelaide Hospital - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03768063	IMbrella-B	Phase 3	Recruiting	NSW, QLD, VIC	05/12/2018		Alectinib; Atezolizumab; Bevacizumab; Cabozantinib; Cobimetinib; Emactuzumab; Enzalutamide; Niraparib; Paclitaxel; Pembrolizumab; Pemetrexed; Rucaparib; Sunitinib; Vemurafenib; Venetoclax	ALK_inhibitor,second_generation; AXL_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; taxane; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; MEK_inhibitor; KIT_inhibitor,first_generation; VEGFR_inhibitor; VEGFR2_inhibitor; PARP_inhibitor; BRAF_V600_inhibitor; anti-CSF1R_monoclonal_antibody; anti-VEGF_monoclonal_antibody; PDGFR_inhibitor; ROS1_inhibitor; RET_inhibitor; antimetabolite; KIT_inhibitor; Bcl2_inhibitor	Atezolizumab; Alectinib; Bevacizumab; Cabozantinib; Cobimetinib; Emactuzumab; Enzalutamide; Niraparib; Paclitaxel; Pembrolizumab; Pemetrexed; Rucaparib; Sunitinib; Vemurafenib; Venetoclax	anti-PD-L1_monoclonal_antibody; ALK_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BRAF_V600_inhibitor; Bcl2_inhibitor; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_2; PARP_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; anti-CSF1R_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; antimetabolite; taxane		An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)	Cancer	2010 - Darlinghurst - St Vincent'S Hospital - (Active, not recruiting); 2050 - Camperdown - Chris O'Brien Lifehouse - (Withdrawn); 3144 - Malvern - Cabrini Hospital Malvern - (Withdrawn); 4032 - Chermside - The Prince Charles Hospital; Oncology Dept. - (Withdrawn); 4810 - Townsville - Townsville Hospital - (Active, not recruiting); 4814 - Douglas - The Townsville Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03768063
NCT03806764	CReSCT	N/A	Enrolling by invitation	VIC	15/01/2019							Assessing the Impact and Complications of Cytomegalovirus (CMV) Reactivation in a Multi-site Study of Allogeneic Haematopoietic Stem Cell Transplant Recipient	Cytomegalovirus Infections; Haematological Malignancy; Organ or Tissue Transplant; Complications; Immune Suppression	3050 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT03806764
NCT03816163	CTR20220914	Phase 2	Recruiting	NSW, VIC, WA, SA	23/01/2019		Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Nab-paclitaxel; Zolbetuximab	gemcitabine; anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; antimetabolite; taxane; anti-CLDN18.2_monoclonal_antibody	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab	anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	2018-002551-15; CTR20220914	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma	5006 - North Adelaide - Site AU61002 - (Withdrawn); 5XRF+WX - Fitzroy - Site AU61005; HVGM+3C - Wollongong - Site AU61007; NSW 2250 - Gosford - Site AU61008; VIC 3280 - Warrnambool - Site AU61006	https://clinicaltrials.gov/ct2/show/NCT03816163
NCT03821935	2018-004303-40	Phase 1	Recruiting	NSW, QLD	28/01/2019		ABBV-151; Budigalimab	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody	Budigalimab; ABBV-151	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody	2018-004303-40	A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors Cancer	2050 - Camperdown - Chris O'Brien Lifehouse /ID# 213236; 4101 - South Brisbane - Icon Cancer Centre /ID# 224961	https://clinicaltrials.gov/ct2/show/NCT03821935
NCT03833154	PACIFIC-4	Phase 3	Recruiting	SA, NSW, VIC	05/02/2019		Durvalumab; Osimertinib; Placebo; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,third_generation; placebo	Durvalumab; Osimertinib; Placebo; Radiotherapy	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	2018-002572-41	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown - Research Site; 3168 - Clayton - Research Site; 5112 - Elizabeth Vale - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03833154
NCT03874884	LuPARP	Phase 1	Recruiting	VIC, NSW	12/03/2019		Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Olaparib; Olaparib	radioligand,PSMA-targeting; PARP_inhibitor; PARP_inhibitor + radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan + Olaparib; Lu-177 vipivotide tetraxetan + Olaparib	PARP_inhibitor + radioligand,PSMA-targeting; PARP_inhibitor + radioligand,PSMA-targeting		177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03874884
NCT03900442	NCT03900442	Phase 1	Unknown status	VIC	30/03/2019		PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor		Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer; PTCL	3002 - Melbourne - Epworth Healthcare; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03900884	PALVEN	Phase 1	Recruiting	VIC	02/04/2019		Letrozole; Letrozole + Palbociclib + Venetoclax; Palbociclib; Venetoclax	aromatase_inhibitor; CDK4/6_inhibitor; Bcl2_inhibitor; Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	Letrozole + Palbociclib + Venetoclax; Letrozole + Palbociclib + Venetoclax	Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor; Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor		A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer	Breast Neoplasm Female	3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Melbourne - Royal Melbourne Hospital; 3084 - Melbourne - Austin Health	https://clinicaltrials.gov/ct2/show/NCT03900884
NCT03905148	NCT03905148	Phase 1	Recruiting	VIC, NSW, WA	04/04/2019		Lifirafenib; Lifirafenib + Mirdametinib; Mirdametinib	MEK_inhibitor; EGFR/RAF_dimer_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor	Lifirafenib + Mirdametinib; Lifirafenib + Mirdametinib	EGFR/RAF_dimer_inhibitor + MEK_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor		A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors	Solid Tumor, Adult	2031 - Randwick - The Prince of Wales Private Hospital - Specialist Medical Randwick; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03905148
NCT03906331	J2G-OX-Y001		Available	NSW, QLD, WA, NZ	04/04/2019		Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	Selpercatinib EAP; J2G-OX-Y001	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	2050 - Camperdown - NSW Health - Sydney Local Health District - (Available); 2065 - St. Leonards - Royal North Shore Hospital - (Available); 4032 - Chermside - Queensland Health - Metro North Hospital and Health Service - (Available); 6009 - Nedlands - Linear Clinical Research - (Available); 91346 - Auckland - University of Auckland - (Available)	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03947385	NCT03947385	Phase 1/Phase 2	Recruiting	NSW	09/05/2019		Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib	MEK_inhibitor; PKC_inhibitor; MEK_inhibitor + PKC_inhibitor; ALK_inhibitor,first_generation; PKC_inhibitor + ROS1_inhibitor; MET_inhibitor,type_1; ROS1_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib; Binimetinib + Darovasertib; Crizotinib + Darovasertib	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; ROS1_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor		A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors	Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03964233	2019-001173-84	Phase 1	Recruiting	WA	24/05/2019		BI 754111; BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin; Brigimadlin + Ezabenlimab; Ezabenlimab	anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; MDM2_inhibitor; anti-LAG3_monoclonal_antibody	BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin + Ezabenlimab; BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin + Ezabenlimab	MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody	2019-001173-84	A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091 (Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors	Neoplasms	6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03964233
NCT03970447	GBM-AGILE	Phase 2/Phase 3	Recruiting	SA, VIC, NSW	30/05/2019		Lomustine; Paxalisib; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083; Regorafenib; Temozolomide; VAL-083	alkylating_agent; dual_PI3K/mTOR_inhibitor; arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent + radiotherapy; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; radiotherapy	Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083; Temozolomide; Lomustine; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + radiotherapy; arginine_deiminase-polyethylene_glycol_conjugate; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + radiotherapy		GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM	Glioblastoma	2065 - St Leonards - Northern Sydney Cancer Centre/Royal North Shore Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3084 - Heidelberg - Austin Health; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03970447
NCT03974022	NCT03974022	Phase 1/Phase 2	Recruiting	VIC, NSW, WA	03/06/2019		Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective		A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	Non-Small Cell Lung Cancer	Blacktown - Blacktown Hospital; Camperdown - Chris O'Brien Lifehouse; Heidelberg - Austin Hospital; Kogarah - St George Hospital; North Melbourne - Peter MacCallum Cancer Centre - East Melbourne; Perth - Linear Cancer trials; Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT03975647	NCT03975647	Phase 3	Recruiting	VIC, Other, NSW, WA	04/06/2019		Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Tucatinib	anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; placebo; ERBB2_inhibitor,third_generation	Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Placebo; Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; placebo		Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)	HER2-positive Breast Cancer	2060 - Sydney - Mater Hospital - (Active, not recruiting); 2145 - Westmead - Westmead Hospital - (Active, not recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre - (Active, not recruiting); 3084 - Melbourne - Austin Health - (Active, not recruiting); 6009 - Nedlands - Breast Cancer Research Centre - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03975647
NCT04008030	CheckMate-8HW	Phase 3	Recruiting	SA, NSW, VIC, QLD	02/07/2019		Bevacizumab; Cetuximab; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin	fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Bevacizumab; Cetuximab; Fluorouracil; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Oxaliplatin	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2018-000040-26	A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2145 - Westmead - Westmead Hospital; 3084 - Heidelberg - Local Institution - 0017; 3168 - Clayton - Monash Medical Centre Clayton; 4102 - Woolloongabba - Local Institution - 0053; 5112 - Elizabeth Vale - Calvary Central Districts Hospital	https://clinicaltrials.gov/ct2/show/NCT04008030
NCT04047290	NCT04047290	Phase 1	Recruiting	NSW, VIC, QLD, SA	05/08/2019		Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody	Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody		A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors	Neoplasms Malignant	Albury - Border Medical Oncology - (Completed); Clayton - Monash Health; Kurralta Park - Adelaide Cancer Centre; Melbourne - Peter MacCallum Cancer Centre; Randwick - Scientia Clinical Research Ltd; South Brisbane - ICON Cancer Foundation; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT04047290
NCT04052971	NCT04052971	Phase 1	Recruiting	NSW, WA	08/08/2019		ABN401	MET_inhibitor,type_1	ABN401	MET_inhibitor,type_1		A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Pilot Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research; 2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - ST George Private Hospital; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04052971
NCT04064060	U1111-1235-8123	Phase 3	Recruiting	NSW, VIC, QLD, SA	19/08/2019		Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	U1111-1235-8123; 2018-002915-93	A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis	2050 - Camperdown - Royal Prince Alfred Hospital; 3168 - Clayton - Local Institution - 102 - (Active, not recruiting); 4101 - South Brisbane - Local Institution - 100 - (Completed); 5000 - Adelaide - Local Institution - 103	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04106492	2020-0185	Phase 1/Phase 2	Recruiting	NSW, SA	25/09/2019		SQ3370	anthracycline	SQ3370	anthracycline	2020-0185	A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - Sydney - Royal North Shore Hospital; 5000 - Adelaide - Cancer Research Institute	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04122339	NCT04122339	Phase 1	Unknown status	WA	08/10/2019		MAX-10181	PD-L1_inhibitor,oral	MAX-10181	PD-L1_inhibitor,oral		A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor	Solid Tumor	6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04122339
NCT04140526	PRESERVE-001	Phase 1/Phase 2	Recruiting	QLD, NSW, SA	24/10/2019		ONC392; ONC392 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ONC392; ONC392 + Pembrolizumab; ONC392 + Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4R44CA250824-02; 20193108	Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)	Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma	2305 - New Lambton Heights - Newcastle Private Hospital; 4120 - Southport - Tasman Oncology Research; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04140526
NCT04170283	NCT04170283	Phase 3	Enrolling by invitation	VIC, QLD, WA	19/11/2019		Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	anti-PD-1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody	Tislelizumab + Zanubrutinib; Zanubrutinib; Tislelizumab + Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + anti-PD-1_monoclonal_antibody		An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	0622 - Takapuna - North Shore Hospital; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Health; 4102 - Brisbane - Princess Alexandra Hospital; 6000 - Perth - Royal Perth Hospital	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04185883	NCT04185883	Phase 1/Phase 2	Recruiting	NSW, QLD, WA, SA	03/12/2019		AMG 404; AMG 404 + Sotorasib; Afatinib; Afatinib + Sotorasib; Atezolizumab; Atezolizumab + Sotorasib; BI 1701963; BI 1701963 + Sotorasib; Bevacizumab; Bevacizumab + Sotorasib; Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Docetaxel; Everolimus; Everolimus + Sotorasib; Paclitaxel; Palbociclib; Palbociclib + Sotorasib; Panitumumab; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab; Pembrolizumab + Sotorasib; Pemetrexed; RMC-4630; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; TNO155; Trametinib	SOS1-KRAS_inhibitor; mTORC1_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; platinum-based_antineoplastic_agent; taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,second_generation; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; SHP2_inhibitor; CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; anti-EGFR_monoclonal_antibody; antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib + TNO155	CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor		A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation	2065 - St Leonards - GenesisCare -North Shore Oncology; 2747 - Kingswood - Nepean Cancer Centre; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 5011 - Woodville South - The Queen Elizabeth Hospital; 6008 - Subiaco - St John of God Healthcare	https://clinicaltrials.gov/ct2/show/NCT04185883
NCT04221035	HR-NBL2	Phase 3	Recruiting	NZ, Randwick, WA, VIC, NSW	06/01/2020		Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Radiotherapy; Temozolomide; Thiotepa; Vincristine	alkylating_agent; vinca_alkaloid; platinum-based_antineoplastic_agent; anti-GD2_monoclonal_antibody; anthracycline; topoisomerase_inhibitor; radiotherapy; doxorubicin	Radiotherapy; Thiotepa; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Temozolomide; Vincristine	alkylating_agent; radiotherapy; anthracycline; anti-GD2_monoclonal_antibody; doxorubicin; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; vinca_alkaloid	2019/2894	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	High-Risk Neuroblastoma	NSW, 2031 - Sydney - Australian and New Zealand Children's Hematology/oncology Group - (Active, not recruiting); NSW, 2031 - Sydney - Sydney children Hospital - (Not yet recruiting); NSW, 2031 - Sydney - sydney children Hospital - (Not yet recruiting); NSW, 2145, - Westmead - Cancer Centre for Children, The Children's Hospital - (Not yet recruiting); NSW, 2305 - New Lambton Heights - Children's Cancer &amp; Haematology Services, John Hunter Children's Hospital - (Not yet recruiting); VIC 3168 - Clayton - Children's Cancer Centre, Monash Children's Hospital - (Not yet recruiting); WA, 6009 - Nedlands - Oncology/Haematology Department, Perth Children's Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04221035
NCT04221542	2021-005052-11	Phase 1	Recruiting	VIC, NSW	06/01/2020		AMG 509; AMG 509 + Abiraterone + Enzalutamide; Abiraterone; Enzalutamide	bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor	AMG 509; AMG 509 + Abiraterone + Enzalutamide; AMG 509 + Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting	2021-005052-11; 2023-504361-23	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04223856	EV-302	Phase 3	Recruiting	SA, NSW, QLD, VIC	08/01/2020		Carboplatin; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Enfortumab Vedotin; Enfortumab Vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-Nectin-4_monoclonal_antibody; gemcitabine; anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab	anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-Nectin-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2019-004542-15; MK-3475-A39; KEYNOTE KN-A39; jRCT2031200284; CTR20220974	An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Urothelial Cancer	2109 - Macquarie Park - Site AUS61002 - (Active, not recruiting); 3084 - Heidelberg - Site AUS61004 - (Active, not recruiting); 3128 - Box Hill - Site AU61003 - (Completed); 4101 - South Brisbane - Site AU61005 - (Active, not recruiting); 4814 - Douglas - Site AUS61001 - (Active, not recruiting); 5112 - South Australia - Site AUS61006 - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04223856
NCT04242199	NCT04242199	Phase 1	Recruiting	NSW, VIC, WA	23/01/2020		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral		A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Advanced Solid Tumor; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma; Cervical Cancer; HepatoCellular Carcinoma; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma	02050 - Camperdown - Chris Obrien Lifehouse; 03004 - Melbourne - Nucleus Network Pty Ltd - (Completed); 03084 - Heidelberg - Austin Hospital - (Completed); 06009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04242199
NCT04249843	NCT04249843	Phase 1	Recruiting	Perth, WA, VIC, NSW	29/01/2020		BGB-3245	RAF_dimer_inhibitor	BGB-3245	RAF_dimer_inhibitor		A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors	Solid Tumor; B-Raf Mutation-Related Tumors	2010 - Melbourne - Peter MacCallum Cancer Centre; 2010 - Sydney - The Kinghorn Cancer Centre, St Vincent Hospital Sydney; 2148 - Blacktown - Blacktown Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04249843
NCT04250155	NCT04250155	Phase 1	Recruiting	VIC	29/01/2020		Atezolizumab; Atezolizumab + XmAb24306; XmAb24306	anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	Atezolizumab + XmAb24306; XmAb24306; Atezolizumab + XmAb24306	IL-15/IL-15R_Fc-fusion_protein; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody		A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	3002 - East Melbourne - Peter Mac Callum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04250155
NCT04277637	CTR20231287	Phase 1	Recruiting	QLD, VIC, NSW, SA, NZ, WA	18/02/2020		BGB-11417; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib; Obinutuzumab; Zanubrutinib	BTK_inhibitor; anti-CD20_monoclonal_antibody; BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody; Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor	BGB-11417; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody; Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody	CTR20231287	A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies	Mature B-Cell Malignancies	0622 - Takapuna - North Shore Hospital; 1023 - Auckland - Auckland City Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2800 - Orange - Orange Health Service (Central West Cancer Care Centre); 3000 - Melbourne - Peter Maccallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Health; 4217 - Benowa - Pindara Private Hospital; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford PK - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research; 6021 - Wellington - Wellington Regional Hospital (Ccdhb)	https://clinicaltrials.gov/ct2/show/NCT04277637
NCT04282018	NCT04282018	Phase 1/Phase 2	Recruiting	VIC, QLD, NSW, SA, WA	20/02/2020		BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; Tislelizumab; Zanubrutinib	anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor; BTK_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + PI3K_delta_inhibitor	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody		A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Advanced Solid Tumor	2010 - Darlinghurst - Saint Vincents Hospital Sydney; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3168 - Clayton - Monash Health; 4120 - Greenslopes - Gallipoli Medical Research Foundation; 4217 - Benowa - Pindara Private Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6005 - West Perth - Perth Blood Institute	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04305249	ERASER	Phase 1	Recruiting	VIC, NSW	10/03/2020		ATG-017; ATG-017 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; ERK_inhibitor; ERK_inhibitor + anti-PD-1_monoclonal_antibody	ATG-017; ATG-017 + Nivolumab; ATG-017 + Nivolumab	ERK_inhibitor; ERK_inhibitor + anti-PD-1_monoclonal_antibody; ERK_inhibitor + anti-PD-1_monoclonal_antibody		A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies	Solid Tumor; Hematological Malignancy	3002 - East Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Hospital; 3084 - Heidelberg - Austin Hospital; Randwick - Scientia Clinical Research; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04305249
NCT04402073	PersoMed-I	Phase 2	Recruiting	NSW, SA, WA	20/05/2020		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy		Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Medulloblastoma	Adelaide - Royal Adelaide Hospital; Brisbane - Princess Alexandra Hospital - University Of Queensland; Melbourne - Austin Health - Austin hospital; Melbourne - Peter Maccallum Cancer Institute; Nedlands - Sir Charles Gairdner Hospital - (Not yet recruiting); New Lambton Heights - John Hunter Children's Hospital - (Not yet recruiting); Sydney - Prince Of Wales Hospital - (Not yet recruiting); Sydney - Royal North Shore Hospital; Sydney - Sydney Children's Hospital; Westmead - Westmead Hospital - Crown Princess Mary Cancer Center - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04402073
NCT04416516	NCT04416516	Phase 2	Recruiting	VIC, QLD, WA	01/06/2020		Gusacitinib; Gusacitinib + Vismodegib; Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SMO_inhibitor,first_generation; SYK/JAK_inhibitor	Gusacitinib; Gusacitinib + Vismodegib; Gusacitinib + Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor; SMO_inhibitor,first_generation + SYK/JAK_inhibitor		A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients	Basal Cell Carcinoma; Basal Cell Nevus Syndrome	3000 - Melbourne - Sinclair Dermatology - (Completed); 3050 - Melbourne - Royal Melbourne Hospital; 4000 - Brisbane - Central Brisbane Dermatology; 4102 - Brisbane - Princess Alexandra Hospital - (Not yet recruiting); 4102 - Brisbane - Veracity Clinical Research - (Completed); 6100 - Perth - Burswood Dermatology; Sunshine Coast - Sunshine Coast University Hospital - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04416516
NCT04423029	2021-000038-33	Phase 1/Phase 2	Recruiting	VIC	05/06/2020		DF6002; Nivolumab	anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein	DF6002; Nivolumab	IL-12_Fc-fusion_protein; anti-PD-1_monoclonal_antibody	2021-000038-33	A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Solid Tumors	3084 - Heidelberg - Local Institution - 0022 - (Withdrawn); 3128 - Box Hill - Local Institution - 0023 - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04423029
NCT04428151	LEAP-009	Phase 2	Recruiting	SA, VIC, QLD, NSW	09/06/2020		Capecitabine; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Cetuximab; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-EGFR_monoclonal_antibody; taxane	Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane	LEAP-009; E7080-G000-228; MK-7902-009; 2019-000569-19	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Squamous Cell Carcinoma of Head and Neck	2148 - Blacktown - Blacktown Hospital ( Site 0101); 2444 - Port Macquarie - Mid North Coast Cancer Institute ( Site 0109) - (Completed); 3168 - Clayton - Monash Health ( Site 0102); 4120 - Brisbane - Gallipoli Medical Research Foundation-GMRF CTU ( Site 0105); 4814 - Douglas - The Townsville Hospital ( Site 0107); 5000 - Adelaide - Royal Adelaide Hospital ( Site 0110)	https://clinicaltrials.gov/ct2/show/NCT04428151
NCT04434482	NCT04434482	Phase 1/Phase 2	Recruiting	VIC, NSW	14/06/2020		Senaparib; Senaparib + Temozolomide; Temozolomide	alkylating_agent; PARP_inhibitor; PARP_inhibitor + alkylating_agent	Senaparib + Temozolomide; Senaparib + Temozolomide	PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent		A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Advanced Solid Tumours; Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital; 2640 - Albury - Border Medical Oncology; 2800 - Orange - Orange Hospital; 3199 - Frankston - Peninsula Health Frankston Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04446260	NCT04446260	Phase 1	Recruiting	SA, VIC, NSW	22/06/2020		SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811	anti-ERBB2_antibody-drug_conjugate		A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	Advanced Solid Tumors	2109 - Macquarie - Macquarie University Hospital; 3004 - Melbourne - Alfred Hospital; 3004 - Melbourne - Nucleus Network - (Active, not recruiting); 3199 - Frankston - Peninsula and South Eastern Haematology &amp; Oncology Group; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04446260
NCT04449874	2020-000084-22	Phase 1	Recruiting	NSW, VIC, WA, NZ	24/06/2020		Atezolizumab; Atezolizumab + Divarasib; Bevacizumab; Bevacizumab + Divarasib; Cetuximab; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971; Erlotinib; Inavolisib; RLY-1971	PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,first_generation; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; SHP2_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor	Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971; Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	2020-000084-22; 2023-506311-18-00	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors	1023 - Auckland - Auckland City Hospital; 1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2010 - Darlinghurst - St Vincent's Hospital Sydney; 2080 - Mount Kuring-gai - Slade Health Inward goods; 3004 - Melbourne - Alfred Health; 3051 - North Melbourne - Peter MacCallum Cancer Center; 6009 - Nedlands - Linear Clinical Research Limited; 8011 - Christchurch - New Zealand Clinical Research - Christchurch	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04450732	NCT04450732	Phase 1	Recruiting	NSW, VIC	25/06/2020		GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate		A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors	HER2-positive Breast Cancer; HER2-positive Biliary Tract Cancer; HER2-Positive Salivary Gland Carcinomas; HER2-Positive Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research Limited; 3050 - Melbourne - Cabrini Institute in Melbourne, Australia - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04450732
NCT04464226	2019-003618-15	Phase 3	Recruiting	SA	07/07/2020		Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	2019-003618-15	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park - Adelaide Cancer Centre Research Pty Ltd - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04503278	2023-507492-21-00	Phase 1	Recruiting	VIC	04/08/2020						2019-004323-20; 2023-507492-21-00	Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors	Solid Tumor	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04503278
NCT04516447	NCT04516447	Phase 1	Recruiting	WA, VIC, QLD	14/08/2020		Carboplatin; Carboplatin + ZN-C3; Gemcitabine; Gemcitabine + ZN-C3; Paclitaxel; Paclitaxel + ZN-C3; Pegylated liposomal doxorubicin; ZN-C3	WEE1_inhibitor + antimetabolite; gemcitabine; WEE1_inhibitor; WEE1_inhibitor + taxane; platinum-based_antineoplastic_agent; anthracycline; taxane; antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent	Carboplatin + ZN-C3; Gemcitabine + ZN-C3; Paclitaxel + ZN-C3; ZN-C3; Carboplatin + ZN-C3; Gemcitabine + ZN-C3; Paclitaxel + ZN-C3; Pegylated liposomal doxorubicin	WEE1_inhibitor; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; anthracycline; gemcitabine		A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	3144 - Melbourne - Site 2706; 4101 - South Brisbane - Site 2707; 4556 - Sunshine Coast - Site 2708; 6009 - Nedlands - Site 2705	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04522323	2019-004338-41	Phase 1	Recruiting	VIC, NSW	19/08/2020		Axitinib; Axitinib + Lenvatinib + MEDI5752; Lenvatinib; Lenvatinib + MEDI5752; MEDI5752	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor; KIT_inhibitor,ATP-competitive; VEGFR/PDGFR_inhibitor	Axitinib + Lenvatinib + MEDI5752; Lenvatinib + MEDI5752; Axitinib + Lenvatinib + MEDI5752; Lenvatinib + MEDI5752	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	2019-004338-41	A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	2298 - Waratah - Research Site - (Completed); 3000 - Melbourne - Research Site - (Withdrawn); 3199 - Frankston - Research Site - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04522323
NCT04534205	AHEAD-MERIT	Phase 2	Recruiting	SA, QLD, VIC, NSW	27/08/2020		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2020-001400-41	An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)	Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 2200 - Bankstown - Bankstown-Lidcombe Hospital - (Withdrawn); 2450 - Coffs Harbour - Coffs Harbour Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Flinders Medical Centre; VIC 3065 - Fitzroy - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT04534205
NCT04553692	NCT04553692	Phase 1	Recruiting	NSW, QLD, VIC, SA	11/09/2020		Azacitidine; Azacitidine + Venetoclax; Bevacizumab; Docetaxel; Docetaxel + Gemcitabine; Gemcitabine; Venetoclax	gemcitabine; anti-VEGF_monoclonal_antibody; antimetabolite + taxane; Bcl2_inhibitor + antimetabolite; taxane; antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor; Bcl2_inhibitor	Azacitidine + Venetoclax; Bevacizumab; Docetaxel + Gemcitabine; Venetoclax; Azacitidine + Venetoclax; Docetaxel + Gemcitabine	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; anti-VEGF_monoclonal_antibody; antimetabolite + taxane; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; antimetabolite + taxane; gemcitabine		An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers	Solid Tumor; Colorectal Cancer; Non Hodgkin Lymphoma; Sarcoma; Chondrosarcoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia	2145 - Westmead - Westmead; 2500 - Wollongong - Southern Medical Day Care Centre; 2747 - Kingswood - Napean Cancer Care; 3052 - Melbourne - Peter MacCallum Cancer Centre; 5011 - Woodville South - Queen Elizabeth Hospital; QLD 4215 - Southport - Tasman Health	https://clinicaltrials.gov/ct2/show/NCT04553692
NCT04565275	NCT04565275	Phase 1/Phase 2	Recruiting	QLD, VIC, NSW	21/09/2020		Gunagratinib	pan-FGFR_inhibitor	Gunagratinib	pan-FGFR_inhibitor		A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumors; Urothelial Carcinoma; Cholangiocarcinoma	1590 - St Leonards - GenesisCare - North Shore; 2109 - Macquarie Park - Macquarie University Hospital; 2145 - Westmead - Westmead Hospital; 3084 - Melbourne - Olivia Newton-John Cancer Research Institute; 3168 - Clayton - Monash Medical Centre Clayton; 3199 - Frankston - Peninsula &amp; South Eastern Haematology &amp; Oncology Group; 4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04565275
NCT04585750	KEYNOTE-D79	Phase 1/Phase 2	Recruiting	WA, NSW, VIC	07/10/2020		PC14586; PC14586 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective	PC14586; PC14586 + Pembrolizumab; PC14586 + Pembrolizumab	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective	KEYNOTE-D79; MK-3475-D79	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer	Camperdown - Chris O'Brien Lifehouse Hospital - (Not yet recruiting); Clayton - Monash Medical Centre - (Not yet recruiting); Nedlands - Linear Clinical Research - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04585750
NCT04589845	2020-001847-16	Phase 2	Recruiting	NSW, VIC, QLD, NT, NZ	11/10/2020		Alectinib; Atezolizumab; Belvarafenib; Camonsertib; Divarasib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	ALK_inhibitor,second_generation; pan-RAF_inhibitor; PI3K_alpha_inhibitor; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; MDM2_inhibitor; TRK_inhibitor,first_generation; KRAS_G12C_inhibitor; ALK_inhibitor,third_generation; ROS1_inhibitor; RET_inhibitor; ATR_inhibitor	Alectinib; Atezolizumab; Belvarafenib; Camonsertib; Divarasib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; ATR_inhibitor; KRAS_G12C_inhibitor; MDM2_inhibitor; PI3K_alpha_inhibitor; RET_inhibitor; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; pan-RAF_inhibitor	2020-001847-16	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Solid Tumors	0810 - Tiwi - Royal Darwin Hospital; Alan Walker Cancer Centre; 1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2031 - Randwick - Sydney Children's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology - (Active, not recruiting); 3052 - Parkville - Royal Children's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; Christchurch - Christchurch Hospital; Dept of Oncology - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04589845
NCT04597411	CAAA817A12101	Phase 1	Recruiting	NSW	16/10/2020		225Ac-PSMA-617; 225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; Enzalutamide; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting; CYP17A1_inhibitor	225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting; radioligand,PSMA-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting	CAAA817A12101	AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy	Prostatic Neoplasms, Castration-Resistant	Darlinghurst - St. Vincent's Hospital Research Office-Translational Research Center	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04606446	KAT6	Phase 1	Recruiting	NSW, VIC, WA, SA	22/10/2020		Fulvestrant; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole; Letrozole + PF-07248144 + Palbociclib; PF-07220060; PF-07248144; Palbociclib	aromatase_inhibitor; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; KAT6_inhibitor	Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib; PF-07248144; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader		A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.	Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse - (Active, not recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Western Health-Sunshine &amp; Footscray Hospitals; 3050 - Parkville - Royal Melbourne Hospital; 5000 - Adelaide - Cancer Research South Australia; 6008 - Subiaco - St. John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT04606446
NCT04607421	BREAKWATER	Phase 3	Recruiting	NZ, SA, VIC, QLD, NSW, BAY OF Plenty	22/10/2020		Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Capecitabine; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Encorafenib; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; fluoropyrimidine; BRAF_V600_inhibitor; folinic_acid; anti-VEGF_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody	Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	2020-001288-99; BREAKWATER	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER	Neoplasms	1023 - Auckland - Auckland City Hospital; 1023 - Auckland - Auckland District Health Board Charitable Trust; 2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - GenesisCare - North Shore; 2065 - St Leonards - GenesisCare North Shore; 2080 - Mount Kuring-Gai - Slade Pharmacy; 2170 - Liverpool - Liverpool Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Health; 3112 - Tauranga - Tauranga Hospital; 3168 - Clayton - Monash Health; 4029 - Herston - Royal Brisbane &amp; Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 5011 - Adelaide - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04607421
NCT04613596	NCT04613596	Phase 2/Phase 3	Recruiting	NSW, QLD, VIC, SA	30/10/2020		Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab; Adagrasib + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody		A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer	2500 - Wollongong - Research Site; 3350 - Ballarat - Research Site; 4102 - Woolloongabba - Research Site; 5042 - Bedford Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT04613596
NCT04618393	NCT04618393	Phase 1/Phase 2	Recruiting	NSW, VIC	04/11/2020		EMB-02	bispecific_PD-1/LAG3_antibody	EMB-02	bispecific_PD-1/LAG3_antibody		A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2500 - Wollongong - Southern Medical Day Care Centre; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula &amp; South Eastern Haematology &amp; Oncology Group (PASO)	https://clinicaltrials.gov/ct2/show/NCT04618393
NCT04624204	MK-7339-013	Phase 3	Recruiting	NSW, QLD, VIC	05/11/2020		Dexamethasone; Etoposide; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Olaparib; Pembrolizumab; Placebo; Radiotherapy	PARP_inhibitor; placebo; radiotherapy; glucocorticoid; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; topoisomerase_inhibitor	Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Dexamethasone; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; glucocorticoid; placebo	MK-7339-013; jRCT2031200296; 2019-003616-31	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	2298 - Waratah - Calvary Mater Newcastle ( Site 3000); 2560 - Campbelltown - Campbelltown Hospital ( Site 3002); 2747 - Kingswood - Nepean Hospital ( Site 3001); 3021 - St Albans - Western Health-Sunshine Hospital ( Site 3004) - (Completed); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3006); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 3007); 4215 - Southport - Gold Coast University Hospital ( Site 3003)	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04631731	ICEMELT	Phase 1/Phase 2	Recruiting	NSW	10/11/2020							Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Lung Cancer, Nonsmall Cell; Renal Cell Carcinoma; Melanoma; Gastric Cancer; Hepatocellular Carcinoma; Endometrial Cancer; Mesothelioma	2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Mt Druitt Hospital	https://clinicaltrials.gov/ct2/show/NCT04631731
NCT04644068	PETRA	Phase 1/Phase 2	Recruiting	VIC	19/11/2020		AZD5305; AZD5305 + Camizestrant; AZD5305 + Carboplatin + Paclitaxel; AZD5305 + Datopotamab deruxtecan; AZD5305 + Paclitaxel; AZD5305 + Trastuzumab Deruxtecan; Camizestrant; Carboplatin; Datopotamab deruxtecan; Paclitaxel; Trastuzumab Deruxtecan	PARP_inhibitor + taxane; anti-ERBB2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; taxane; selective_estrogen_receptor_degrader; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor; anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor + selective_estrogen_receptor_degrader	AZD5305; AZD5305 + Camizestrant; AZD5305 + Carboplatin + Paclitaxel; AZD5305 + Datopotamab deruxtecan; AZD5305 + Paclitaxel; AZD5305 + Trastuzumab Deruxtecan; AZD5305 + Camizestrant; AZD5305 + Carboplatin + Paclitaxel; AZD5305 + Datopotamab deruxtecan; AZD5305 + Paclitaxel; AZD5305 + Trastuzumab Deruxtecan	PARP_inhibitor; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + taxane; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + taxane	2020-002688-77	A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer; Additional Indications Below for Module 4 and 5; Non-small Cell Lung Cancer; Colorectal Cancer; Bladder Cancer; Gastric Cancer; Biliary Cancer; Cervical Cancer; Endometrial Cancer; Small Cell Lung Cancer Only in Module 5	3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04644068
NCT04645069	NCT04645069	Phase 1/Phase 2	Recruiting	WA, QLD, VIC, NSW	20/11/2020		ADG106; ADG106 + ADG126; ADG126	anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody; anti-4-1BB_agonistic_antibody; anti-CTLA-4_monoclonal_antibody	ADG106 + ADG126; ADG126; ADG106 + ADG126	anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody		A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	2228 - Miranda - Southside Cancer Care Centre - (Active, not recruiting); 3144 - Malvern - Cabrini Health Limited; 4575 - Birtinya - Sunshine Coast University Private Hospital; 6009 - Nedlands - One Clinical Research Pty Ltd; Sydney - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT04645069
NCT04649385	CTR20212721	Phase 1	Recruiting	NZ, SA, WA, VIC, NSW	25/11/2020		BGB-15025; BGB-15025 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor	BGB-15025; BGB-15025 + Tislelizumab; BGB-15025 + Tislelizumab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	CTR20212721	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	1023 - Auckland - Auckland City Hospital; 2031 - Randwick - Prince of Wales Hospital; 3000 - Melbourne - Peter Maccallum Cancer Centre; 5087 - Windsor Gardens - Ashford Cancer Centre Research Northeast; 6009 - Nedlands - Linear Clinical Research; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04649385
NCT04650581	FINER	Phase 3	Recruiting	NZ, WA, QLD, VIC, ACT, NSW	01/12/2020		Fulvestrant; Fulvestrant + Ipatasertib; Ipatasertib; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; pan-AKT_inhibitor	Fulvestrant + Ipatasertib; Fulvestrant + Ipatasertib; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; placebo	2101; M041883	Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor	Breast Cancer	1023 - Auckland - Auckland City Hospital - (Suspended); 2 - Wellington - Wellington Cancer Centre, Wellington Hospital - (Suspended); 2109 - Macquarie University - Macquarie University Hospital; 2250 - Gosford - Gosford Hospital - (Suspended); 2324 - Gateshead - Lake Macquarie Private Hospital - (Suspended); 2541 - Nowra - Shoalhaven Cancer Care Centre - (Suspended); 2576 - Bowral - Southern Highlands Cancer Centre - (Suspended); 3002 - East Melbourne - Victorian Breast and Oncology Care - (Suspended); 3004 - Melbourne - Alfred Hospital - (Not yet recruiting); 3021 - St. Albans - Sunshine Hospital - (Suspended); 3076 - Epping - The Northern Hospital - (Suspended); 3199 - Frankston - Frankston Hospital; 4029 - Herston - Royal Brisbane and Womens Hospital - (Suspended); 4350 - Toowoomba - Toowoomba Hospital; 4575 - Birtinya - Sunshine Coast University Hospital - (Suspended); 6150 - Murdoch - Fiona Stanley Hospital - (Suspended); 6230 - Bunbury - St John of God Bunbury - (Suspended); ACT 2605 - Garran - Canberra Hospital - (Suspended)	https://clinicaltrials.gov/ct2/show/NCT04650581
NCT04665206	NCT04665206	Phase 1	Recruiting	VIC, WA	10/12/2020		VT3989	TEAD_palmitoylation_inhibitor	VT3989	TEAD_palmitoylation_inhibitor		Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene	Solid Tumor, Adult; Mesothelioma	3000 - Melbourne - Peter MacCullum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04674683	NCT04674683	Phase 3	Recruiting	QLD, VIC, NSW, NZ, WA	14/12/2020		Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo		A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors	Unresectable or Metastatic Melanoma; Progressive Brain Metastasis	3112 - Tauranga - Tauranga Hospital; 4556 - Buderim - University of the Sunshine Coast; 4556 - Sippy Downs - University of the Sunshine; Auckland - Auckland City Hospital; Ballarat - Ballarat Health Services; Brisbane - Royal Brisband and Women's Hospital; Hamilton - Waikato Hospital; Liverpool - Liverpool Hospital; Nedlands - Affinity Clinical Research; Shepparton - Goulburn Valley Health; South Brisbane - Icon Cancer Centre Wesley; Tweed Heads - Tweed Hospital; Wahroonga - Sydney Adventist Hospital; Waratah - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT04674683
NCT04675294	KEYNOTE-B87	Phase 2	Recruiting	VIC, QLD, NSW, WA	15/12/2020		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-B87; MK-3475-B87; 2020-004093-21	A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	2146 - Sydney - St. Vincent's; 3051 - Melbourne - Peter MacCallum Cancer Centre; 4029 - Brisbane - Royal Brisbane and Womens Hospital; 6009 - Perth - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04675294
NCT04675333	KEYNOTE-B88	Phase 2	Recruiting	SA	17/12/2020		Carboplatin; Cisplatin; Fluorouracil; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; fluoropyrimidine	Pembrolizumab; Carboplatin; Cisplatin; Fluorouracil	anti-PD-1_monoclonal_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent	KEYNOTE-B88; MK-3475-B88; 2020-004662-19	A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	5037 - Adelaide - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04675333
NCT04676828	ASPECT	N/A	Recruiting	NSW	15/12/2020		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy		Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial	Lung Cancer; Radiation-Induced Disorder; Radiation Pneumonitis; Pulmonary Disease; Lung Function Decreased	2145 - Sydney - Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04676828
NCT04677855	NCT04677855	Phase 1	Recruiting	NSW, SA	16/12/2020		Abiraterone; Abiraterone + PCUR-101 + Prednisone; PCUR-101; Prednisone	glucocorticoid; synthetic_plumbagin; CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; CYP17A1_inhibitor	Abiraterone + PCUR-101 + Prednisone; PCUR-101; Abiraterone + PCUR-101 + Prednisone	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; synthetic_plumbagin; CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin		A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2170 - Liverpool - Sydney South West Private Hospital - (Withdrawn); 2217 - Kogarah - St. George Private Hospital - (Completed); 5042 - Bedford Park - Southern Oncology Clinical Research - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04677855
NCT04686305	DL03	Phase 1	Recruiting	VIC, WA, SA	22/12/2020		Carboplatin; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + MEDI5752 + Trastuzumab Deruxtecan; Cisplatin; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; MEDI5752; MEDI5752 + Trastuzumab Deruxtecan; Pemetrexed; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite	Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + MEDI5752 + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; MEDI5752 + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + MEDI5752 + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; MEDI5752 + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent	2020-003260-31	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	3084 - Heidelberg - Research Site - (Withdrawn); 5000 - Adelaide - Research Site; 6009 - Nedlands - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04686305
NCT04691804	NCT04691804	Phase 3	Recruiting	SA, VIC, NSW	30/12/2020		Abiraterone; Fuzuloparib; Placebo; Prednisone	glucocorticoid; PARP_inhibitor; placebo; CYP17A1_inhibitor	Fuzuloparib; Abiraterone; Placebo; Prednisone	PARP_inhibitor; CYP17A1_inhibitor; glucocorticoid; placebo		A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Bendigo - Bendigo Health; Concord - Concord Repatriation General Hospital - (Not yet recruiting); Fitzroy - St Vincents Hospital Melbourne - (Not yet recruiting); Gosford - Gosford Hospital; Kurralta Park - Ashford Cancer Centre Research; Melbourne - The Alfred Hospital; St Albans - Western Health; Sydney - Macquarie University; Wagga Wagga - Riverina Cancer Care Centre; Wahroonga - Sydney Adventist Hospital	https://clinicaltrials.gov/ct2/show/NCT04691804
NCT04699188	KontRASt-01	Phase 1/Phase 2	Recruiting	VIC	05/01/2021		JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab; TNO155; Tislelizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; anti-PD-1_monoclonal_antibody; SHP2_inhibitor	JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	2020-004129-22	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung; Cancer of the Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04702880	U1111-1250-4427	Phase 2	Recruiting	QLD, VIC, NSW, WA	07/01/2021		BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Carboplatin + Etoposide + Nivolumab; Etoposide; Nivolumab	anti-fucosyl-GM1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001863-10; U1111-1250-4427	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead - Local Institution - 0003 - (Completed); 3144 - Malvern - Local Institution - 0001 - (Completed); 3350 - Ballarat Central - Local Institution - 0078 - (Withdrawn); 4120 - Greenslopes - Local Institution - 0023 - (Active, not recruiting); 6150 - Murdoch - Local Institution - 0004 - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04713891	NCT04713891	Phase 1	Unknown status	NSW	15/01/2021		Atezolizumab; Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody; prostaglandin_EP4_receptor_inhibitor	Atezolizumab + KF-0210; KF-0210; Atezolizumab + KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor		A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Colorectal Cancer; Lung Cancer; Squamous Cell Carcinoma of the Esophagus; Gastric Cancer; Bladder Cancer	2031 - Randwick - Scientia Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04720768	CELEBRATE	Phase 1/Phase 2	Recruiting	VIC	19/01/2021		Binimetinib; Encorafenib; Palbociclib	MEK_inhibitor; CDK4/6_inhibitor; BRAF_V600_inhibitor	Encorafenib; Binimetinib; Palbociclib	BRAF_V600_inhibitor; CDK4/6_inhibitor; MEK_inhibitor		A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)	Melanoma; Metastasis	3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Hospital; 3128 - Box Hill - Box Hill Hospital	https://clinicaltrials.gov/ct2/show/NCT04720768
NCT04728893	MK-1026-003	Phase 2	Recruiting	NSW, VIC, WA	25/01/2021		Nemtabrutinib	BTK_inhibitor	Nemtabrutinib	BTK_inhibitor	MK-1026-003; 2020-002324-36	A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies	Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia	2747 - Sydney - Nepean Hospital-Nepean Cancer Care Centre ( Site 0204); 3128 - Box Hill - Box Hill Hospital ( Site 0203); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 0200)	https://clinicaltrials.gov/ct2/show/NCT04728893
NCT04739670	BELLA	Phase 2	Recruiting	NSW, VIC, QLD, SA	01/02/2021		Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	gemcitabine; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine		A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer	2065 - St Leonards - Royal North Shore; 4101 - South Brisbane - Mater Health; Melbourne - Monash Health; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04771130	2021-003285-12	Phase 1/Phase 2	Recruiting	WA, NZ, NSW, VIC, QLD	23/02/2021		Azacitidine; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Posaconazole	Bcl2_inhibitor + antimetabolite + azole_antifungal; azole_antifungal; Bcl2_inhibitor + antimetabolite; antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor	Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal	2021-003285-12	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm	0622 - Takapuna - North Shore Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2217 - Kogarah - St George Hospital; 2800 - Orange - Orange Health Hospital; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 4215 - Southport - Gold Coast University Hospital; 4224 - Tugun - John Flynn Private Hospital; 6009 - Nedlands - Linear Clinical Research; 6009 - Nedlands - One Clinical Research; 6021 - Wellington - Wellington Regional Hospital (Ccdhb); 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04789096	TUGETHER	Phase 2	Recruiting	SA, QLD, VIC, TAS, NSW	07/03/2021		Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; fluoropyrimidine; ERBB2_inhibitor,third_generation	Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine		A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer	Breast Cancer; HER2-positive Breast Cancer	2031 - Randwick - Prince of Wales Hospital; 2109 - Macquarie Park - Macquarie University; 2145 - Westmead - Westmead Hospital; 2250 - Gosford - Gosford Hospital; 2310 - Waratah - Calvary Mater Newcastle; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2640 - Albury - Border Medical Oncology - (Not yet recruiting); 2747 - Kingswood - Nepean Cancer Care Centre - (Not yet recruiting); 3002 - Parkville - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Hospital; 3121 - Richmond - Epworth Richmond Hospital; 3350 - Ballarat - Ballarat Health Services (Grampians Health) - (Not yet recruiting); 4575 - Birtinya - Sunshine Coast University Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT04789096
NCT04794699	NCT04794699	Phase 1	Recruiting	SA, NSW	09/03/2021		Docetaxel; Docetaxel + Paclitaxel; IDE397; Paclitaxel; Pemetrexed	taxane; antimetabolite; MAT2A_inhibitor	Docetaxel + Paclitaxel; Docetaxel + Paclitaxel; IDE397; Pemetrexed	taxane; MAT2A_inhibitor; antimetabolite		An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors	Solid Tumor	02010 - Darlinghurst - The Kinghorn Cancer Centre, St Vincent's Health Network Sydney; 05042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04794699
NCT04799054	transcendIT-101	Phase 1/Phase 2	Recruiting	SA, NSW, VIC	11/03/2021		Pembrolizumab; Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody; TLR7/8_agonist	Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist; Pembrolizumab + TransCon TLR7/8 agonist	TLR7/8_agonist; TLR7/8_agonist + anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	transcendIT-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Head and Neck Squamous Cell Carcinoma HNSCC; HPV-associated Cancers; Neoadjuvant Melanoma; Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)	2500 - Wollongong - Ascendis Pharma Investigational Site; 3168 - Clayton - Ascendis Pharma Investigational Site - (Withdrawn); 3199 - Frankston - Ascendis Pharma Investigational Site; 5042 - Bedford Park - Ascendis Investigational Site - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04799054
NCT04801095	NCT04801095	Phase 1	Recruiting	WA, VIC	14/03/2021		WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor		A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor; Colorectal Cancer; Lung Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer	3084 - Heidelberg - Austin Hospital; 3168 - Clayton - Monash Medical Center; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04801095
NCT04802759	2020-004889-19	Phase 1/Phase 2	Recruiting	VIC, WA, SA	16/03/2021		Abemaciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab; Atezolizumab + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Inavolisib; Ipatasertib; Palbociclib; Ribociclib; Samuraciclib	mTORC1_inhibitor; PI3K_alpha_inhibitor; CDK4/6_inhibitor; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib	CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	2020-004889-19	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3199 - Frankston - Peninsula Health-Frankston Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04819100	LIBRETTO-432	Phase 3	Recruiting	VIC, QLD, NSW	25/03/2021		Placebo; Selpercatinib	RET_inhibitor; placebo	Selpercatinib; Placebo	RET_inhibitor; placebo	J2G-MC-JZJX; 2020-005191-35; 2023-506784-33-00	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	Carcinoma, Non-Small-Cell Lung	2640 - Albury - Border Medical Oncology; 3280 - Warrnambool - South West Healthcare; 3350 - Ballarat Central - Ballarat Health Services; 3550 - Bendigo - Bendigo Health Care Group; 3630 - Shepparton - Goulburn Valley Health; 4575 - Birtinya - Sunshine Coast University Hospital; 4700 - Rockhampton - Rockhampton Hospital; 4814 - Townsville - The Townsville Hospital	https://clinicaltrials.gov/ct2/show/NCT04819100
NCT04822961	NCT04822961	Phase 2	Not yet recruiting	NSW, QLD, SA	26/03/2021		Docetaxel; Placebo; Senaparib	taxane; PARP_inhibitor; placebo	Senaparib; Docetaxel; Placebo	PARP_inhibitor; placebo; taxane		A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	mCRPC	Brisbane - Princess Alexandra Hospital; Melbourne - Cabrini Hospital; Sydney - Macquarie University Hospital; Tugun - John Flynn Hospital	https://clinicaltrials.gov/ct2/show/NCT04822961
NCT04829604	NCT04829604	Phase 2	Recruiting	SA, WA, QLD, VIC	01/04/2021		ARX788; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	ARX788; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate		A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd	HER2 Positive Metastatic Breast Cancer	3135 - Ringwood East - Research Site - (Withdrawn); 3168 - Clayton - Research Site - (Withdrawn); 3199 - Frankston - Research Site - (Completed); 3220 - Geelong - Research Site - (Completed); 4101 - South Brisbane - Research Site - (Withdrawn); 4102 - Woolloongabba - Research Site - (Withdrawn); 6009 - Nedlands - Research Site - (Completed); Melbourne - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04829604
NCT04830124	ARTISTRY-6	Phase 2	Recruiting	SA, NSW, QLD	01/04/2021		Nemvaleukin alfa	IL-2_fusion_protein	Nemvaleukin alfa	IL-2_fusion_protein		A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6	Cutaneous Melanoma; Mucosal Melanoma	2298 - Waratah - Mural Oncology Investigator Site; 4224 - Tugun - Mural Oncology Investigator Site; 5011 - Woodville - Mural Oncology Investigator Site	https://clinicaltrials.gov/ct2/show/NCT04830124
NCT04830202	NCT04830202		Available	WA	31/03/2021		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate		Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	6005 - West Perth - Western Heamatology and Oncology Clinics /ID# 243364 - (Available)	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04844073	NCT04844073	Phase 1/Phase 2	Recruiting	NSW, VIC, SA	13/04/2021		MVC-101	bispecific_T-cell_engager,EGFR-targeting	MVC-101	bispecific_T-cell_engager,EGFR-targeting		A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Squamous Cell Cancer of Head and Neck (SCCHN); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer	2031 - Randwick - Scientia Clinical Research Limited, Corner High &amp; Avoca Street, 5th Floor, Bright Building; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Hospital, 145 Studley Road, Intensive Care Unit; 3168 - Clayton - Monash Health, Monash Medical Center, 246 Clayton Road; 5042 - Bedford Park - Southern Oncology Clinical Research Unit, 1 Flinders Drive	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04857372	NCT04857372	Phase 1	Recruiting	VIC	20/04/2021		IAG933	YAP-TEAD_inhibitor	IAG933	YAP-TEAD_inhibitor		An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors	Mesothelioma	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04857372
NCT04861779	NCT04861779	Phase 1	Recruiting	WA	22/04/2021		HSK29116	PROTAC_antineoplastic_drug	HSK29116	PROTAC_antineoplastic_drug		A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy	Relapsed/Refractory B-Cell Malignancies	Perth - One Clinical Research - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04861779
NCT04862663	CAPItello-292	Phase 3	Recruiting	WA, NSW	23/04/2021		Abemaciclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Palbociclib + Ribociclib; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	2020-004637-20	A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2076 - Wahroonga - Research Site; 2228 - Miranda - Research Site - (Terminated); 2298 - Waratah - Research Site; 6009 - Nedlands - Research Site - (Active, not recruiting); 6009 - Perth - Research Site	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04879329	MK-3475-D78	Phase 2	Recruiting	NSW, QLD, Other, VIC	07/05/2021		Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	KEYNOTE-D78; MK-3475-D78; 2022-500030-28	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Urothelial Carcinoma	2065 - St Leonards - Royal North Shore Hospital; 2109 - New South Whales - Macquarie University Hospital; 3199 - Frankston - Peninsula and South East Oncology; 4101 - South Brisbane - Mater Cancer Care Centre	https://clinicaltrials.gov/ct2/show/NCT04879329
NCT04879368	INTEGRATEIIb	Phase 3	Recruiting	QLD, VIC, TAS, NSW, SA, NT, WA	06/05/2021		Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; taxane; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-1_monoclonal_antibody; taxane; topoisomerase_inhibitor	2020-004617-12	A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	0810 - Tiwi - Royal Darwin Hospital; 2010 - Darlinghurst - St Vincent's Public Hospital; 2031 - Randwick - Prince of Wales Hospital; 2035 - New Lambton Heights - Newcastle Private Hospital; 2065 - Sydney - Royal North Shore Private Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2250 - Gosford - Gosford Hospital; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - The Tweed Hospital; 2640 - East Albury - Border Medical Oncology Research Unit; 3084 - Melbourne - Austin Health; 3168 - Clayton - Monash Health; 3355 - Wendouree - Ballarat Oncology and Haematology Services; 4029 - Herston - Royal Brisbane and Womens Hospital; 4560 - Sunshine Coast - Sunshine Coast University Hospital; 4814 - Douglas - The Townsville Hospital; 5011 - Adelaide - The Queen Elizabeth Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6008 - Subiaco - St John of God Hospital Subiaco; 6009 - Nedlands - Sir Charles Gairdner Hospital; 700 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04879368
NCT04886804	2020-004563-47	Phase 1	Recruiting	VIC, NSW	12/05/2021		Zongertinib	ERBB2_inhibitor,second_generation	Zongertinib	ERBB2_inhibitor,second_generation	2020-004563-47	Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations	Neoplasm Metastasis; Non-Small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University; 3144 - Malvern - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT04886804
NCT04895709	U1111-1265-4508	Phase 1/Phase 2	Recruiting	NSW, QLD, VIC, WA	19/05/2021		BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; taxane; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane	2021-001188-26; U1111-1265-4508	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Microsatellite Stable Colorectal Cancer; Non-Small-Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Urothelial Carcinoma; Pancreatic Adenocarcinoma; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms	2148 - Blacktown - Blacktown Hospital; 2170 - Liverpool - Local Institution - 0058; 3065 - Melbourne - St Vincent's Hospital; 3144 - Malvern - Local Institution - 0053; 4102 - Brisbane - Princess Alexandra Hospital; 6009 - Nedlands - Local Institution - 0056 - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04895709
NCT04909125	NCT04909125	N/A	Recruiting	NSW	26/05/2021		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy		Standard Versus Investigatioinal Fractionation Trial - Nodal Radiation	Breast Cancer; Post Mastectomy	2065 - St Leonards - Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04909125
NCT04913285	NCT04913285	Phase 1	Recruiting	NSW, WA	28/05/2021		Binimetinib; Binimetinib + Exarafenib; Exarafenib	MEK_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	Binimetinib + Exarafenib; Exarafenib; Binimetinib + Exarafenib	MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor		A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.	Solid Tumor, Adult; Non-small Cell Lung Cancer; Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04913285
NCT04918810	GUIDE	Phase 2	Recruiting	VIC, NSW	02/06/2021		Docetaxel	taxane	Docetaxel	taxane		A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)	Castration Resistant Prostatic Cancer	2021 - Darlinghurst - St Vincent's Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2830 - Dubbo - Dubbo Base Hospital; 3199 - Frankston - Frankston Hospital-Peninsula Health; 3630 - Shepparton - Goulburn Valley Health; 3844 - Traralgon - LaTrobe Regional Hospital - (Not yet recruiting); Sydney - Concord Repatriation General Hospital	https://clinicaltrials.gov/ct2/show/NCT04918810
NCT04924075	PT2977	Phase 2	Recruiting	NSW, VIC	08/06/2021		Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	MK-6482-015; PT2977; jRCT2011220024; 2023-504853-11-00; 2020-005028-13	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations	Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers	2031 - Randwick - Prince of Wales Hospital-Medical Oncology ( Site 1601); 3050 - Parkville - The Royal Melbourne Hospital ( Site 1602)	https://clinicaltrials.gov/ct2/show/NCT04924075
NCT04925284	NCT04925284	Phase 1	Recruiting	NSW, WA	07/06/2021		Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody		A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Non Small Cell Lung Cancer; Cervical Cancer; SCCHN; Pancreatic Cancer; Esophageal SCC; Metastatic Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Epithelial Ovarian Cancer; Endometrial Cancer; Tissue Factor-Expressing Solid Tumors	2010 - Darlinghurst - Exelixis Clinical Site #37; 2065 - Saint Leonards - Exelixis Clinical Site #35; 2170 - Liverpool - Exelixis Clinical Site #44; 2228 - Miranda - Exelixis Clinical Site#75; 6009 - Nedlands - Exelixis Clinical Site#70	https://clinicaltrials.gov/ct2/show/NCT04925284
NCT04925648	PICASSO	Phase 2	Recruiting	NSW, VIC	07/06/2021		Darolutamide; Dasatinib	BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; KIT_inhibitor	Dasatinib; Darolutamide	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation		PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04928846	2021-001811-94	Phase 3	Recruiting	VIC	14/06/2021		Docetaxel; Telisotuzumab Vedotin	taxane; anti-cMET_antibody-drug_conjugate	Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	2021-001811-94	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer	3084 - Heidelberg - Austin Health /ID# 247507; 3220 - Geelong - Barwon Health /ID# 241920	https://clinicaltrials.gov/ct2/show/NCT04928846
NCT04929223	NCT04929223	Phase 1	Recruiting	VIC	11/06/2021		Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab; Bevacizumab + Inavolisib; Cetuximab; Cetuximab + Divarasib; Cetuximab + Inavolisib; Divarasib; Inavolisib; SY-5609; Tiragolumab	PI3K_alpha_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor; CDK7_inhibitor; anti-VEGF_monoclonal_antibody; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib	CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody		A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	Metastatic Colorectal Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04929223
NCT04931342	BOUQUET	Phase 2	Recruiting	VIC	16/06/2021		Abemaciclib; Abemaciclib + Giredestrant; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab; Bevacizumab + Inavolisib; Cobimetinib; Cyclophosphamide; Giredestrant; Giredestrant + Inavolisib; Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib; Ipatasertib + Paclitaxel; Letrozole; Olaparib; Paclitaxel; Palbociclib; Trastuzumab Emtansine	alkylating_agent; PI3K_alpha_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor; CDK4/6_inhibitor; pan-AKT_inhibitor + taxane; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; taxane; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; aromatase_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; MEK_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor; anti-VEGF_monoclonal_antibody; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody	Abemaciclib + Giredestrant; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab + Inavolisib; Cobimetinib; Giredestrant + Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib + Paclitaxel; Trastuzumab Emtansine; Abemaciclib + Giredestrant; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab + Inavolisib; Giredestrant + Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib + Paclitaxel	CDK4/6_inhibitor + PI3K_alpha_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; MEK_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane; CDK4/6_inhibitor + PI3K_alpha_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane	GOG-3051; ENGOT-GYN2	A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	Ovarian Cancer	3144 - Malvern - Cabrini Hospital; Cabrini Foundation	https://clinicaltrials.gov/ct2/show/NCT04931342
NCT04947189	4CAST	Phase 1/Phase 2	Recruiting	NSW	26/06/2021		Dexamethasone; Dexamethasone + Docetaxel + Seviteronel; Docetaxel; Seviteronel	glucocorticoid; CYP17A1_inhibitor + glucocorticoid + taxane; taxane; CYP17A1_inhibitor	Dexamethasone + Docetaxel + Seviteronel; Dexamethasone + Docetaxel + Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane; CYP17A1_inhibitor + glucocorticoid + taxane		4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04947189
NCT04950075	ChonDRAgon	Phase 2	Recruiting	QLD, NSW, SA	30/06/2021		INBRX-109; Placebo	placebo; DR5_agonistic_antibody	INBRX-109; Placebo	DR5_agonistic_antibody; placebo		A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Conventional Chondrosarcoma	2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 5000 - Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Woolloongabba - Princess Alexandra Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04950075
NCT04956640	J3M-OX-JZQA	Phase 1/Phase 2	Recruiting	NSW, VIC, WA, SA	02/07/2021		Carboplatin; Cetuximab; Cisplatin; LY3537982; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; antimetabolite	LY3537982; Carboplatin; Cetuximab; Cisplatin; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	2021-000595-12; J3M-OX-JZQA; KEYNOTE E27	A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms	2010 - Sydney - St Vincent's Hospital Sydney; 2065 - St Leonards - Royal North Shore Hospital; 3199 - Frankston - Peninsula and Southeast Oncology; 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04956640
NCT04964375	NCT04964375	Phase 1	Unknown status	VIC, QLD, NSW	06/07/2021		ABSK-043	PD-L1_inhibitor,oral	ABSK-043	PD-L1_inhibitor,oral		A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor	Neoplasms	4101 - Brisbane - Icon Cancer Centre South Brisbane; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; Liverpool - Sydney South West Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04964375
NCT04964934	SERENA-6	Phase 3	Recruiting	WA, NSW, QLD	14/07/2021		Abemaciclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Anastrozole; Camizestrant; Letrozole; Palbociclib; Placebo; Ribociclib	aromatase_inhibitor; CDK4/6_inhibitor; placebo; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; placebo	2023-503990-39-00; 2021-000546-17	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ER-Positive HER2-Negative Breast Cancer	2010 - Darlinghurst - Research Site; 4575 - Birtinya - Research Site; 6008 - Subiaco - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04964934
NCT04974398	NCT04974398	Phase 3	Recruiting	WA, VIC, NSW	21/07/2021		Cisplatin; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Gemcitabine; Penpulimab; Placebo	gemcitabine; placebo; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo		A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	2010 - Darlinghurst - St Vincent's Public Hospital Sydney - (Active, not recruiting); 2065 - St Leonards - Genesis Care North Shore - (Active, not recruiting); 3084 - Heidelberg - Sir Charles Gardner - (Active, not recruiting); 6009 - Nedlands - Austin Health - (Active, not recruiting); Camperdown - Chris O'Brien Lifehouse - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04974398
NCT04975308	EMBER-3	Phase 3	Recruiting	SA, NSW, VIC, QLD	22/07/2021		Abemaciclib; Abemaciclib + Imlunestrant; Exemestane; Exemestane + Fulvestrant; Fulvestrant; Imlunestrant	aromatase_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Abemaciclib + Imlunestrant; Exemestane + Fulvestrant; Imlunestrant; Abemaciclib + Imlunestrant; Exemestane + Fulvestrant	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	J2J-OX-JZLC; 2021-000079-35	EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy	Breast Neoplasms; Neoplasm Metastasis	2010 - Darlinghurst - St Vincent's Hospital - (Active, not recruiting); 3128 - Box Hill - Box Hill Hospital - (Completed); 3135 - Melbourne - Maroondah Hospital - (Active, not recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital - (Completed); 5000 - Adelaide - Cancer Research SA - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04975308
NCT04976634	MK-6482-016	Phase 2	Recruiting	NSW, VIC, Auckland, NZ	16/07/2021		Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-6482-016; 2020-005007-40	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors	Carcinoma, Hepatocellular; Colorectal Neoplasms; Pancreatic Ductal Adenocarcinoma; Biliary Tract Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms	1023 - Auckland - Auckland City Hospital-Cancer &amp; Blood Research ( Site 4200); 1023 - Grafton - Auckland City Hospital-Liver Research Unit ( Site 4201); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 4001); 2250 - Gosford - Gosford Hospital-Oncology Trials ( Site 4004); 3076 - Epping - Northern Hospital-Department of Medical Oncology ( Site 4003); 3144 - Malvern - Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000) - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04976634
NCT04985604	NCT04985604	Phase 1/Phase 2	Recruiting	VIC	30/07/2021		Pimasertib; Pimasertib + Tovorafenib; Tovorafenib	MEK_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	Pimasertib + Tovorafenib; Tovorafenib; Pimasertib + Tovorafenib	MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor		A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations	Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusion; CRAF Gene Fusion; CRAF Fusion; RAF1 Gene Fusion; RAF1 Fusion; Thyroid Cancer, Papillary; Spitzoid Melanoma; Pilocytic Astrocytoma; Pilocytic Astrocytoma, Adult; Non Small Cell Lung Cancer; Non-Small Cell Adenocarcinoma; Colorectal Cancer; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; Bladder Cancer; Bladder Urothelial Carcinoma; MAP Kinase Family Gene Mutation; RAS Mutation; RAF Mutation; MEK Mutation	Clayton - Monash Medical Centre - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04985604
NCT04985721	IMPARP-HRD	Phase 2	Recruiting	VIC	29/07/2021		Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor	Pamiparib + Tislelizumab; Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody		An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Fitzroy - St Vincent's Hospital; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT04985721
NCT04986852	NCT04986852	Phase 2	Recruiting	WA	22/07/2021		Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody		A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Metastatic Triple-Negative Breast Cancer	6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04986852
NCT04986865	PROBE	Phase 1	Recruiting	NSW, VIC, SA	23/07/2021		ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101	bispecific_PD-L1/4-1BB_antibody		A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Advanced Solid Tumor; Metastatic Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma	2031 - Randwick - Scientia Clinical Research Ltd; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health - Olivia Newton-John Cancer Centre; 5000 - Adelaide - Royal Adelaide Hospital; 8006 - East Melbourne - Peter MacCallum Cancer Centre (PMCC) - Victorian Comprehensive Cancer Centre Location (Peter MacCallum Cancer Centre - East Melbourne)	https://clinicaltrials.gov/ct2/show/NCT04986865
NCT04995523	ARTEMIDE-01	Phase 1/Phase 2	Recruiting	VIC	29/07/2021		AZD2936	bispecific_PD-1/TIGIT_antibody	AZD2936	bispecific_PD-1/TIGIT_antibody	2021-000857-23	Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC	Non-Small-Cell Lung Carcinoma	3000 - Melbourne - Research Site - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT04996875	2021-001010-10	Phase 2	Recruiting	NSW, VIC, QLD	06/08/2021		CGT9486	KIT_inhibitor	CGT9486	KIT_inhibitor	2021-001010-10	A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis	Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL); Aggressive Systemic Mastocytosis (ASM)	2747 - Kingswood - Nepean Hospital; 3051 - Melbourne N. - Peter MacCallum Cancer Centre; 4215 - Southport - Gold Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT04996875
NCT05006716	2022-502157-33-00	Phase 1/Phase 2	Recruiting	VIC, NSW, WA	09/08/2021		BGB-16673	BTK-PROTAC	BGB-16673	BTK-PROTAC	2022-502157-33-00	A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies	B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma; Waldenström Macroglobulinemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma	2139 - Concord - Concord Repatriation General Hospital; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 6005 - West Perth - Perth Blood Institute; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05006716
NCT05007782	2022-501684-40	Phase 1	Recruiting	NSW, VIC	11/08/2021		Tegafur-gimeracil-oteracil pPotassium; Zimberelimab	anti-PD-1_monoclonal_antibody; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Zimberelimab; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	2022-501684-40	A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Advanced Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05007782
NCT05021120	NCT05021120	Early Phase 1	Recruiting	SA, NSW	24/08/2021		AK104; AK127	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA-4_antibody	AK104; AK127	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA-4_antibody		A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours	Advanced or Metastatic Solid Tumours	Adelaide - Ashford Cancer Centre Research; Melbourne - Austin Health; Melbourne - Monash Health; Sydney - Southside Cancer Care Centre - (Completed); Sydney - The Kinghorn Cancer Centre, St Vincents Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT05021120
NCT05028478	NCT05028478	Phase 1/Phase 2	Unknown status		25/08/2021		CN202	PD-L1/TGF-beta_fusion_protein	CN202	PD-L1/TGF-beta_fusion_protein		An Open-Label, Multi-center, Phase I/II Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Locally Advanced Solid Tumor; Metastatic Solid Tumor; Hematologic Malignancies		https://clinicaltrials.gov/ct2/show/NCT05028478
NCT05029882	2023-509335-60-00	Phase 1	Recruiting	VIC, QLD	30/08/2021		ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; Trifluridine/Tipiracil	anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride; Trifluridine + anti-VEGF_monoclonal_antibody; Trifluridine; thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; antimetabolite; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	2023-509335-60-00	A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors	Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer	3084 - Heidelberg - Austin Health /ID# 247667; 4101 - South Brisbane - Mater Misericordiae Limited /ID# 249995	https://clinicaltrials.gov/ct2/show/NCT05029882
NCT05041309	MOH-2022-08-21-010606	Phase 2	Enrolling by invitation	VIC	07/09/2021		KTE-X19	autologous_CAR-T-cell_therapy,CD19-targeting	KTE-X19	autologous_CAR-T-cell_therapy,CD19-targeting	2020-005843-21; MOH_2022-08-21_010606; 2023-507041-28	Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells	Solid and Hematological Malignancies	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05041309
NCT05043090	SAMETA	Phase 3	Recruiting	VIC, NSW	09/09/2021		Durvalumab; Durvalumab + Savolitinib; Savolitinib; Sunitinib	KIT_inhibitor,first_generation; VEGFR_inhibitor; MET_inhibitor,type_1; anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Savolitinib; Sunitinib; Durvalumab + Savolitinib	KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody	2021-000336-55	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	Papillary Renal Cell Carcinoma	2065 - St Leonards - Research Site; 2109 - Macquarie University - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT05043090
NCT05052801	FORTITUDE-101	Phase 3	Recruiting	NSW, WA	13/09/2021		Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	2023-505457-40	A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	2170 - Liverpool - Liverpool Hospital; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05052801
NCT05053854	PARLuNET	Phase 1	Recruiting	VIC	20/09/2021		Octreotate; Octreotate + Talazoparib; Talazoparib	radionuclide_therapy; PARP_inhibitor; PARP_inhibitor + radionuclide_therapy	Octreotate + Talazoparib; Octreotate + Talazoparib	PARP_inhibitor + radionuclide_therapy; PARP_inhibitor + radionuclide_therapy		Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05059522	2021-002457-29	Phase 3	Recruiting	NZ, NSW, QLD	17/09/2021		Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Axitinib; PF-04518600; Pemetrexed; Talazoparib; Utomilumab	VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-4-1BB_agonistic_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; PARP_inhibitor; KIT_inhibitor,ATP-competitive; antimetabolite	Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite	2021-002457-29	Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.	Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors	1023 - Auckland - Auckland City Hospital - (Active, not recruiting); 2060 - Wollstonecraft - Mater Hospital Sydney - (Active, not recruiting); 2065 - Wollstonecraft - Melanoma Institute Australia - (Active, not recruiting); 2109 - North Ryde - Macquarie University; 4032 - Chermside - The Prince Charles Hospital; 4032 - Chermside - The Prince Charles Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05059522
NCT05067283	MK-1084-001	Phase 1	Recruiting	NSW, VIC, Canterbury, NZ	01/10/2021		Carboplatin; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; Fluorouracil; Leucovorin; MK-1084; MK-1084 + Pembrolizumab; Oxaliplatin; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; fluoropyrimidine; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid; Fluorouracil; anti-EGFR_monoclonal_antibody; antimetabolite; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084; MK-1084 + Pembrolizumab; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; Fluorouracil; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	MK-1084-001; jRCT2041220034; 2021-004024-15	A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRAS G12C Mutant Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris O'Brien Lifehouse ( Site 0002); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 0006); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 0001); 3168 - Clayton - Monash Health-Oncology Research ( Site 0003); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 0004) - (Completed)	https://clinicaltrials.gov/ct2/show/NCT05067283
NCT05075577	NCT05075577	Phase 1/Phase 2	Recruiting	Australian Capital Territory, VIC, NSW, ACT	07/10/2021		EPI-7386; EPI-7386 + Enzalutamide; Enzalutamide	antiandrogen,AR_NTD_inhibitor; antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation	EPI-7386 + Enzalutamide; Enzalutamide; EPI-7386 + Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation		A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2010 - Darlinghurst - St. Vincent's Hospital Sydney; 2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 2605 - Garran - The Canberra Hospital; 3128 - Box Hill - Eastern Health	https://clinicaltrials.gov/ct2/show/NCT05075577
NCT05081609	IL-Believe	Phase 1/Phase 2	Recruiting	QLD, SA	05/10/2021		Pembrolizumab; TransCon TLR7/8 agonist	anti-PD-1_monoclonal_antibody; TLR7/8_agonist	Pembrolizumab; TransCon TLR7/8 agonist	TLR7/8_agonist; anti-PD-1_monoclonal_antibody		IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung Cancer	4215 - Southport - Ascendis Pharma Investigational Site; 5000 - Adelaide - Ascendis Pharma Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05081609
NCT05086692	ABILITY-1	Phase 1/Phase 2	Recruiting	NSW, QLD	07/10/2021		MDNA11; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_superkine	MDNA11; Pembrolizumab	IL-2_superkine; anti-PD-1_monoclonal_antibody	KEYNOTE-E53; MK3475-E53	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer	2031 - Randwick - Scientia Clinical Research; 2109 - Sydney - Macquarie University; 4120 - Greenslopes - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05094336	MTAP	Phase 1/Phase 2	Recruiting	NSW	14/10/2021		AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; Docetaxel; Pemetrexed	PRMT5_inhibitor + antimetabolite; taxane; antimetabolite; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor	AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed	PRMT5_inhibitor; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane		A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	Advanced MTAP-null Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05094336
NCT05102214	NCT05102214	Phase 1/Phase 2	Recruiting	SA, VIC, QLD, NSW	20/10/2021		HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301	bispecific_PD-L1/TIGIT_antibody		A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancer	4575 - Birtinya - Sunshine Coast University Private Hospital; Adelaide - Southern Oncology Clinical Research Unit - (Not yet recruiting); Blacktown - Blacktown Hospital - (Not yet recruiting); Brighton - Cabrini Hospital - (Not yet recruiting); Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05102214
NCT05111626	FORTITUDE-102	Phase 3	Recruiting	NSW, VIC, SA	29/10/2021		Bemarituzumab; Bemarituzumab + Nivolumab; Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Bemarituzumab + Nivolumab; Nivolumab; Bemarituzumab + Nivolumab; Placebo	anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2023-505458-16	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	2065 - St Leonards - GenesisCare -North Shore Oncology; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3084 - Heidelberg - Austin Health, Austin Hospital; 3350 - Ballarat - Ballarat Health Services; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05111626
NCT05116202	NCT05116202	Phase 1/Phase 2	Recruiting	NSW, WA	02/11/2021		Atezolizumab; Atezolizumab + Tiragolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; RO7247669; RO7247669 + Tiragolumab; Tiragolumab	bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669; RO7247669 + Tiragolumab; Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669 + Tiragolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody		A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	Melanoma	2060 - North Sydney - Melanoma Institute Australia; 6009 - Nedlands - Linear Clinical Research Limited - (Completed)	https://clinicaltrials.gov/ct2/show/NCT05116202
NCT05117476	NCT05117476	Phase 1	Recruiting	VIC, WA	02/11/2021		CLN-619; CLN-619 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody	CLN-619; CLN-619 + Pembrolizumab; CLN-619 + Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody		A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3004 - Melbourne - Alfred Health; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05117476
NCT05118789	NCT05118789	Phase 1/Phase 2	Recruiting	NSW, VIC	03/11/2021		NVL-520; Tegafur-gimeracil-oteracil pPotassium	ROS1_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	NVL-520; Tegafur-gimeracil-oteracil pPotassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor		A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05118789
NCT05123482	2021-000736-66	Phase 1/Phase 2	Recruiting	QLD, VIC, WA	05/11/2021		AZD8205	anti-B7H4_antibody-drug_conjugate	AZD8205	anti-B7H4_antibody-drug_conjugate	2021-000736-66	A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies	Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer; Endometrial Cancer	4101 - South Brisbane - Research Site - (Withdrawn); 6009 - Nedlands - Research Site; VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05128825	NCT05128825	Phase 2	Recruiting	SA, QLD	09/11/2021		ZN-C3	WEE1_inhibitor	ZN-C3	WEE1_inhibitor		A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	4032 - Brisbane - Site 2715 - Icon Cancer Centre - Chermside; 4101 - South Brisbane - Site 2707 - Mater Brisbane; 5037 - Adelaide - Site 2709 - Icon Cancer Research Adelaide; 5065 - Toorak Gardens - Site 2702 - Burnside War Memorial Hospital - The Brian Fricker Oncology Centre	https://clinicaltrials.gov/ct2/show/NCT05128825
NCT05132075	KontRASt-02	Phase 3	Recruiting	QLD	11/11/2021		Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	2021-002605-10	A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	4066 - Auchenflower - Novartis Investigative Site; 4101 - South Brisbane - Novartis Investigative Site; 4215 - Southport - Novartis Investigative Site; 4812 - Hyde Park - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05132075
NCT05132582	HER2CLIMB-05	Phase 3	Recruiting	WA, SA, NSW, Other, VIC	12/11/2021		Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; placebo; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation	Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo		A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)	HER2 Positive Breast Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - Macquarie University - Macquarie University Hospital; 2145 - Sydney - Westmead Hospital; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3199 - Frankston - Peninsula and South East Oncology - (Completed); 5000 - Adelaide - Cancer Research South Australia; 5042 - Bedford Park - Flinders Medical Centre; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT05132582
NCT05150457	NCT05150457	Phase 1	Recruiting	NSW, VIC, QLD	03/12/2021		BNA35	bispecific_EGFR/4-1BB_antibody	BNA35	bispecific_EGFR/4-1BB_antibody		A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah - St George Private Hospital; 3065 - Fitzroy - St. Vincents Hospital Melbourne; 4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05150691	NCT05150691	Phase 1/Phase 2	Recruiting	QLD, NSW	26/11/2021		DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; Itraconazole; Pertuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate; SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; SMO_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Itraconazole; DB-1303 + Pertuzumab	SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor		A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors	HER2-positive Advanced Solid Tumor	2109 - Sydney - Macquarie Clinical Trials Unit; 4101 - South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05150691
NCT05152147	HERIZON-GEA-01	Phase 3	Recruiting	NSW, VIC, WA, SA	03/12/2021		Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Cisplatin; Fluorouracil; Oxaliplatin; Tislelizumab; Tislelizumab + Zanidatamab; Trastuzumab; Zanidatamab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; bispecific_ERBB2/ERBB2_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Tislelizumab + Zanidatamab; Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Tislelizumab + Zanidatamab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody; Fluorouracil; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody	2021-000296-36; jRCT2061230026	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma	2170 - Liverpool - Liverpool Hospital; 2640 - Albury - Border Medical Oncology Research Unit - (Withdrawn); 3084 - Heidelberg - Austin Health; 5042 - Bedford Park - Flinders Medical Centre; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05152147
NCT05153239	NCT05153239	Phase 3	Recruiting	VIC, NSW, WA	29/11/2021		Irinotecan; Irinotecan + Lurbinectedin; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; DNA_minor_groove-binding_agent	Irinotecan + Lurbinectedin; Lurbinectedin; Irinotecan + Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor; DNA_minor_groove-binding_agent + topoisomerase_inhibitor		A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)	Relapsed Small Cell Lung Cancer	2050 - Camperdown - The Chris Obrien Lifehouse; 2250 - Gosford - Gosford Hospital GH - Central Coast Cancer Centre; 3128 - Box Hill - Box Hill Hospital Eastern Health Clinical School; 3350 - Ballarat Central - BRICC - Ballarat Health Services; NSW 2086 - Frenchs Forest - Northern Beaches Hospital; NSW 2500 - Wollongong - Southern Medical Day Care Centre; VIC 3084 - Heidelberg - Austin Hospital- Medical Oncology Unit; WA 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05153239
NCT05156892	TICTOC	Phase 1	Recruiting	NSW	13/12/2021		Itraconazole; Itraconazole + Tamoxifen; Tamoxifen	SMO_inhibitor + selective_estrogen_receptor_modulator; SMO_inhibitor; selective_estrogen_receptor_modulator	Itraconazole + Tamoxifen; Itraconazole + Tamoxifen	SMO_inhibitor + selective_estrogen_receptor_modulator; SMO_inhibitor + selective_estrogen_receptor_modulator		A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer	Ovarian Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT05156892
NCT05159388	2019-003456-36	Phase 1/Phase 2	Recruiting	NSW, VIC, SA	02/12/2021		Dexamethasone; PRS-344	glucocorticoid; bispecific_PD-L1/4-1BB_antibody	PRS-344; Dexamethasone	bispecific_PD-L1/4-1BB_antibody; glucocorticoid	2019-003456-36	A First in Human Phase 1-2 Open-Label, Multicenter, Dose Escalation and Expansion Study of PRS-344/S095012 in Patients With Solid Tumors	Solid Tumor	Camperdown - Chris O'Brian Lifehouse; Malvern - Cabrini Oncology Research; Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05159388
NCT05166577	NCT05166577	Phase 1/Phase 2	Recruiting	NSW	20/12/2021		Nanatinostat; Nanatinostat + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	Nanatinostat; Nanatinostat + Pembrolizumab; Nanatinostat + Pembrolizumab	HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody		An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Leiomyosarcoma; EBV Related Carcinoma; EBV-Related Sarcoma	Blacktown - Blacktown Hospital; Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05166577
NCT05169697	NCT05169697	Phase 1	Recruiting	VIC, NSW	10/12/2021		YH001; YH001 + YH002; YH002	anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody	YH001 + YH002; YH001 + YH002	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody		A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Sydney - Macquarie University Hospital - (Active, not recruiting); 2800 - Orange - Orange Health Services; 3144 - Malvern - Cabrini Hospital Malvern - (Active, not recruiting); 3199 - Frankston - Peninsula and South Eastern Haematology &amp; Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05169697
NCT05176483	STELLAR-002	Phase 1	Recruiting	QLD, NSW, NZ	15/12/2021		Ipilimumab; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Relatlimab; Zanzalintinib	anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor	Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Zanzalintinib; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody		A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors	Renal Cell Carcinoma; Metastatic Castration-resistant Prostate Cancer; Urothelial Carcinoma; Solid Tumor; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Head and Neck Squamous Cell Carcinoma	1023 - Grafton - Exelixis Clinical Site #30; 2065 - Saint Leonards - Exelixis Clinical Site #42; 2109 - Sydney - Exelixis Clinical Site #36; 2640 - Albury - Exelixis Clinical Site #116; 3204 - Hamilton - Exelixis Clinical Site #45; 4102 - Brisbane - Exelixis Clinical Site #16; 4575 - Birtinya - Exelixis Clinical Site #35	https://clinicaltrials.gov/ct2/show/NCT05176483
NCT05176509	NCT05176509	Phase 1	Recruiting	NSW, VIC, SA	15/12/2021		Pembrolizumab; YH001; YH003	anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody	Pembrolizumab; YH001; YH003	anti-CTLA-4_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-PD-1_monoclonal_antibody		A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor	2148 - Blacktown - Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road; 2217 - Kogarah - &quot;Oncology Clinical Trial Unit St George Private Hospital 1 South Street&quot;; Melbourne - 55 Commercial Rd, Level 2 WBRC; Prahran - Level 3, Suite 7, North Building, Frankston Private, 5 Susono Way, Frankston	https://clinicaltrials.gov/ct2/show/NCT05176509
NCT05180799	NCT05180799	Phase 1/Phase 2	Recruiting	SA, NSW	05/01/2022		BA3071; Nivolumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	BA3071; Nivolumab; Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody		A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors	Solid Tumor, Adult; NSCLC; Urothelial Carcinoma; Gastric Cancer; Small Cell Lung Cancer; Hepatocellular Carcinoma; Cervical Carcinoma; Melanoma; Renal Cell Carcinoma; Carcinoma	2228 - Miranda - Cancer Care Foundation; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT05180799
NCT05182931	I-FIRST	Phase 2	Recruiting	VIC, QLD, NSW, SA, WA	20/12/2021		Dabrafenib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor		A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3084 - Heidelberg - Austin Health; 3128 - Box Hill - Eastern Health - (Not yet recruiting); 3168 - Clayton - Monash Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; Adelaide - Royal Adelaide Hsopital; Melbourne - Peter MacCallum Cancer Centre; Perth - Sir Charles Gairdner Hospital; Prahran - Alfred Hospital - (Not yet recruiting); Sydney - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05187624	2021-001197-37	Phase 1	Recruiting	VIC	07/01/2022		RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	2021-001197-37	An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III	Glioblastoma	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05187624
NCT05198752	NCT05198752	Phase 1	Recruiting	VIC, QLD	19/01/2022		SW1115C3	mRNA_personalised_cancer_vaccine	SW1115C3	mRNA_personalised_cancer_vaccine		A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours	Solid Tumor	Benowa - Pindara Private Hospital; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05198752
NCT05199753	NCT05199753	Phase 1/Phase 2	Recruiting	QLD, VIC, NSW, WA	06/01/2022		LM-108	anti-CCR8_monoclonal_antibody	LM-108	anti-CCR8_monoclonal_antibody		A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours	Advanced Solid Tumor	NSW 2148 - Sydney - Blacktown Hospital; QLD 4101 - South Brisbane - ICON Cancer Centre; QLD 4575 - Birtinya - Sunshine Coast University Private Hospital; VIC 3004 - Melbourne - Alfred Hospital; VIC 3144 - Malvern - Cabrini Health Limited; WA 6009 - Nedlands - One Clinical Research Pty Ltd.	https://clinicaltrials.gov/ct2/show/NCT05199753
NCT05200273	NCT05200273	Phase 1	Unknown status	SA	07/01/2022		AK114	anti-IL-1beta_monoclonal_antibody	AK114	anti-IL-1beta_monoclonal_antibody		A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors; Malignancy; Metastasis	Kurralta Park - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05200273
NCT05201547	DOMENICA	Phase 3	Recruiting	NSW, ACT	20/01/2022		Carboplatin; Carboplatin + Paclitaxel; Dostarlimab; Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane	Carboplatin + Paclitaxel; Dostarlimab; Carboplatin + Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane		Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting	Endometrial Cancer	2298 - Waratah - Calvary Mater Newcastle - (Active, not recruiting); 2605 - Garran - Canberra Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05201547
NCT05205109	KEYNOTE-E73	Phase 1	Recruiting	VIC, QLD, NSW, SA, WA	11/01/2022		ATG 037; ATG 037 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor	ATG 037 + Pembrolizumab; ATG 037 + Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody	KEYNOTE-E73	A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2298 - Sydney - Calvary Mater Newcastle; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 4217 - Benowa - Pindara Private Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research Unit; WA6153 - Mount Pleasant - One Clinical Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT05205109
NCT05208047	NCT05208047	Phase 3	Recruiting	WA, NSW	14/01/2022		CGT9486; CGT9486 + Sunitinib; Sunitinib	KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor,first_generation; VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor; KIT_inhibitor + VEGFR_inhibitor	CGT9486 + Sunitinib; Sunitinib; CGT9486 + Sunitinib	KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor		A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors	Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer	2200 - Bankstown - Bankstown-Lidcombe Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05208047
NCT05208944	2021-005136-34	Phase 2	Recruiting	QLD, VIC, SA	13/01/2022		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2021-005136-34	A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	3065 - Fitzroy - St. Vincent Hospital Melbourne - (Active, not recruiting); 4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic - (Active, not recruiting); 5000 - Adelaide - Cancer Research SA - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05208944
NCT05215340	TROPION-Lung08	Phase 3	Recruiting	SA, VIC, NSW	18/01/2022		Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-002555-10; KEYNOTE-C73; MK3475-C73	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Metastatic Non Small Cell Lung Cancer	2050 - Camperdown - Chris Obrien Lifehouse; 3084 - Heidelberg - Austin Hospital; 3149 - Mount Waverley - Peninsula and South Eastern Haematology and Oncology Group; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05215340
NCT05217446	SEAMARK	Phase 2	Recruiting	VIC, QLD, NSW	19/01/2022		Cetuximab; Cetuximab + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor	Cetuximab + Encorafenib + Pembrolizumab; Pembrolizumab; Cetuximab + Encorafenib + Pembrolizumab	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2021-003715-26; SEAMARK; MK-3475-D31; KEYNOTE-D31	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER	Metastatic Colorectal Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - GenesisCare North Shore; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Parkville - Royal Melbourne Hospital; 3084 - Heidelberg - Austin Health; 4120 - Brisbane - Gallipoli Medical Research Foundation; 4120 - Greenslopes - Greenslopes Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05217446
NCT05220098	2023-504012-16	Phase 1/Phase 2	Recruiting	SA, VIC, NSW	01/02/2022		TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280	bispecific_T-cell_engager,B7H3-targeting	2023-504012-16	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Unresectable Locally Advanced or Metastatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse Hospital; 3144 - Malvern - Cabrini Health; 3168 - Clayton - Monash Medical Centre; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05220098
NCT05221840	PACIFIC-9	Phase 3	Recruiting	SA, QLD, VIC, NSW	02/02/2022		Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Monalizumab; Oleclumab; Placebo; Radiotherapy	placebo; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; radiotherapy; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Placebo; Radiotherapy	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	2023-503999-24-00; 2021-004346-37	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	Non-Small Cell Lung Cancer	2065 - St. Leonards - Research Site; 2145 - Westmead - Research Site; 2217 - Kogarah - Research Site; 2250 - Gosford - Research Site; 3002 - East Melbourne - Research Site; 3021 - St Albans - Research Site; 3084 - Heidelberg - Research Site; 3128 - Box Hill - Research Site; 4101 - South Brisbane - Research Site; 5112 - Elizabeth Vale - Research Site	https://clinicaltrials.gov/ct2/show/NCT05221840
NCT05245968	NCT05245968	Phase 1	Recruiting	SA	17/02/2022		Imatinib; Imatinib + Pimitespib; Pimitespib; Sunitinib	HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; HSP90_inhibitor; VEGFR_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; BCR-ABL1_inhibitor,first_generation; PDGFR_inhibitor; KIT_inhibitor; HSP90_inhibitor + KIT_inhibitor	Imatinib + Pimitespib; Sunitinib; Imatinib + Pimitespib	BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor		A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumors	Adelaide - Flinders Medical Center; Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05245968
NCT05252390	NCT05252390	Phase 1/Phase 2	Recruiting	WA, VIC, NSW	11/02/2022		Enzalutamide; Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Olaparib	BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor; BET_inhibitor; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor	Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Enzalutamide + NUV-868; NUV-868 + Olaparib	BET_inhibitor; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation		Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor	2109 - North Ryde - Macquarie University Hospital; 2298 - Waratah - Calvary Mater Hospital Newcastle; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3144 - Malvern - Cabrini Hospital Malvern; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05252390
NCT05253651	MOUNTAINEER-03	Phase 3	Recruiting	VIC, Other, QLD	14/02/2022		Bevacizumab; Bevacizumab + Cetuximab; Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin; Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	fluoropyrimidine; folinic_acid; anti-VEGF_monoclonal_antibody; ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	Bevacizumab + Cetuximab; Trastuzumab + Tucatinib; Bevacizumab + Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin; Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent	2021-002672-40	An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer	Colorectal Neoplasms	3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 4814 - Townsville - Townsville Cancer Center	https://clinicaltrials.gov/ct2/show/NCT05253651
NCT05254171	ASPIRE	Phase 2/Phase 3	Recruiting	VIC, NSW, ACT, Australia Capital Territory, SA, WA	21/02/2022		Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + SBP-101; Nab-paclitaxel; Placebo; SBP-101	gemcitabine; placebo; antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; taxane; antimetabolite; polyamine_analogue	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + SBP-101; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + SBP-101; Placebo	antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; gemcitabine; placebo		A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV	2485 - Tweed Heads - The Tweed Hospital - (Withdrawn); 2605 - Garran - Canberra Region Cancer Centre; 3084 - Heidelberg - Austin Hospital; 5307 - Kurralta Park - Ashford Cancer Centre Research; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05254171
NCT05257408	GOG-3073	Phase 3	Recruiting	NSW, VIC, QLD	16/02/2022		Nab-paclitaxel	taxane	Nab-paclitaxel	taxane	ROSELLA Study 556; GOG-3073; ENGOT-OV72; APGOT-Ov10; LACOG 0223; ANZGOG2221/2023	A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms	2065 - St. Leonards - Site 426; 3000 - Melbourne - Site 414; 3128 - Melbourne - Site 419; 4217 - Benowa - Site 417	https://clinicaltrials.gov/ct2/show/NCT05257408
NCT05261399	SAFFRON	Phase 3	Recruiting	VIC, NSW, WA	25/02/2022		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Osimertinib + Savolitinib; Pemetrexed; Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; MET_inhibitor,type_1; EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib; Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent	2021-006374-24	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Carcinoma; Non-Small-Cell Lung	2170 - Liverpool - Research Site; 2298 - Waratah NSW - Research Site; 3168 - Clayton - Research Site; 3220 - Geelong - Research Site - (Withdrawn); 6160 - Fremantle - Research Site	https://clinicaltrials.gov/ct2/show/NCT05261399
NCT05263180	NCT05263180	Phase 1	Recruiting	NSW, VIC	22/02/2022		EMB-09	bispecific_PD-L1/OX40_antibody	EMB-09	bispecific_PD-L1/OX40_antibody		A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	Frankston - Peninsula and South Eastern Haematology &amp; Oncology Group; Leonards Hill - GenesisCareNorthShore; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05263180
NCT05263739	NCT05263739	Phase 1	Not yet recruiting		28/02/2022		ESG206	anti-BAFFR_monoclonal_antibody	ESG206	anti-BAFFR_monoclonal_antibody		A First-in-Human Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb, ESG206 in Subjects With B-cell Lymphoid Malignancies	B-cell Lymphoid Malignancies		https://clinicaltrials.gov/ct2/show/NCT05263739
NCT05266105	NCT05266105	Phase 1	Unknown status	WA, VIC, QLD, NSW	23/02/2022		Palazestrant; Palazestrant + Palbociclib; Palbociclib	CDK4/6_inhibitor; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	Palazestrant + Palbociclib; Palazestrant + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist		A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	2145 - Westmead - Site 6104 - (Not yet recruiting); 3168 - Clayton - Site 6101; 3220 - Geelong - Site 6103; 4101 - South Brisbane - Site 6102; 6009 - Nedlands - Site 6105	https://clinicaltrials.gov/ct2/show/NCT05266105
NCT05267626	NCT05267626	Phase 1/Phase 2	Recruiting	VIC, NSW	23/02/2022		AU-007; AU-007 + Aldesleukin; Aldesleukin	IL-2_variant; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin	IL-2_variant + anti-IL-2_monoclonal_antibody; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody		A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Advanced Solid Tumor; Metastatic Cancer	2228 - Miranda - Southside Cancer Care Centre; 3004 - Melbourne - The Alfred Hospital; 3021 - Saint Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health	https://clinicaltrials.gov/ct2/show/NCT05267626
NCT05269316	NCT05269316	Phase 1	Recruiting	NSW, WA	03/03/2022		IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor		A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors	Solid Tumor; Advanced Solid Tumor	2148 - Blacktown - Blacktown Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05269316
NCT05277051	2021-004968-95	Phase 1	Recruiting	WA	03/03/2022		Dostarlimab	anti-PD-1_monoclonal_antibody	Dostarlimab	anti-PD-1_monoclonal_antibody	2021-004968-95	A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors	Neoplasms	6009 - Nedlands - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05277051
NCT05277168	NCT05277168	Phase 1/Phase 2	Recruiting	WA, VIC, QLD, NSW	03/03/2022		SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate	SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate		AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research Ltd; 2109 - Sydney - Macquarie University - (Not yet recruiting); 2145 - Westmead - Westmead Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology &amp; Oncology Group (PASO); 4215 - Southport - Gold Coast Private Hospital - (Not yet recruiting); 8000 - Nedlands - One Clinical Research (OCR); Liverpool - Sydney South West Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05277168
NCT05279300	NCT05279300	Phase 1	Recruiting	SA, NSW	14/03/2022		CS5001	anti-ROR1_antibody-drug_conjugate	CS5001	anti-ROR1_antibody-drug_conjugate		A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas	Advanced Solid Tumor; Advanced Lymphoma	2031 - Randwick - Scientia Clinical Research Limited; Adelaide - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05279300
NCT05286801	PEPN2121	Phase 1/Phase 2	Recruiting	QLD	15/03/2022		Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	NCI-2022-01992; PEPN2121; PEPN2121; UM1CA228823	A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor	4101 - South Brisbane - Queensland Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05290597	NCT05290597	Phase 1	Recruiting	NSW	13/03/2022		IBI363	anti-PD-1_IL-2-immunocytokine_conjugate	IBI363	anti-PD-1_IL-2-immunocytokine_conjugate		A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas	Solid Malignancies or Lymphomas	2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05290597
NCT05303532	ROSY-D	Phase 3	Enrolling by invitation	VIC	21/03/2022		Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	2021-003031-29	ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment	Cancer	3000 - Melbourne - Research Site; 3128 - Box Hill - Research Site	https://clinicaltrials.gov/ct2/show/NCT05303532
NCT05306444	NCT05306444	Phase 1	Recruiting	NSW	22/03/2022		CLN-418	bispecific_4-1BB/B7H4_antibody	CLN-418	bispecific_4-1BB/B7H4_antibody		A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2217 - Kogarah - St George Private Hospital; 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05306444
NCT05307705	PIKASSO-01	Phase 1	Recruiting	SA, NSW, VIC	25/03/2022		Abemaciclib; Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Anastrozole; Exemestane; Fulvestrant; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; Imlunestrant; LOXO-783; LOXO-783 + Paclitaxel; Letrozole; Paclitaxel	PI3Kalpha_H1047R_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; taxane; selective_estrogen_receptor_degrader; aromatase_inhibitor; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; LOXO-783; LOXO-783 + Paclitaxel; Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Anastrozole; Exemestane; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; LOXO-783 + Paclitaxel; Letrozole	CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; aromatase_inhibitor	J4C-OX-JZUA; 2022-000175-40	A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation	Breast Cancer; Solid Tumour	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Center; 5000 - Adelaide SA - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05307705
NCT05315700	NCT05315700	Phase 1/Phase 2	Recruiting	NSW, WA	06/04/2022		ORIC-114	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	ORIC-114	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective		An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Solid Tumors	Camperdown - Chris O'Brien Lifehouse; Nedlands - One Clinical Research, Hollywood Medical Centre; Sydney - Sydney Adventist Health - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05315700
NCT05325866	FORTITUDE-301	Phase 1/Phase 2	Recruiting	WA, NSW, QLD, VIC	06/04/2022		Bemarituzumab	anti-FGFR2_monoclonal_antibody	Bemarituzumab	anti-FGFR2_monoclonal_antibody		A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)	Solid Tumors	2031 - Randwick - Prince of Wales Hospital; 2170 - Liverpool - Liverpool Hospital; 2500 - Wollongong - Wollongong Hospital; 3144 - Malvern - Cabrini Hospital; 4350 - Toowoomba - Toowoomba Hospital; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05325866
NCT05327530	2021-003669-36	Phase 2	Recruiting	SA, NSW, VIC, TAS	13/04/2022		Avelumab; Avelumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Avelumab; Avelumab + Sacituzumab Govitecan; Avelumab + Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-003669-36	A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)	Locally Advanced or Metastatic Urothelial Carcinoma	Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre Clayton; Footscray - Sunshine Hospital - PARENT; Heidelberg - Austin Health; Kurralta Park - Ashford Cancer Centre Research; Liverpool - Liverpool Hospital - PARENT; Newcastle - Calvary Mater Newcastle - PARENT; Southport - Tasman Oncology Research Ltd - Oncology; St Leonards - Royal North Shore Hospital - PARENT; Sydney - Macquarie University Hospital - PARENT; Westmead - The Kinghorn Can Cen	https://clinicaltrials.gov/ct2/show/NCT05327530
NCT05332574	NCT05332574	Phase 1/Phase 2	Recruiting	VIC, NSW	12/04/2022		GB263T	trispecific_EGFR/cMET/cMET_antibody	GB263T	trispecific_EGFR/cMET/cMET_antibody		A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific EGFR/cMET/cMET Antibody GB263T in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	NSCLC; Other Solid Tumors	2065 - Saint Leonards - Genesis Care; 2145 - Westmead - Westmead Hospital; 3065 - Melbourne - St Vincent's Hospital Melbourne; 3144 - Malvern - Cabrini Hospital Malvern	https://clinicaltrials.gov/ct2/show/NCT05332574
NCT05337137	RELATIVITY-106	Phase 1/Phase 2	Recruiting	WA, SA, NSW, VIC	13/04/2022		Bevacizumab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Nivolumab; Placebo; Relatlimab	placebo; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2021-003606-53; U1111-1267-1579	A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	2050 - Camperdown - Local Institution - 0045; 3065 - Fitzroy - Local Institution - 0013; 3084 - Heidelberg - Local Institution - 0026; 5000 - Adelaide - Local Institution - 0022; 6009 - Nedlands - Local Institution - 0017	https://clinicaltrials.gov/ct2/show/NCT05337137
NCT05338346	ATRIUM	Phase 1	Recruiting	NSW, VIC, SA	14/04/2022		ATG-018	ATR_inhibitor	ATG-018	ATR_inhibitor		A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies	Advanced Solid Tumors; Hematological Malignancies	Brisbane - Icon Cancer Centre South Brisbane; Camperdown - Chris O'Brien Lifehouse; Heidelberg - Austin Health; Melbourne - Alfred Health; Sydney - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT05338346
NCT05340374	LuCAB	Phase 1/Phase 2	Recruiting	VIC	14/04/2022		Cabazitaxel; Cabazitaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; taxane; radioligand,PSMA-targeting + taxane	Cabazitaxel + Lu-177 vipivotide tetraxetan; Cabazitaxel + Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting + taxane		Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; mCRPC	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05340374
NCT05348577	CAPItello280	Phase 3	Recruiting	SA, NSW, QLD	21/04/2022		Capivasertib; Capivasertib + Docetaxel; Docetaxel; Placebo	taxane; placebo; pan-AKT_inhibitor + taxane; pan-AKT_inhibitor	Capivasertib + Docetaxel; Docetaxel; Capivasertib + Docetaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; pan-AKT_inhibitor + taxane; placebo	2023-504996-26; 2021-005201-27	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Prostate Cancer	2076 - Wahroonga - Research Site; 2217 - Kogarah - Research Site; 2228 - Miranda - Research Site - (Not yet recruiting); 2800 - Orange - Research Site; 4020 - Redcliffe - Research Site; 4120 - Greenslopes - Research Site; 4575 - Birtinya - Research Site; 5000 - North Adelaide - Research Site	https://clinicaltrials.gov/ct2/show/NCT05348577
NCT05349643	NCT05349643	Phase 2	Recruiting	NSW, QLD	22/04/2022		AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-05X	anti-CSF1R_monoclonal_antibody		A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor	Pigmented Villonodular Synovitis; TGCT; Tenosynovial Giant Cell Tumor	Camperdown - AmMax Bio, Clinical Site; Woolloongabba - AmMax Bio, Clinical Site	https://clinicaltrials.gov/ct2/show/NCT05349643
NCT05352672	2021-004453-23	Phase 2/Phase 3	Recruiting	TAS, QLD	25/04/2022		Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; placebo	Cemiplimab; Cemiplimab + Fianlimab; Pembrolizumab; Cemiplimab + Fianlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2021-004453-23; 2023-505772-30-00	A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	03004 - Melbourne - The Alfred Hospital; 03220 - Geelong - Barwon Health Andrew Love Cancer Centre, University Hospital Geelong; 03355 - Wendouree - Ballarat Oncology and Haematology Clinical Trials Unit; 04814 - Townsville - The Townsville Hospital and Health Service; 05006 - Adelaide - Calvary North Adelaide Hospital; 4215 - Southport - Gold Coast University Hospital - (Suspended); 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05352672
NCT05355298	NCT05355298	Phase 1/Phase 2	Recruiting	VIC, QLD, NSW	27/04/2022		AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; taxane; antimetabolite	AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; antimetabolite; taxane		A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients	Pancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinoma	2065 - St Leonards - GenesisCare; 2145 - Westmead - Westmead Hospital; 3021 - St Albans - Western Health; 3121 - Richmond - Epworth Healthcare; 3128 - Box Hill - Epworth Healthcare; 3168 - Clayton - Monash Health; 4120 - Greenslopes - Gallipolli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05355298
NCT05356741	TCD17730	Phase 1/Phase 2	Recruiting	VIC, NSW	26/04/2022		AMX-818; AMX-818 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; bispecific_T-cell_engager,ERBB2-targeting	AMX-818; AMX-818 + Pembrolizumab; AMX-818 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting	TCD17730; MK-3475-D14; KEYNOTE-D14	A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Locally Advanced or Metastatic HER2-Expressing Cancers	2031 - Randwick - Investigational site number #101; 3000 - Melbourne - Investigational site number #100	https://clinicaltrials.gov/ct2/show/NCT05356741
NCT05361395	2021-005462-17	Phase 1	Recruiting	NSW	29/04/2022		Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin; Durvalumab; Durvalumab + Tarlatamab; Etoposide; Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Durvalumab; Durvalumab + Tarlatamab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Durvalumab + Tarlatamab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2021-005462-17	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer	Extensive Stage Small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05361395
NCT05364073	NCT05364073	Phase 1	Recruiting	NSW, VIC	03/05/2022		Furmonertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	Furmonertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective		A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations	Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I	2065 - St Leonards - ArriVent Investigative Site; 2148 - Blacktown - ArriVent Investigative Site; 3084 - Heidelberg - ArriVent Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05364073
NCT05367440	PETRANHA	Phase 1/Phase 2	Recruiting	VIC, NSW	05/05/2022		AZD5305; AZD5305 + Abiraterone; AZD5305 + Darolutamide; AZD5305 + Enzalutamide; Abiraterone; Darolutamide; Enzalutamide	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor; PARP_inhibitor; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	AZD5305 + Abiraterone; AZD5305 + Darolutamide; AZD5305 + Enzalutamide; AZD5305 + Abiraterone; AZD5305 + Darolutamide; AZD5305 + Enzalutamide	CYP17A1_inhibitor + PARP_inhibitor; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation	2021-006289-19	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)	Metastatic Prostate Cancer	2010 - Darlinghurst - Research Site; 2050 - Camperdown - Research Site; 2065 - St. Leonards - Research Site; 3002 - East Melbourne - Research Site; 3004 - Melbourne - Research Site; 3084 - Heidelberg - Research Site	https://clinicaltrials.gov/ct2/show/NCT05367440
NCT05381909	CTR20232532	Phase 1	Recruiting	QLD, VIC, NZ	16/05/2022		BGB-24714; BGB-24714 + Paclitaxel; Carboplatin; Docetaxel; Docetaxel + Paclitaxel; Paclitaxel	IAP_inhibitor + taxane; SMAC_mimetic + taxane; platinum-based_antineoplastic_agent; taxane; IAP_inhibitor; SMAC_mimetic	BGB-24714; BGB-24714 + Paclitaxel; Docetaxel + Paclitaxel; BGB-24714 + Paclitaxel; Carboplatin; Docetaxel + Paclitaxel	IAP_inhibitor; IAP_inhibitor + taxane; SMAC_mimetic; SMAC_mimetic + taxane; taxane; IAP_inhibitor + taxane; SMAC_mimetic + taxane; platinum-based_antineoplastic_agent	CTR20232532	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors	Solid Tumor, Adult	1023 - Auckland - Auckland City Hospital; 3084 - Heidelberg - Austin Health; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4102 - Brisbane - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05381909
NCT05382286	ASCENT-04	Phase 3	Recruiting	SA, WA, VIC, TAS, QLD, NSW	16/05/2022		Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	gemcitabine; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005742-14; KEYNOTE-D19; jRCT2041220123	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	Triple Negative Breast Cancer; PD-L1 Positive	2060 - North Sydney - Mater Hospital - North Sydney; 2065 - St Leonards - GenesisCare - North Shore; 2217 - Kogarah - Saint George Hospital - Australia; 2640 - Albury - Border Medical Oncology; 3050 - Parkville - Peter MacCallum Cancer Centre; 3084 - Melbourne - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Misericordiae Limited and Mater Research Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 5000 - Adelaide - Cancer Research SA (CRSA); 6009 - Nedlands - Breast Cancer Research Center - Western Australia; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05382286
NCT05382299	ASCENT-03	Phase 3	Recruiting	NSW, QLD, TAS, VIC, WA, SA	16/05/2022		Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	platinum-based_antineoplastic_agent; taxane; gemcitabine; antimetabolite; anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel	anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005743-79; DOH-27082022-7958; jRCT2041220122; CTR20234162	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	Triple Negative Breast Cancer; PD-L1 Negative	2060 - North Sydney - Mater Hospital - North Sydney; 2065 - St Leonards - GenesisCare - North Shore; 2217 - Kogarah - Saint George Hospital - Australia; 2640 - Albury - Border Medical Oncology; 3084 - Melbourne - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Misericordiae Limited and Mater Research Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 5000 - Adelaide - Cancer Research SA (CRSA); 6009 - Nedlands - Breast Cancer Research Center - Western Australia; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05382299
NCT05383079	AlphaBet	Phase 1/Phase 2	Recruiting	VIC	16/05/2022		Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Radium-223; Radium-223	radioligand,PSMA-targeting; radioligand,PSMA-targeting + radium_223_radionucleotide; radium_223_radionucleotide	Lu-177 vipivotide tetraxetan + Radium-223; Lu-177 vipivotide tetraxetan + Radium-223	radioligand,PSMA-targeting + radium_223_radionucleotide; radioligand,PSMA-targeting + radium_223_radionucleotide		Combination of Radium-223 and Lutetium-177 PSMA-I&amp;T in Men With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; mCRPC; Prostate Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05383079
NCT05383352	SIRACUSA	Phase 1	Recruiting	SA, VIC	16/05/2022		Fluorouracil; Fluorouracil + Liposomal Irinotecan; Irinotecan; Leucovorin; Liposomal Irinotecan	fluoropyrimidine + topoisomerase_inhibitor; Fluorouracil; topoisomerase_inhibitor; fluoropyrimidine; folinic_acid	Fluorouracil + Liposomal Irinotecan; Fluorouracil + Liposomal Irinotecan; Leucovorin	fluoropyrimidine + topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine + topoisomerase_inhibitor; folinic_acid	2021-003264-26	A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Agents in Adult Participants With Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma	Bedford Park - Flinders Medical Centre; Frankston - Peninsula and Southeast Oncology - Frankston Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05383352
NCT05384626	NCT05384626	Phase 1/Phase 2	Recruiting	VIC, NSW	17/05/2022		Lorlatinib; NVL-655	ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation	Lorlatinib; NVL-655	ALK_inhibitor,fourth_generation; ALK_inhibitor,third_generation; ROS1_inhibitor		A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Saint Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05384626
NCT05393791	ANZadapt	Phase 2	Recruiting	NSW, QLD, WA, SA	23/05/2022		Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	ANZUP 2101	ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 2065 - St Leonards - Genesis Care North Shore; 2076 - Wahroonga - Sydney Adventist Hospital - (Not yet recruiting); 2298 - Newcastle - Calvary Mater Newcastle; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 4101 - South Brisbane - Mater Hospital Brisbane; 5000 - Adelaide - Royal Adelaide Hospital; 6150 - Murdoch - Fiona Stanly Hospital	https://clinicaltrials.gov/ct2/show/NCT05393791
NCT05399654	INCLINE-101	Phase 1/Phase 2	Recruiting	WA	26/05/2022		TAC-001	TLR9_agonistic_antibody_conjugate	TAC-001	TLR9_agonistic_antibody_conjugate		A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	6009 - Nedlands - Clinical Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05399654
NCT05410145	NCT05410145	Phase 1	Recruiting	VIC, NSW	06/06/2022		D3S-001	KRAS_G12C_inhibitor	D3S-001	KRAS_G12C_inhibitor		A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation	KRAS P.G12C	2109 - Sydney - D3 Bio Investigative Site; 3144 - Malvern - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05410145
NCT05411133	NCT05411133	Phase 1	Recruiting	NSW, SA	05/06/2022		ARB202	bispecific_T-cell_engager,CDH17-targeting	ARB202	bispecific_T-cell_engager,CDH17-targeting		A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies	Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Gastroesophageal Junction	Adelaide - Southern Oncology Clinical Research Unit; Sydney - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05411133
NCT05415072	2021-003380-95	Phase 1/Phase 2	Recruiting	VIC, NSW	08/06/2022		DYP688; Tebentafusp	GNAQ/GNA11_inhibitor; anti-CD3/scFv_fusion_protein,gp100-targeting	Tebentafusp; DYP688	anti-CD3/scFv_fusion_protein,gp100-targeting; GNAQ/GNA11_inhibitor	2021-003380-95	A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas	Metastatic Uveal Melanoma	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05415072
NCT05417594	CERTIS1	Phase 1/Phase 2	Recruiting	NSW	09/06/2022		AZD9574; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan; Datopotamab deruxtecan; Temozolomide; Trastuzumab Deruxtecan	alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor	AZD9574; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan; Datopotamab deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	2021-006227-17	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)	Advanced Solid Malignancies	2010 - Darlinghurst - Research Site; 2031 - Randwick - Research Site; 2050 - Camperdown - Research Site	https://clinicaltrials.gov/ct2/show/NCT05417594
NCT05419375	NCT05419375	Phase 2	Recruiting	VIC, NSW, NZ, WA	13/06/2022							Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors	Solid Tumors	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2050 - Camperdown - Lifehouse; 2065 - St Leonards - Northern Cancer Institute; 2145 - Westmead - Westmead Hospital; Medical Oncology and Pallative Care; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 6009 - Nedlands - One Clinical Research - (Completed)	https://clinicaltrials.gov/ct2/show/NCT05419375
NCT05419388	NCT05419388	Phase 1/Phase 2	Recruiting	NZ, WA, QLD, NSW	13/06/2022		RO7247669	bispecific_PD-1/LAG3_antibody	RO7247669	bispecific_PD-1/LAG3_antibody		A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research - (Active, not recruiting); 2060 - North Sydney - Melanoma Institute Australia - (Active, not recruiting); 2450 - Coffs Harbour - Coffs Harbour Health Campus - (Active, not recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital; Cancer Trials Unit - (Active, not recruiting); 6002 - Wellington - Wellington Hospital; Regional Oncology Unit - (Active, not recruiting); 6009 - Nedlands - One Clinical Research - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05419388
NCT05425940	STELLAR-303	Phase 3	Recruiting	NZ, SA, VIC, NSW	16/06/2022		Atezolizumab; Atezolizumab + Zanzalintinib; Regorafenib; Zanzalintinib	anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor	Atezolizumab + Zanzalintinib; Regorafenib; Atezolizumab + Zanzalintinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	2021-003243-21	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer	Colorectal Cancer	1023 - Auckland - Exelixis Clinical Site #57; 2200 - Bankstown - Exelixis Clinical Site #53; 2444 - Port Macquarie - Exelixis Clinical Site #27; 2640 - Albury - Exelixis Clinical Site #83; 3002 - Melbourne - Exelixis Clinical Site #19; 3021 - Melbourne - Exelixis Clinical Site #23; 3084 - Heidelberg - Exelixis Clinical Site #97; 3204 - Hamilton - Exelixis Clinical Site #69; 5011 - Woodville South - Exelixis Clinical Site #64; 5042 - Bedford Park - Exelixis Clinical Site #117; 6021 - Wellington - Exelixis Clinical Site #104; 9016 - Dunedin - Exelixis Clinical Site #49	https://clinicaltrials.gov/ct2/show/NCT05425940
NCT05428735	DRAGON-2	N/A	Recruiting	VIC	17/06/2022							An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) With PVE Alone in Patients With Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)	Colorectal Cancer Liver Metastases (CRLM); Small Future Liver Remnant (FLR)	3168 - Clayton - Monash Medical Centre - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05428735
NCT05440786	J1S-MC-JP04	Phase 2	Recruiting	NSW, VIC	28/06/2022		Abemaciclib; Abemaciclib + Irinotecan + Temozolomide; Irinotecan; Irinotecan + Temozolomide; Temozolomide	alkylating_agent; topoisomerase_inhibitor; CDK4/6_inhibitor; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor	Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide; Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide	CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor	J1S-MC-JP04	A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma	Sarcoma, Ewing; Neoplasm Metastasis	2145 - Westmead - The Children's Hospital at Westmead; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Melbourne - Royal Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05440786
NCT05450692	LATIFY	Phase 3	Recruiting	SA, WA, VIC, NSW	06/07/2022		Ceralasertib; Ceralasertib + Durvalumab; Docetaxel; Durvalumab	anti-PD-L1_monoclonal_antibody; ATR_inhibitor; taxane; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	Ceralasertib + Durvalumab; Docetaxel; Ceralasertib + Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	2022-000493-26	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY	Advanced or Metastatic Non-Small Cell Lung Cancer	2480 - Lismore - Research Site; 3355 - Wendouree - Research Site; 5112 - Elizabeth Vale - Research Site; 6150 - Murdoch - Research Site	https://clinicaltrials.gov/ct2/show/NCT05450692
NCT05450744	IPAX-2	Phase 1	Recruiting	NZ, SA, VIC, QLD	06/07/2022		131I-IPA	radioiodine_conjugate	131I-IPA	radioiodine_conjugate		A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	Adelaide - Royal Adelaide Hospital; Auckland - Mercy Hospital; Gold Coast - Gold Coast University Hospital - (Not yet recruiting); Melbourne - Olivia Newton John Cancer Research Institute/Austin Health	https://clinicaltrials.gov/ct2/show/NCT05450744
NCT05458219	NCT05458219	Phase 1	Recruiting	QLD	11/07/2022		IBI343	anti-CLDN18.2_antibody-drug_conjugate	IBI343	anti-CLDN18.2_antibody-drug_conjugate		A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05458219
NCT05462236	MK-3475-D65	Phase 2	Recruiting	QLD, VIC, NSW	13/07/2022		AUM001; Irinotecan; Irinotecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; MNK_inhibitor; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	Irinotecan + Pembrolizumab; AUM001; Irinotecan + Pembrolizumab	anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor; MNK_inhibitor; anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	KEYNOTE-D65; MK-3475-D65	A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2500 - Wollongong - Prince of Wales Hospital; 3144 - Malvern - Cabrini Hospital; 3355 - Wendouree - Ballarat Oncology and Haematology; 4217 - Benowa - Pindara Private Hospital, Gold Coast Cancer Care	https://clinicaltrials.gov/ct2/show/NCT05462236
NCT05462717	NCT05462717	Phase 1	Recruiting	VIC, NSW	13/07/2022		RMC-6291	KRAS_G12C_inhibitor	RMC-6291	KRAS_G12C_inhibitor		Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma; Advanced Solid Tumor	2228 - Sydney - Southside Cancer Care Centre; 3084 - Heidelberg - Austin Health, Olivia Newton-John Cancer Research &amp; Wellness Centre; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 3280 - Warrnambool - South West Health Care	https://clinicaltrials.gov/ct2/show/NCT05462717
NCT05466799	TRIPP-FFX	Phase 2	Recruiting	SA, VIC, QLD	18/07/2022		OncoSil	brachytherapy	OncoSil	brachytherapy		An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.	Locally Advanced Pancreatic Cancer	Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Richmond - Epworth Healthcare - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05466799
NCT05468697	MK-6482-024	Phase 1/Phase 2	Recruiting	NSW	18/07/2022		Belzutifan; Palbociclib; Thiotepa	alkylating_agent; CDK4/6_inhibitor; HIF2a_inhibitor	Palbociclib; Belzutifan; Thiotepa	CDK4/6_inhibitor; HIF2a_inhibitor; alkylating_agent	MK-6482-024; LITESPARK-024; 2023-504963-17	A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 2001)	https://clinicaltrials.gov/ct2/show/NCT05468697
NCT05480865	Argonaut	Phase 1	Recruiting	SA, WA, VIC, NSW	27/07/2022		BBP-398; BBP-398 + Sotorasib; Sotorasib	SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	BBP-398 + Sotorasib; BBP-398 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor		A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation	Solid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer	3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 5000 - Adelaide - Cancer Research SA; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6008 - Subiaco - St John of God Subiaco Hospital; 6009 - Perth - One Clinical Research; NSW 2800 - Orange - Orange Health Service	https://clinicaltrials.gov/ct2/show/NCT05480865
NCT05483530	NCT05483530	Phase 1	Recruiting	NSW	01/08/2022		HLX10; HLX10 + HLX60; HLX60	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody	HLX10 + HLX60; HLX10 + HLX60	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody		A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Efficacy of HLX60 (Anti-GARP Monoclonal Antibody) Combination With HLX10 (Anti-PD-1 Monoclonal Antibody) in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Sydney - Macquarie University Hospital &amp; Nepean Hospital	https://clinicaltrials.gov/ct2/show/NCT05483530
NCT05487235	2021-006479-40	Phase 1	Recruiting	VIC, NSW, SA, NZ, WA	02/08/2022		Atezolizumab; Atezolizumab + RLY-1971; RLY-1971	anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor	Atezolizumab + RLY-1971; Atezolizumab + RLY-1971	SHP2_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody	2021-006479-40	A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	1124 - Auckland - Auckland City Hospital; 2010 - Darlinghurst - St Vincent's Hospital Sydney; 3084 - Heidelberg - Austin Hospital; 3690 - Wodonga - Border Medical Oncology; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - One Clinical Research Perth	https://clinicaltrials.gov/ct2/show/NCT05487235
NCT05494918	NCT05494918	Phase 1	Recruiting	WA	08/08/2022		JSKN003	anti-ERBB2_antibody-drug_conjugate	JSKN003	anti-ERBB2_antibody-drug_conjugate		A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	6009 - Perth - Breast Cancer Research Centre	https://clinicaltrials.gov/ct2/show/NCT05494918
NCT05498597	NCT05498597	Phase 1	Recruiting	WA, SA, NSW, VIC, QLD	10/08/2022		AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151	anti-FR-alpha_antibody-drug_conjugate		First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	Advanced Solid Tumor; Advanced Cancer; Advanced Carcinoma; Ovarian Cancer; Ovarian Carcinoma; Ovarian Epithelial Cancer; Ovarian Endometrioid Adenocarcinoma; Endometrial Cancer; Endometrial Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Lung Adenocarcinoma; Triple Negative Breast Cancer; Pancreatic Ductal Adenocarcinoma; Malignant Pleural Mesothelioma; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Mucinous Adenocarcinoma	Adelaide - Cancer Research SA; Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital; Perth - One Clinical Research (OCR); South Brisbane - Mater Cancer Care Centre; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05498597
NCT05500508	NCT05500508	Phase 1/Phase 2	Recruiting	NSW	12/08/2022		AMXT-1501	polyamine_transport_inhibitor	AMXT-1501	polyamine_transport_inhibitor		A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer	Cancer; Solid Tumor; Solid Carcinoma; Advanced Cancer; DIPG Brain Tumor; Ovary Cancer; Breast Cancer; Papillary Thyroid Cancer; Head and Neck Cancer; Gastric Cancer; Nsclc; Mesotheliomas Pleural; Mesothelioma Peritoneum; Esophageal Cancer; Diffuse Midline Glioma, H3 K27M-Mutant; Endometrial Cancer; Cervical Cancer; Melanoma; Colorectal Cancer; Glioma, Malignant	Sydney - Kids Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05500508
NCT05501886	VIKTORIA-1	Phase 3	Recruiting	NSW, QLD, VIC, TAS, WA, SA	12/08/2022		Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Gedatolisib; Palbociclib	pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor	Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Alpelisib + Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader	2021-005235-24	Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant &amp; With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy	Breast Cancer	Adelaide - Adelaide Oncology &amp; Haematology; Fitzroy - St Vincent's Hospital (Melbourne) Ltd; Frankston - Peninsula &amp; South Eastern Hematology and Oncology Group (PSEHOG); Nedlands - Hollywood Private Hospital, Breast Cancer Research Centre; South Brisbane - Mater Hospital Brisbane, Mater Cancer Care Centre; Southport - Icon Cancer Centre- Southport; Wahroonga - Sydney Adventist Hospital; Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05501886
NCT05505825	NCT05505825	Phase 1/Phase 2	Recruiting	NSW, QLD, VIC, SA	16/08/2022		AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody		A Phase Ib/II Clinical Study of Anti-PD-1 and CTLA-4 Bispecific Antibody, Cadonilimab(AK104), in Combination With Chiauranib in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Who Failed First-line Platinum-based Chemotherapy in Combination With Programmed Cell Death-1(PD1)/Programmed Cell Death Protein Ligand-1(PDL1) Inhibitors	SCLC,Extensive Stage	Bedford Park - Flinders Medical Centre; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; South Brisbane - Icon Cancer Centre; St Albans - Sunshine Hospital; Westmead - Westmead Hospital; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05505825
NCT05508906	NCT05508906	Phase 1	Recruiting	WA, NSW	18/08/2022		Alpelisib; Alpelisib + Palazestrant; Palazestrant; Palazestrant + Ribociclib; Ribociclib	PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor; CDK4/6_inhibitor; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	Alpelisib + Palazestrant; Palazestrant + Ribociclib; Alpelisib + Palazestrant; Palazestrant + Ribociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist		A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer	Metastatic Breast Cancer; Advanced Breast Cancer; HR-positive Breast Cancer; HER2-negative Breast Cancer	2109 - New South Wales - Macquarie Health; 6009 - Nedlands - Breast Cancer Research Center- Western Australia	https://clinicaltrials.gov/ct2/show/NCT05508906
NCT05509985	NCT05509985	Phase 1	Not yet recruiting	SA, NSW	18/08/2022		ASKG315; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-15_prodrug	ASKG315; Pembrolizumab	IL-15_prodrug; anti-PD-1_monoclonal_antibody		A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Melbourne - The Alfred Hospital; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05509985
NCT05512377	U1111-1292-3392	Phase 2	Recruiting	SA, VIC, QLD, NSW	22/08/2022		Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	2022-001500-18; U1111-1292-3392	Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours	Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer; Lung Neoplasms; Bladder Cancer	2031 - Randwick - Prince of Wales Hospital; 3084 - Heidelberg - Austin Health; 4101 - South Brisbane - ICON; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05512377
NCT05513703	2022-500608-23-00	Phase 2	Recruiting	VIC	23/08/2022		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	2022-500608-23-00	Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Non Small Cell Lung Cancer	3168 - Clayton - Monash Medical Centre /ID# 247679	https://clinicaltrials.gov/ct2/show/NCT05513703
NCT05519449	ENGAGER-PSMA-01	Phase 1	Recruiting	NSW, WA, SA	25/08/2022		JANX007	PSMA-tumor-activated_T-cell_engager	JANX007	PSMA-tumor-activated_T-cell_engager	ENGAGER-PSMA-01	A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse (COBLH); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SoCRU); 6009 - Nedlands - Linear Clinical Research Ltd.	https://clinicaltrials.gov/ct2/show/NCT05519449
NCT05523947	NCT05523947	Phase 1/Phase 2	Recruiting	WA, SA, NSW	29/08/2022		YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367	bispecific_ERBB2/4-1BB_antibody		A Phase 1/2, Non-randomized, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors	HER2-Positive Solid Tumor	Adelaide - Southern Oncology Clinical Research Unit; Perth - Breast Cancer Research Centre - WA - (Withdrawn); Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05523947
NCT05525247	NCT05525247	Phase 1/Phase 2	Recruiting	NSW, Perth, WA	30/08/2022		Gemcitabine	gemcitabine; antimetabolite	Gemcitabine	antimetabolite; gemcitabine		A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah - Selecxine Investigator site - (Not yet recruiting); 6153 - Brentwood - Selecxine Investigator site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05525247
NCT05533697	2023-504506-11-00	Phase 1/Phase 2	Recruiting	WA, VIC, NSW	07/09/2022		Pembrolizumab; Pembrolizumab + mRNA-4359; mRNA-4359	anti-PD-1_monoclonal_antibody; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	Pembrolizumab + mRNA-4359; mRNA-4359; Pembrolizumab + mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	2023-504506-11-00	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2065 - Wollstonecraft - Melanoma Institute Australia; 3084 - Melbourne - Austin Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05533697
NCT05537051	NCT05537051	Phase 1	Not yet recruiting		08/09/2022		PM8001	bifunctional_PD-L1/TGF-beta_fusion_protein	PM8001	bifunctional_PD-L1/TGF-beta_fusion_protein		A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PM1021 (Anti-TIGIT) Monotherapy and PM1021 in Combination With PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours	Advanced Solid Tumours		https://clinicaltrials.gov/ct2/show/NCT05537051
NCT05543629	U1111-1283-1243	Phase 1/Phase 2	Recruiting	NSW, VIC, QLD, WA	14/09/2022		Carboplatin; Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel; Docetaxel + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel + Nivolumab; Nivolumab; Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + taxane	2022-501676-26; U1111-1283-1243	A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer	Advanced Solid Tumors; Non-small Cell Lung Cancer	2010 - Darlinghurst - Local Institution - 0018; 2145 - Westmead - Local Institution - 0001; 3168 - Clayton - Local Institution - 0002; 4215 - Southport - Local Institution - 0086 - (Not yet recruiting); 6150 - Murdoch - Local Institution - 0084	https://clinicaltrials.gov/ct2/show/NCT05543629
NCT05544552	SURF301	Phase 1/Phase 2	Recruiting	WA, QLD, VIC, NSW	15/09/2022		TYRA-300	FGFR3_inhibitor	TYRA-300	FGFR3_inhibitor		A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Bladder Cancer; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; FGFR3 Gene Alteration; Advanced Solid Tumor; Advanced Urothelial Carcinoma; Urinary Tract Cancer; Urinary Tract Tumor; Urinary Tract Carcinoma	2109 - Macquarie Park - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Research Unit; 3084 - Heidelberg - Austin Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4215 - Southport - Tasman Oncology; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05544552
NCT05549297	NCT05549297	Phase 2/Phase 3	Recruiting	NSW, VIC, QLD	19/09/2022		Pembrolizumab; Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody	Pembrolizumab + Tebentafusp; Tebentafusp; Pembrolizumab + Tebentafusp	anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody		Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	Advanced Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia; 3004 - Melbourne - Alfred Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4120 - Greenslopes - Gallipoli Medical Research Foundation (GMRF)	https://clinicaltrials.gov/ct2/show/NCT05549297
NCT05555732	2022-500802-16-00	Phase 3	Recruiting	SA, NSW, VIC, QLD	22/09/2022		Carboplatin; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Pembrolizumab; Pemetrexed	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate	2022-500802-16-00	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS &lt;50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Metastatic Non Small Cell Lung Cancer	2500 - Wollongong - Southern Medical Day Care Centre; 3199 - Frankston - PSEHOG (Peninsula and South Eastern Haematology and Oncology Group); 5000 - Adelaide - CRSA/ St Andrews Hospital; QLD 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05555732
NCT05568095	STAR-221	Phase 3	Recruiting	VIC, NSW, WA	03/10/2022		Capecitabine; Capecitabine + Domvanalimab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Domvanalimab; Fluorouracil; Leucovorin; Nivolumab; Oxaliplatin; Zimberelimab	fluoropyrimidine; anti-TIGIT_monoclonal_antibody; folinic_acid; anti-PD-1_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Capecitabine + Domvanalimab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Nivolumab; Capecitabine + Domvanalimab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	2022-002222-27; jRCT2051220179; MOH_2023-04-30_012590; CTR20233469; CTR20233470	A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma	Advanced Upper Gastrointestinal Tract Adenocarcinoma	Clayton - Monash University; Gosford - Gosford Hospital; Liverpool - Liverpool Hospital; Murdoch - Oncology West - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05568095
NCT05570227	MetaMel	N/A	Recruiting	VIC	04/10/2022							Identification of Metabolic Phenotypes Associated With Prognosis and Therapeutic Response in Patients With Melanoma	Melanoma	3002 - Melbourne - Peter Mac Callum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05570227
NCT05577715	MORAb-202-G000-203	Phase 2	Recruiting	WA, VIC, NSW	10/10/2022		Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	2022-000131-23; MORAb-202-G000-203	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	1871 - Liverpool - Local Institution - 0032 - (Not yet recruiting); 2500 - Wollongong - Local Institution - 0040; 3350 - Ballarat Central - Local Institution - 0012; 6150 - Murdoch - Local Institution - 0022	https://clinicaltrials.gov/ct2/show/NCT05577715
NCT05580770	NCT05580770	Phase 1/Phase 2	Recruiting	NSW, VIC	11/10/2022		BGB-3245; Mirdametinib	MEK_inhibitor; RAF_dimer_inhibitor	BGB-3245; Mirdametinib	MEK_inhibitor; RAF_dimer_inhibitor		A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05580770
NCT05581004	2021-006708-34	Phase 1	Recruiting	WA, NSW, VIC	12/10/2022		Atezolizumab; Atezolizumab + RO7502175; RO7502175	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7502175; RO7502175; Atezolizumab + RO7502175	anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	2021-006708-34	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; NSCLC; HNSCC; Melanoma; TNBC; Esophageal Cancer; Gastric Cancer; Cervical Cancer; Urothelial Carcinoma; Clear Cell RCC; HCC	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 3168 - Clayton - Monash Health Monash Medical Centre; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05581004
NCT05598151	NCT05598151	Phase 1	Recruiting	SA, VIC	24/10/2022		HM97662	EZH1/2_inhibitor	HM97662	EZH1/2_inhibitor		A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Adelaide - Cancer Research SA; Ballarat - Grampians Health; Clayton - Monash Medical Centre; Frankston - Peninsula and Southeast Oncology	https://clinicaltrials.gov/ct2/show/NCT05598151
NCT05599984	NCT05599984	Phase 1	Recruiting	VIC	28/10/2022		Budigalimab; Carboplatin; Carboplatin + Cisplatin; Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Budigalimab; Carboplatin + Cisplatin; Carboplatin + Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent		A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Ctr /ID# 259197	https://clinicaltrials.gov/ct2/show/NCT05599984
NCT05605522	NCT05605522	Phase 1	Recruiting	NSW	31/10/2022							A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours	Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer	2145 - Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05605522
NCT05607498	NCT05607498	Phase 1	Recruiting	VIC, WA	03/11/2022		EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting	EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting		A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma	Frankston - Peninsula and South Eastern Haematology and Oncology Group; Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05607498
NCT05607550	2022-502977-41-00	Phase 3	Recruiting	VIC, QLD, NSW	04/11/2022		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Furmonertinib; Pemetrexed	EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Furmonertinib; Carboplatin + Cisplatin + Pemetrexed	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2022-502977-41-00	A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations	2148 - Blacktown - Arrivent Investigative Site; 3084 - Heidelberg - ArriVent Investigative Site - (Not yet recruiting); 4102 - Woolloongabba - Arrivent Investigative Site; NSW 2065 - St Leonards - Arrivent Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05607550
NCT05609370	CTR20223077	Phase 1/Phase 2	Recruiting	WA, NSW, QLD, VIC	01/11/2022		Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab; Capecitabine; Fluorouracil; LBL-007; Tislelizumab	anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Fluorouracil; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody	Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; Fluorouracil; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine	CTR20223077	A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2298 - Waratah - Calvary Mater Newcastle; 2640 - East Albury - Border Medical Oncology; 2650 - Wagga Wagga - Riverina Cancer Care Centre; 2800 - Orange - Orange Health Service (Central West Cancer Care Centre); 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4217 - Benowa - Pindara Private Hospital; 6009 - Nedlands - One Clinical Research; 6150 - Murdoch - St John of God, Murdoch	https://clinicaltrials.gov/ct2/show/NCT05609370
NCT05609968	MK-3475-D46	Phase 3	Recruiting	NSW, VIC, SA	02/11/2022		Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	MK-3475-D46; PHRR230203-005387; jRCT2031230031; 2022-000836-49	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Carcinoma, Non-Small-Cell Lung	2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 0600); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 0601); 5000 - Adelaide - Cancer Research SA-St Andrews Hospital ( Site 0603)	https://clinicaltrials.gov/ct2/show/NCT05609968
NCT05611931	XPORT-EC-042	Phase 3	Recruiting	SA, NSW, VIC, TAS, QLD	03/11/2022		Placebo; Selinexor	selective_inhibitor_of_nuclear_export; placebo	Selinexor; Placebo	selective_inhibitor_of_nuclear_export; placebo	GOG-3083; ENGOT-EN20	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Endometrial Cancer	2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 2145 - Wentworthville - Westmead Hospital - (Not yet recruiting); 2250 - Gosford - Central Coast LHD - Gosford &amp; Wyong Hospitals; 2305 - New Lambton Heights - Newcastle Private Hospital; 2640 - Albury East - Border Medical Oncology and Haematology; 3000 - Melbourne - Peter MacCallum Cancer Centre/RWH/RMH; 3128 - Box Hill - Box Hill Hospital - Eastern Health (Oncology) - (Not yet recruiting); 3144 - Malvern - Cabrini Health; 3168 - Clayton - Monash Health; 3199 - Frankston - Frankston Hospital; 4215 - Southport - ICON Cancer Centre Southport; 4350 - Toowoomba - Toowoomba Hospital - (Not yet recruiting); 5000 - Southport - The Royal Adelaide Hospital - (Not yet recruiting); 7000 - Hobart - Royal Hobart Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05611931
NCT05613088	2021-004807-42	Phase 2	Recruiting	QLD, VIC, NSW, WA	04/11/2022		Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; anthracycline; topoisomerase_inhibitor; taxane	Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; anthracycline; taxane; topoisomerase_inhibitor	2021-004807-42	A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Neoplasms, Ovarian	2065 - Sydney - Local Institution - 0016; 2298 - Waratah - Calvary Mater Newcastle; 3144 - Melbourne - Local Institution - 0027 - (Not yet recruiting); 3168 - Clayton - Local Institution - 0015; 4032 - Chermside - Local Institution - 0031; 6009 - Nedlands - Local Institution - 0058; 6009 - Perth - Local Institution - 0075	https://clinicaltrials.gov/ct2/show/NCT05613088
NCT05614258	NCT05614258	Phase 1	Recruiting	VIC, SA	09/11/2022		ADG206	anti-4-1BB_agonistic_antibody	ADG206	anti-4-1BB_agonistic_antibody		A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	3168 - Clayton - Monash Health; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05614258
NCT05614739	J4G-OX-JZVA	Phase 1	Recruiting	NSW	07/11/2022		LOXO-435; LOXO-435 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor	LOXO-435; LOXO-435 + Pembrolizumab; LOXO-435 + Pembrolizumab	FGFR3_inhibitor; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	J4G-OX-JZVA; 2022-502755-59-00; KEYNOTE-F35; MK-3475-F35	An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations	Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms	2065 - Saint Leonards - GenesisCare North Shore; NSW 2010 - Darlinghurst - Kinghorn Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05614739
NCT05618028	NCT05618028	Phase 1	Recruiting	VIC	14/11/2022		ABBV-525	MALT1_inhibitor	ABBV-525	MALT1_inhibitor		A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies	Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia; B Cell Malignancies; Non-Hodgkin's Lymphoma	3004 - Melbourne - Alfred Health /ID# 248592; 3168 - Clayton - Monash University /ID# 246366	https://clinicaltrials.gov/ct2/show/NCT05618028
NCT05619913	EPOCH	Phase 2	Recruiting	QLD, VIC, NSW	09/11/2022		Eribulin; Eribulin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue	Eribulin; Eribulin + Pembrolizumab; Eribulin + Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue		The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Ovarian Carcinosarcoma; Uterine Carcinosarcoma	8006 - Melbourne - Peter MacCallum Cancer Centre; Clayton - Monash Health; Herston - Royal Brisbane and Women's Hospital; Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT05619913
NCT05625399	RELATIVITY-127	Phase 3	Recruiting	NSW, QLD, VIC, WA, SA	15/11/2022		Nivolumab; Nivolumab + Relatlimab; Relatlimab; rHuPH20	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; recombinant_human_hyaluronidase	Nivolumab + Relatlimab; Nivolumab + Relatlimab; rHuPH20	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	2022-000575-39; U1111-1274-0193	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma	Melanoma	2065 - Wollstonecraft - University of Sydney - Melanoma Institute Australia MIA; 2145 - Westmead - Westmead Hospital; 2298 - Waratah - Local Institution - 0184 - (Not yet recruiting); 2444 - Port Macquarie - Local Institution - 0172; 2450 - Coffs Harbour - North Coast Area Health Service NCAHS - The North Coast Cancer Institute NCCI - Coffs Harbour Health Campus; 2650 - Wagga Wagga - Riverina Cancer Care Centre; 2800 - Orange - Orange Health Service; 3004 - Prahran - The Alfred Hospital; 3084 - Heidelberg - Austin Hospital - Medical Oncology Unit; 3128 - Box Hill - Local Institution - 0059; 3550 - Bendigo - Local Institution - 0008; 3844 - Traralgon - Latrobe Regional Health; 4575 - Birtinya - Sunshine Coast University Private Hospital; 5011 - Woodville South - Local Institution - 0183 - (Not yet recruiting); 6009 - Nedlands - One Clinical Research; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05625399
NCT05625412	2022-500930-27	Phase 1	Recruiting	VIC, QLD, NSW	15/11/2022		BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; Capecitabine; Docetaxel; Nivolumab	JNK_inhibitor + fluoropyrimidine; fluoropyrimidine; JNK_inhibitor; JNK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; JNK_inhibitor + taxane	BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab	JNK_inhibitor; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane	2022-500930-27	A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital - The Kinghorn Cancer Center; 2065 - St Leonards - GenesisCare North Shore; 3199 - Frankston - Frankston Hospital; 4120 - Brisbane - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05625412
NCT05635708	CTR20230892	Phase 2	Recruiting	WA, NSW	23/11/2022		BGB-15025; BGB-15025 + Tislelizumab; BGB-A445; BGB-A445 + Tislelizumab; Carboplatin; Cisplatin; LBL-007; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed; Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; HPK1_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	BGB-15025 + Tislelizumab; BGB-A445 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; BGB-15025 + Tislelizumab; BGB-A445 + Tislelizumab; Carboplatin; Cisplatin; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	CTR20230892	Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer	2050 - Camperdown - Chris Obrien Lifehouse; 2086 - Frenchs Forest - Northern Beaches Hospital; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2444 - Port Macquarie - Port Macquarie Base Hospital; 6008 - Subiaco - St John of God Health Care; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05635708
NCT05636215	NCT05636215	Phase 1/Phase 2	Not yet recruiting	VIC, QLD, NSW	23/11/2022		IBI354	anti-ERBB2_antibody-drug_conjugate	IBI354	anti-ERBB2_antibody-drug_conjugate		A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	2031 - Randwick - Scientia Clinical Research Ltd; 3168 - Clayton - Monash Health; 4575 - Sunshine Coast - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05636215
NCT05642949	NCT05642949	Phase 1/Phase 2	Not yet recruiting	VIC, QLD, SA	30/11/2022		MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C	anti-Trop2_antibody-drug_conjugate		Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05642949
NCT05645692	NCT05645692	Phase 2	Recruiting	SA, NSW	07/12/2022		Atezolizumab; Tiragolumab; Tiragolumab + Tobemstomig; Tobemstomig	anti-PD-L1_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; Tiragolumab + Tobemstomig; Tobemstomig; Tiragolumab + Tobemstomig	anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody		A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy	Urothelial Cancer	2109 - Macquarie Park - Macquarie University Hospital; 5037 - Kurralta Park - ICON Cancer Care Adelaide; 5112 - Adelaide - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT05645692
NCT05646862	INAVO121	Phase 3	Recruiting	WA, QLD, VIC, NSW	02/12/2022		Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Inavolisib; Inavolisib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor	Alpelisib + Fulvestrant; Fulvestrant + Inavolisib; Alpelisib + Fulvestrant; Fulvestrant + Inavolisib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	2022-502322-41-00	A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy	Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2139 - Concord - Concord Repatriation General Hospital; Concord Cancer Centre; 2250 - Gosford - Gosford Hospital; Cancer Care Services; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2560 - Campbelltown - Campbelltown Hospital; Macarthur Cancer Therapy Centre; 3550 - Bendigo - Bendigo Cancer Centre; 4066 - Auchenflower - Icon Cancer Care Wesley; 4556 - Sippy Downs - University of the Sunshine Coast; 6009 - Perth - Sir Charles Gairdner Hospital; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05646862
NCT05647122	EGRET	Phase 1	Recruiting	NSW, VIC	02/12/2022		AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; Bevacizumab; Fluorouracil; Leucovorin; Osimertinib	bispecific_cMET/EGFR_antibody; fluoropyrimidine; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid; folinic_acid; anti-VEGF_monoclonal_antibody; Fluorouracil; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; Fluorouracil; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid		A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms	2217 - Kogarah - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05647122
NCT05650879	HER2	Phase 1	Recruiting	NSW, WA	06/12/2022		ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate		A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation; HER2 Amplification	2010 - Darlinghurst - Blacktown Hospital; 2145 - Westmead - Macquarie University Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05650879
NCT05652855	NCT05652855	Phase 1/Phase 2	Not yet recruiting	SA, QLD, VIC	07/12/2022		MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C	anti-B7H3_antibody-drug_conjugate		Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05652855
NCT05652868	KisMET-01	Phase 1	Recruiting	NSW, SA	07/12/2022		MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011	anti-cMET_antibody-drug_conjugate	KisMET-01	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01	NSCLC; NSCLC Stage IV; NSCLC Stage IIIB; Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Advanced Non-Small Cell Lung Cancer; Advanced Non-Small Cell Non-Squamous Lung Cancer	2050 - Camperdown - KisMET-01 Clinical Site; 2148 - Blacktown - KisMET-01 Clinical Site; 5000 - Adelaide - KisMET-01 Clinical Site; 5011 - Adelaide - KisMET-01 Clinical Site	https://clinicaltrials.gov/ct2/show/NCT05652868
NCT05654623	VERITAC-2	Phase 3	Recruiting	VIC, TAS, QLD	08/12/2022		ARV-471; Fulvestrant	ER_PROTAC_degrader; selective_estrogen_receptor_degrader	ARV-471; Fulvestrant	ER_PROTAC_degrader; selective_estrogen_receptor_degrader	2022-500544-38-00	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)	Advanced Breast Cancer	3144 - Malvern - Cabrini Hospital - Malvern; 3186 - Brighton - Cabrini Hospital -Brighton; 3220 - Geelong - Barwon Health; 4575 - Birtinya - Sunshine Coast University Private Hospital; 4575 - Birtinya - Sunshine Coast University Private Hospital - (Not yet recruiting); 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05654623
NCT05671510	PRESERVE-003	Phase 3	Recruiting	SA, NSW, QLD, VIC	31/12/2022		Docetaxel; ONC392	taxane; anti-CTLA-4_monoclonal_antibody	Docetaxel; ONC392	taxane; anti-CTLA-4_monoclonal_antibody		Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors	Non Small Cell Lung Cancer	2200 - Bankstown - Bankstown Hospital - 3305; 4006 - Newstead - Mater - 3301; 5000 - Adelaide - Cancer Research SA - 3303; New Lambton Heights - Newcastle Private Hospital - 3302	https://clinicaltrials.gov/ct2/show/NCT05671510
NCT05676931	EDGE-Lung	Phase 2	Recruiting	NSW, SA	05/01/2023		Docetaxel; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab; Domvanalimab + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + taxane	Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab + Zimberelimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane	2022-502916-35-00	A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Cancer	Adelaide - Cancer Research SA; Coffs Harbour - Coffs Harbour Health Campus	https://clinicaltrials.gov/ct2/show/NCT05676931
NCT05678673	STELLAR-304	Phase 3	Recruiting	QLD	23/12/2022		Nivolumab; Nivolumab + Zanzalintinib; Sunitinib; Zanzalintinib	KIT_inhibitor,first_generation; VEGFR_inhibitor; PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor	Nivolumab + Zanzalintinib; Sunitinib; Nivolumab + Zanzalintinib	KIT_inhibitor,first_generation; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody	EU CTR: 2022-501703-27-0	A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	Non-Clear Cell Renal Cell Carcinoma	4032 - Chermside - Exelixis Clinical Site #14; 4101 - South Brisbane - Exelixis Clinical Site #29	https://clinicaltrials.gov/ct2/show/NCT05678673
NCT05694936	NCT05694936	Phase 2	Recruiting	VIC, NSW, SA	19/01/2023		Cetuximab; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Panitumumab; Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; HDAC_inhibitor	Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody		A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)	Metastatic Colorectal Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Institute; 3084 - Melbourne - Austin Health; 3128 - Box Hill - Eastern Health; 3199 - Frankston - Peninsula Health; 3280 - Warrnambool - South West Healthcare; 3350 - Ballarat Central - Eben-Marie Garzina; 5000 - Adelaide - Queen Elizabeth Hospital; 5042 - Bedford Park - Southern Adelaide Local Health Network Incorporated	https://clinicaltrials.gov/ct2/show/NCT05694936
NCT05696626	ELAINEIII	Phase 3	Recruiting	NSW, QLD	13/01/2023		Abemaciclib; Fulvestrant; Lasofoxifene; Palbociclib; Palbociclib + Ribociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_modulator	Palbociclib + Ribociclib; Abemaciclib; Fulvestrant; Lasofoxifene; Palbociclib + Ribociclib	CDK4/6_inhibitor; selective_estrogen_receptor_degrader; selective_estrogen_receptor_modulator		An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Metastatic Breast Cancer	Blacktown - Blacktown Hospital - (Not yet recruiting); Concord - Concord Repatriation General Hospital - (Not yet recruiting); South Brisbane - Mater Misericordiae Ltd, South Brisbane - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05696626
NCT05712889	NCT05712889	Phase 1	Recruiting	NSW, Southern Australia, QLD, SA	25/01/2023		VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting	VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting		An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer	Neoplasms	2109 - Macquarie Park - Macquarie University; 4101 - Brisbane - ICON Brisbane; 5037 - Adelaide - ICON Adelaide	https://clinicaltrials.gov/ct2/show/NCT05712889
NCT05718895	CLINCH	Phase 1	Recruiting	SA, QLD	30/01/2023		ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG 022	anti-CLDN18.2_antibody-drug_conjugate		An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	Adelaide - Cancer Research SA Pty Ltd; Malvern - Cabrini Health Limited; South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05718895
NCT05720130	NCT05720130	Phase 1/Phase 2	Recruiting	QLD	07/02/2023		212Pb-ADVC001; Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	radioligand,PSMA-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; 212Pb-ADVC001; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; radioligand,PSMA-targeting		TheraPb: Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma	Prostatic Neoplasms; Castration-Resistant	4029 - Brisbane - Royal Brisbane &amp; Women's Hospital; 4102 - Brisbane - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05720130
NCT05725291	NCT05725291	Phase 1	Recruiting	QLD, NSW	02/02/2023		AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116	anti-CD44v9_antibody-drug_conjugate		First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Brisbane - ICON Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05725291
NCT05727904	TILVANCE	Phase 3	Recruiting	WA, QLD	06/02/2023		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	TILVANCE-301; TILVANCE	A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma	Metastatic Melanoma; Unresectable Melanoma; Melanoma	4120 - Greenslopes - Greenslopes Private Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05727904
NCT05735080	INX-315-01	Phase 1/Phase 2	Recruiting	QLD, VIC	09/02/2023		INX-315	CDK2_inhibitor	INX-315	CDK2_inhibitor		A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer	Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer	3052 - Parkville - Peter MacCallum Cancer Center; 4101 - South Brisbane - Mater Hospital	https://clinicaltrials.gov/ct2/show/NCT05735080
NCT05740566	DeLLphi-304	Phase 3	Recruiting	NSW, VIC	21/02/2023		Amrubicin; Lurbinectedin; Tarlatamab; Topotecan	anthracycline; topoisomerase_inhibitor; DNA_minor_groove-binding_agent; bispecific_T-cell_engager,DLL3-targeting	Tarlatamab; Amrubicin; Lurbinectedin; Topotecan	bispecific_T-cell_engager,DLL3-targeting; DNA_minor_groove-binding_agent; anthracycline; topoisomerase_inhibitor		A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy	Small Cell Lung Cancer (SCLC)	2170 - Liverpool - Liverpool Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3004 - Melbourne - The Alfred Hospital; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05740566
NCT05743036	Z0011001	Phase 1/Phase 2	Recruiting	SA, VIC	15/02/2023		Cetuximab; Cetuximab + Encorafenib + ZN-C3; Encorafenib; ZN-C3	WEE1_inhibitor; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor	Cetuximab + Encorafenib + ZN-C3; Cetuximab + Encorafenib + ZN-C3	BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody	Z0011001	A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05743036
NCT05756907	NCT05756907	Phase 1/Phase 2	Recruiting	SA, NSW	23/02/2023		Atezolizumab; Atezolizumab + SON-1010; SON-1010	anti-PD-L1_monoclonal_antibody; IL-12_variant + anti-PD-L1_monoclonal_antibody; IL-12_variant	Atezolizumab + SON-1010; SON-1010; Atezolizumab + SON-1010	IL-12_variant; IL-12_variant + anti-PD-L1_monoclonal_antibody; IL-12_variant + anti-PD-L1_monoclonal_antibody		A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer	Advanced Solid Tumor; Platinum-resistant Ovarian Cancer	2148 - Blacktown - Blacktown Mt Druitt Hospital; 2640 - Albury - The Border Cancer Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05756907
NCT05759728	NCT05759728	Phase 1/Phase 2	Recruiting	SA	26/02/2023		CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting		A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	5000 - Adelaide - Carina Biotech Investigators	https://clinicaltrials.gov/ct2/show/NCT05759728
NCT05763004	MK-3475-F49	Phase 1	Recruiting	SA, WA, VIC	28/02/2023		Pembrolizumab; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Pembrolizumab; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	KEYNOTE-F49 / MK-3475-F49	A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors	Solid Tumor, Adult	Clayton - Monash Health Medical Center - (Not yet recruiting); Heidelberg - Austin Health / Cancer Clinical Trials Center - (Not yet recruiting); Melbourne - Alfread Health - (Not yet recruiting); Melbourne - Peter MacCallum Cancer Center - (Not yet recruiting); Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05763004
NCT05774873	NCT05774873	Phase 1/Phase 2	Recruiting	NSW	07/03/2023		IBI334	bispecific_EGFR/B7H3_antibody	IBI334	bispecific_EGFR/B7H3_antibody		A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	2145 - Waratah - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05774873
NCT05775289	NCT05775289	Phase 2	Recruiting	VIC, QLD, NSW, SA	16/03/2023		Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Tobemstomig; Paclitaxel; Pembrolizumab; Pemetrexed; Tobemstomig	bispecific_PD-1/LAG3_antibody; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Tobemstomig; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Tobemstomig; Paclitaxel	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; taxane		A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	2145 - Westmead - Westmead Hospital - (Active, not recruiting); 3168 - Clayton - Monash Health - (Active, not recruiting); 3220 - Geelong - Barwon Health - (Active, not recruiting); 4217 - Benowa - Pindara Private Hospital - (Withdrawn); 5112 - Adelaide - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT05775289
NCT05785754	NCT05785754	Phase 1	Recruiting	WA, SA, NSW, VIC	14/03/2023		DCSZ11; DCSZ11 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody	DCSZ11; DCSZ11 + Pembrolizumab; Pembrolizumab; DCSZ11 + Pembrolizumab	anti-CD93_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody		A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	2010 - Sydney - St Vicent's Hospital; 2031 - Randwick - Scientia Clinical Research; 3144 - Malvern - Cabrini Hospital; 3168 - Clayton - Monash Health - (Not yet recruiting); 5011 - Woodville South - The Queen Elizabeth Hospital (TQEH) - (Not yet recruiting); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU) - (Not yet recruiting); 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05785754
NCT05785767	2022-501483-18-00	Phase 2/Phase 3	Recruiting	NSW, VIC	14/03/2023		Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Placebo	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; placebo	Cemiplimab; Cemiplimab + Fianlimab; Cemiplimab + Fianlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2022-501483-18-00	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%	Advanced Non-Small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital; NSW 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05785767
NCT05789082	Krascendo-170	Phase 1/Phase 2	Recruiting	VIC, NSW	28/03/2023		Carboplatin; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Cisplatin; Divarasib; Divarasib + Pembrolizumab; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2022-003048-28; 2023-507171-22-00	A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Non-Small Cell Lung Cancer	2139 - Concord - Concord Repatriation General Hospital; Concord Cancer Centre; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05789082
NCT05797168	FONTANA	Phase 1/Phase 2	Recruiting	NSW, VIC	21/03/2023		AZD5305; AZD5305 + AZD5335; AZD5335	anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor	AZD5305 + AZD5335; AZD5335; AZD5305 + AZD5335	PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate		FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.	Ovarian Cancer; Lung Adenocarcinoma	2170 - Liverpool - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05797168
NCT05800015	2022-501577-40-00	Phase 2/Phase 3	Recruiting	VIC, NSW, WA	23/03/2023		Carboplatin; Cemiplimab; Cemiplimab + Fianlimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed; Placebo	placebo; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Carboplatin; Cemiplimab + Fianlimab; Cisplatin; Paclitaxel; Pemetrexed; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; placebo; platinum-based_antineoplastic_agent; taxane	2022-501577-40-00	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels	Non-small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 3065 - Fitzroy - St Vincents Hospital; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital; 6150 - Murdoch - St John of God Murdoch Hospital; NSW 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05800015
NCT05800665	2023-504013-68-00	Phase 1	Recruiting	VIC, NSW	24/03/2023		RO-7656594	unknown_drug_class	RO-7656594	unknown_drug_class	2023-504013-68-00	A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer	Advanced Prostate Cancer; Metastatic Prostate Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT05800665
NCT05800964	2022-502867-39	Phase 1	Recruiting	NSW, VIC	24/03/2023		AMG 305	bispecific_T-cell_engager,MSLN-targeting	AMG 305	bispecific_T-cell_engager,MSLN-targeting	2022-502867-39	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05800964
NCT05807035	NCT05807035	Phase 1	Recruiting	SA	07/04/2023		Radvax	autologous_anticancer_vaccine	Radvax	autologous_anticancer_vaccine		A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers	Solid Tumor	5046 - Adelaide - ARASMI	https://clinicaltrials.gov/ct2/show/NCT05807035
NCT05818683	78278343PCR1003	Phase 1	Recruiting	QLD, VIC, NSW	06/04/2023		Cetrelimab	anti-PD-1_monoclonal_antibody	Cetrelimab	anti-PD-1_monoclonal_antibody	2022-503132-14; 78278343PCR1003; 2022-503132-14-00	A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms	2109 - Macquarie University - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05818683
NCT05840211	ASCENT-07	Phase 3	Recruiting	VIC, TAS, QLD, ME, NSW	21/04/2023		Capecitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	taxane; fluoropyrimidine; anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan; Capecitabine; Nab-paclitaxel	anti-Trop2_antibody-drug_conjugate; fluoropyrimidine; taxane	2022-502593-17-00; jRCT2061230032; DOH-27-082023-6901; MOH_2023-07-17_012821; CTR20233370	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy	Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2065 - St Leonards - GenesisCare North Shore (Oncology); 3021 - St Albans - Sunshine Hospital (Western Health); 3084 - Melbourne - Austin Health; 4029 - Queensland - Royal Brisbane and Women's Hospital; 4066 - Auchenflower - Icon Cancer Centre Wesley; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05840211
NCT05848011	NCT05848011	Phase 2	Recruiting	VIC	04/05/2023		Docetaxel; Docetaxel + Prednisone; Prednisone	glucocorticoid; glucocorticoid + taxane; taxane	Docetaxel + Prednisone; Docetaxel + Prednisone	glucocorticoid + taxane; glucocorticoid + taxane		A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Recurrent; Androgen-Insensitive Prostatic Cance; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Immunotherapy; Immune Checkpoint Inhibitor; Inhibitory Checkpoint Molecule	North Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05848011
NCT05852691	NCT05852691	Phase 2	Recruiting	VIC, SA, WA	02/05/2023		Nab-paclitaxel; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Pembrolizumab; RO7247669; Tobemstomig	bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + taxane	Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; RO7247669	anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane		A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Breast Cancer	5037 - Kurralta Park - ICON Cancer Care Adelaide; 6149 - Bull Creek - Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit; St Albans - Sunshine Hospital; Oncology Research - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT05852691
NCT05855200	AZUR-2	Phase 3	Recruiting	NSW, VIC, QLD	03/05/2023		Dostarlimab	anti-PD-1_monoclonal_antibody	Dostarlimab	anti-PD-1_monoclonal_antibody	2023-503265-27-00	A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer	Colonic Neoplasms; Neoplasms, Colon	2065 - St Leonards - GSK Investigational Site; 2298 - Waratah - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 4102 - Woolloongabba - GSK Investigational Site; VIC 3004 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05855200
NCT05858164	2024-510998-26-00	Phase 1	Recruiting	NSW, QLD	05/05/2023		BAY2862789	DGK-alpha_inhibitor	BAY2862789	DGK-alpha_inhibitor	2024-510998-26-00	An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKαi) BAY 2862789 in Participants With Advanced Solid Tumors	Advanced Solid Tumors; Non-small Cell Lung Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre - Medical Oncology Department - (Not yet recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital Australia - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05858164
NCT05858736	PRESERVE-009	Phase 1	Recruiting	NSW, QLD, SA	12/05/2023		AI-025; ONC392	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	AI-025; ONC392	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody		Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study	Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Renal Cell Carcinoma; Bladder Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; Colorectal Cancer; Anal Cancer; Hepatocellular Carcinoma; Bile Duct Cancer	2010 - Darlinghurst - St. Vincent's Private Hospital - (Not yet recruiting); 4006 - Brisbane - Mater Misericordiae Ltd.; 4120 - Southport - Tasman Oncology Research; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Southern Oncology Clinical Research Unit - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05858736
NCT05867121	2022-502615-11-00	Phase 1	Recruiting	NSW, NZ	10/05/2023		Atezolizumab; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium; Gemcitabine; Nab-paclitaxel; Nivolumab; Oxaliplatin; RO7496353; Tegafur-gimeracil-oteracil pPotassium	anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; orotate_phosphoribosyltransferase_inhibitor; anti-TGF-beta_monoclonal_antibody; gemcitabine; fluoropyrimidine; DPD_inhibitor; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium	DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine	2022-502615-11-00	A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Non-small Cell Lung Cancer; Gastric Cancer; Pancreatic Ductal Adenocarcinoma	1023 - Auckland - Auckland City Hospital; 2010 - Darlinghurst - St Vincent'S Hospital	https://clinicaltrials.gov/ct2/show/NCT05867121
NCT05867303	NCT05867303	Phase 1	Recruiting	VIC, QLD, SA	17/05/2023		RC198	undisclosed_fusion_protein	RC198	undisclosed_fusion_protein		A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Melanoma; Urothelial Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Carcinoma	3144 - Malvern - Cabrini Hospital Malvern; 4066 - Auchenflower - ICON Cancer Centre Wesley; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05867303
NCT05868174	NCT05868174	Phase 1	Recruiting	NSW, SA, WA	11/05/2023		177Lu-TLX250; 177Lu-TLX250 + Peposertib; Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate	177Lu-TLX250 + Peposertib; 177Lu-TLX250 + Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor		A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors	Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma	Adelaide - Ashford (Icon) Cancer Centre; Brisbane - Princess Alexandra Hospital - (Not yet recruiting); Melbourne - Austin Health - (Not yet recruiting); North Ryde - Macquarie University - (Not yet recruiting); Perth - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT05868174
NCT05870748	NCT05870748	Phase 2	Recruiting	NSW	12/05/2023		Pegfilgrastim	granulocyte_colony_stimulating_factor	Pegfilgrastim	granulocyte_colony_stimulating_factor		REFRaME-O1: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)	Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer	2031 - Randwick - Prince of Wales Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05870748
NCT05872295	NCT05872295	Phase 1	Recruiting	WA, NSW, VIC	14/05/2023		IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014	anti-ERBB2_antibody-drug_conjugate		A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	Breast Cancer; Gastric Cancer; Gastroesophageal-junction Cancer	2139 - Concord - Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit; 2145 - Westmead - Westmead Hospital; 3004 - Melbourne - Alfred Health; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group (PSEHOG); 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05872295
NCT05876754	ProvIDHe	Phase 3	Recruiting	NSW, VIC, WA, SA	17/05/2023		Ivosidenib	IDH1_R132_inhibitor	Ivosidenib	IDH1_R132_inhibitor	2022-501463-40	An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Cholangiocarcinoma	Brisbane - Royal brisbane &amp; Women's Hospital; Fitzroy - St Vincent's Hospital; Subiaco - St John of God Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC); Sydney - Kinghorn Cancer Centre; Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05876754
NCT05878288	DISCERN	Phase 2	Recruiting	VIC	17/05/2023		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody		Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients	Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Neoplasms; Non-melanoma Skin Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05878288
NCT05884398	LIBERTAS	Phase 3	Recruiting	QLD, VIC, NSW	23/05/2023		Apalutamide	antiandrogen,nonsteroidal,second_generation	Apalutamide	antiandrogen,nonsteroidal,second_generation	56021927PCR3020; 2022-502686-24-00	A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate-sensitive Prostate Cancer	2109 - Macquarie University - Macquarie University Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4101 - South Brisbane - Mater Misericordiae Hospital	https://clinicaltrials.gov/ct2/show/NCT05884398
NCT05886868	NCT05886868	Phase 1	Recruiting	NSW, QLD	24/05/2023		BL0020	unknown_drug_class	BL0020	unknown_drug_class		A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Birtinya - Sunshine Coast University Private Hospital - (Active, not recruiting); Sydney - Cancer Care Foundation Limited - (Active, not recruiting); Sydney - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05886868
NCT05886920	NCT05886920	Phase 1	Recruiting	WA, SA, NSW	24/05/2023		D3S-002	ERK_inhibitor	D3S-002	ERK_inhibitor		A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Advanced Solid Tumors With MAPK Pathway Mutations	2148 - Blacktown - D3 Bio Investigative Site; 5042 - Bedford Park - D3 Bio Investigative Site; 6009 - Nedlands - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05886920
NCT05888844	2022-502476-23-00	Phase 2	Recruiting	NSW, QLD, VIC, NZ	24/05/2023		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	2022-502476-23-00	A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	02640 - Albury - Border Medical Oncology Research Unit; 03128 - Box Hill - Box Hill Hospital; 03168 - Clayton - Monash Medical Centre Clayton; 03200 - Hamilton - Waikato Hospital; 03550 - Bendigo - Bendigo Hospital - (Withdrawn); 04102 - Woolloongabba - Princess Alexandra Hospital Australia; 04814 - Townsville - Townsville Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05888844
NCT05894239	2022-502046-28-00	Phase 3	Recruiting	NSW, QLD, WA	07/06/2023		Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	2022-502046-28-00	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Metastatic Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2250 - Gosford - Gosford Hospital; Cancer Care Services; 4556 - Sippy Downs - University of the Sunshine Coast; 6009 - Perth - Sir Charles Gairdner Hospital; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05894239
NCT05904496	U1111-1290-6118	Phase 1	Recruiting	VIC, WA	06/06/2023		BGB-30813; BGB-30813 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor	BGB-30813; BGB-30813 + Tislelizumab; BGB-30813 + Tislelizumab	DGK-zeta_inhibitor; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody	U1111-1290-6118; 2023-503996-38	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumors	3000 - Melbourne - Peter Maccallum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05904496
NCT05906862	NCT05906862	Phase 1	Recruiting	NSW, VIC, QLD, SA	07/06/2023		AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253	anti-MUC18_antibody-drug_conjugate		First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Adelaide - Southern Oncology Clinical Research - (Not yet recruiting); Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital - (Not yet recruiting); Sydney - Blacktown - (Not yet recruiting); Sydney - Chris O'Brien Lifehouse - (Not yet recruiting); Sydney - Maquarie University Hospital - (Not yet recruiting); VIC 3004 - Melbourne - Alfred Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05906862
NCT05907304	SEACRAFT-1	Phase 1	Recruiting	WA	07/06/2023		Naporafenib; Naporafenib + Trametinib; Trametinib	MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor	Naporafenib + Trametinib; Naporafenib + Trametinib	MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor		An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations	Advanced or Metastatic Solid Tumors	Perth - Linear Clinical Research, LTD	https://clinicaltrials.gov/ct2/show/NCT05907304
NCT05907954	NCT05907954	Phase 2	Recruiting	VIC, NSW	14/06/2023		Darovasertib	PKC_inhibitor	Darovasertib	PKC_inhibitor		(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Uveal Melanoma	2010 - Sydney - St. Vincent's Health Sydney; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05907954
NCT05909397	VERITAC-3	Phase 3	Recruiting	SA, VIC	08/06/2023		ARV-471; Letrozole; Palbociclib	aromatase_inhibitor; ER_PROTAC_degrader; CDK4/6_inhibitor	ARV-471; Letrozole; Palbociclib	CDK4/6_inhibitor; ER_PROTAC_degrader; aromatase_inhibitor	2022-500545-24-00	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)	Breast Cancer	3144 - Malvern - Cabrini Hospital - Malvern - (Not yet recruiting); 3186 - Brighton - Cabrini Hospital -Brighton - (Not yet recruiting); 3220 - Geelong - Barwon Health; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05909397
NCT05909904	NCT05909904	Phase 2	Recruiting	NSW, QLD, VIC, WA, SA	09/06/2023		BGB-A425; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007; LBL-007 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody		A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	2065 - St Leonards - North Shore Private Hospital; 2747 - Kingswood - Nepean Hospital; 3677 - Wangaratta - Northeast Health Wangaratta; 4120 - Greenslopes - Greenslopes Private Hospital; 4215 - Gold Coast - Gold Coast Private Hospital; 5000 - Adelaide - Cancer Research South Australia; 6150 - Murdoch - St John of God, Murdoch	https://clinicaltrials.gov/ct2/show/NCT05909904
NCT05909995	2023-503243-34-00	Phase 1	Recruiting	SA, VIC	09/06/2023		INCB099280; INCB099280 + Ipilimumab; Ipilimumab	PD-L1_inhibitor,oral; anti-CTLA-4_monoclonal_antibody; PD-L1_inhibitor,oral + anti-CTLA-4_monoclonal_antibody	INCB099280 + Ipilimumab; INCB099280 + Ipilimumab	PD-L1_inhibitor,oral + anti-CTLA-4_monoclonal_antibody; PD-L1_inhibitor,oral + anti-CTLA-4_monoclonal_antibody	2023-503243-34-00	A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors	Melanoma; Hepatocellular Carcinoma (HCC); Renal Cell Carcinoma (RCC); Microsatellite Instability - High (MSI-H); Mismatch Repair Deficient (dMMR); Colorectal Carcinoma (CRC)	03128 - Box Hill - Box Hill Hospital - (Not yet recruiting); 05000 - Adelaide - Cancer Research Sa - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05909995
NCT05910827	NCT05910827	Phase 1/Phase 2	Recruiting	SA, WA, QLD, VIC, NSW	16/06/2023		Cetuximab; Cetuximab + Docetaxel + HMBD-001; Docetaxel; Docetaxel + HMBD-001; HMBD-001	anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody; taxane; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane	Cetuximab + Docetaxel + HMBD-001; Docetaxel + HMBD-001; Cetuximab + Docetaxel + HMBD-001; Docetaxel + HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane		A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers	Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	2065 - Sydney - GenesisCare North Shore; 3144 - Malvern - Cabrini Health; 4101 - Brisbane - ICON Cancer Centre South Brisbane; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05910827
NCT05911295	KEYNOTE-D74	Phase 3	Recruiting	NSW, Other	09/06/2023		Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	gemcitabine; anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	KEYNOTE-D74; MK-3475-D74; 2022-501105-12	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)	Urothelial Carcinoma	2109 - Brisbane - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT05911295
NCT05914116	NCT05914116	Phase 1/Phase 2	Recruiting	NSW, WA	13/06/2023		DB-1311	anti-B7H3_antibody-drug_conjugate	DB-1311	anti-B7H3_antibody-drug_conjugate		A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors	Advanced Solid Tumors	2031 - Sydney - Site 201; 6009 - Nedlands - Site 202 - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05914116
NCT05919537	NCT05919537	Phase 1	Recruiting	WA, SA, NSW, QLD, VIC	16/06/2023		Docetaxel; Gemcitabine; HMBD-001; Nab-paclitaxel	anti-ERBB3_monoclonal_antibody,third_generation; taxane; gemcitabine; antimetabolite	Docetaxel; Gemcitabine; HMBD-001; Nab-paclitaxel	anti-ERBB3_monoclonal_antibody,third_generation; antimetabolite; gemcitabine; taxane		A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations	Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Sydney - GenesisCare North Shore; 3144 - Malvern - Cabrini Health; 4101 - Brisbane - ICON Cancer Centre South Brisbane; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05919537
NCT05920356	2022-501863-41	Phase 3	Recruiting	SA, VIC, QLD, NSW	26/06/2023		Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Pembrolizumab; Pemetrexed; Sotorasib	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2022-501863-41	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)	Non-Small Cell Lung Cancer (NSCLC)	2065 - St Leonards - GenesisCare -North Shore Oncology; 2139 - Concord - Concord Repatriation General Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4350 - Toowoomba - Toowoomba Hospital; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT05920356
NCT05923008	NCT05923008	Phase 1/Phase 2	Recruiting	QLD	19/06/2023		IBI130	anti-Trop2_monoclonal_antibody	IBI130	anti-Trop2_monoclonal_antibody		A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	4575 - Birtinya - Sunshine Coast University	https://clinicaltrials.gov/ct2/show/NCT05923008
NCT05935098	2023-505322-34-00	Phase 1	Recruiting	WA, QLD	05/07/2023		BGB-A3055; BGB-A3055 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A3055; BGB-A3055 + Tislelizumab; BGB-A3055 + Tislelizumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2023-505322-34-00	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor; Solid Tumor	4101 - South Brisbane - Icon Cancer Care South Brisbane; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05935098
NCT05936359	LIMBER	Phase 1	Recruiting	VIC, QLD, SA	30/06/2023		Ruxolitinib	JAK1/JAK2_inhibitor	Ruxolitinib	JAK1/JAK2_inhibitor	2022-502514-86-00	A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	03000 - Melbourne - Peter Maccallum Cancer Centre; 03004 - Melbourne - The Alfred Hospital; 04029 - Herston - Royal Brisbane and Women'S Hospital; 05000 - Adelaide - Royal Adelaide Hospital	https://clinicaltrials.gov/ct2/show/NCT05936359
NCT05954871	2022-502530-10-00	Phase 1	Recruiting	SA, NSW, VIC	12/07/2023		Cetuximab; Cetuximab + RLY-1971; Osimertinib; Osimertinib + RLY-1971; RLY-1971	SHP2_inhibitor; EGFR_inhibitor,third_generation; anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	Cetuximab + RLY-1971; Osimertinib + RLY-1971; Cetuximab + RLY-1971; Osimertinib + RLY-1971	EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	2022-502530-10-00	A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer	Colorectal Cancer; Non-Small Cell Lung Cancer	3065 - Fitzroy - St Vincent's Hospital Melbourne; 3690 - Wodonga - Border Medical Oncology; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05954871
NCT05957081	MarkV-01	Phase 1	Not yet recruiting	QLD, VIC	19/07/2023		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-E80	A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3004 - Melbourne - Alfred Health; 3144 - Malvern - Cabrini Health Limited; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (Grampians Health); 4217 - Benowa - Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05957081
NCT05967689	REZILIENT2	Phase 2	Recruiting	NSW, SA, WA	21/07/2023		TAS6417	EGFR_inhibitor,exon_20_selective	TAS6417	EGFR_inhibitor,exon_20_selective	2023-503865-48	An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.	Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	2065 - Saint Leonards - GenesisCare - North Shore; 2200 - Bankstown - Bankstown-Lidcombe Hospital - (Not yet recruiting); 6027 - Joondalup - Joondalup Health Campus - (Not yet recruiting); Melbourne - Joondalup Health Campus - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05967689
NCT05969041	MYE-Symphony	Phase 1	Recruiting	SA, WA, VIC, NSW	28/07/2023		MT-302	Trop2-targeting_lipid-nanoparticles	MT-302	Trop2-targeting_lipid-nanoparticles		MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors	Epithelial Tumors, Malignant	2010 - Darlinghurst - St Vincent's Public Hospital Sydney; 2031 - Randwick - Scientia Clinical Research Ltd; 2145 - Westmead - Westmead Hospital; 3144 - Malvern - Cabrini Health; 5042 - Bedford Park - Souther Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05969041
NCT05975073	NCT05975073	Phase 1/Phase 2	Recruiting	SA, VIC	27/07/2023		AMG 193; AMG 193 + IDE397; IDE397; Pemetrexed	antimetabolite; MAT2A_inhibitor + PRMT5_inhibitor; PRMT5_inhibitor; MAT2A_inhibitor	AMG 193 + IDE397; AMG 193 + IDE397; Pemetrexed	MAT2A_inhibitor + PRMT5_inhibitor; MAT2A_inhibitor + PRMT5_inhibitor; antimetabolite		A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors	3168 - Clayton - Monash Medical Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05975073
NCT05981703	NCT05981703	Phase 1	Recruiting	NSW, WA, SA, NZ	31/07/2023		Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody		A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Solid Tumor	1023 - Auckland - Auckland City Hospital; 2228 - Miranda - Southside Cancer Care; 5037 - Kurralta Park - Ashford Cancer Centre Research; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05981703
NCT05983159	TARGET-VM	Phase 2	Not yet recruiting	VIC	07/08/2023		Alpelisib; Mirdametinib	MEK_inhibitor; PI3K_alpha_inhibitor	Alpelisib; Mirdametinib	MEK_inhibitor; PI3K_alpha_inhibitor		A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)	Slow-Flow Vascular Malformation; Fast-Flow Vascular Malformation; Vascular Malformations; Venous Malformation; Lymphatic Malformation, Low Flow; Lymphatic Malformation; Lymphangioma; Arteriovenous Malformations; Venous Malformation, Low Flow; Cystic Hygroma; Vascular Anomaly; Vascular Anomalies; PI3K Gene Mutation; MAP2K1 Gene Mutation; PIK3CA-related Overgrowth Spectrum; Arteriovenous Malformation (AVM); KRAS G12C; KRAS G12D	3052 - Parkville - Peter MacCallum Cancer Centre; 3052 - Parkville - The Royal Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05983159
NCT05984277	eVOLVE-Lung02	Phase 3	Recruiting	QLD, VIC, NSW	02/08/2023		Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA-4_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite	Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA-4_antibody	2023-000056-38	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).	Metastatic Non-small Cell Lung Cancer	3065 - Fitzroy - Research Site; 3084 - Heidelberg - Research Site; 3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site; NSW 2145 - Sydney - Research Site	https://clinicaltrials.gov/ct2/show/NCT05984277
NCT05987332	NCT05987332	Phase 2/Phase 3	Recruiting	VIC, QLD, NSW, SA, WA	03/08/2023		Crizotinib; Crizotinib + Darovasertib; Dacarbazine; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Darovasertib; Ipilimumab; Nivolumab; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor; ALK_inhibitor,first_generation; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PKC_inhibitor + ROS1_inhibitor; MET_inhibitor,type_1; ROS1_inhibitor; anti-CTLA-4_monoclonal_antibody; ALK_inhibitor,first_generation + PKC_inhibitor	Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody		IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)	Metastatic Uveal Melanoma	2145 - Sydney - Westmead Hospital; 3168 - Melbourne - Alfred Health; 4102 - Brisbane - Princess Alexander Hospital; 6009 - Perth - Sir Charles Gairdner Hospital - (Not yet recruiting); Adelaide - Queen Elizabeth Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05987332
NCT05991349	NCT05991349	Phase 1/Phase 2	Not yet recruiting	NSW	06/08/2023		IBI129	anti-B7H3_antibody-drug_conjugate	IBI129	anti-B7H3_antibody-drug_conjugate		A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2217 - Sydney - St George private Hospital	https://clinicaltrials.gov/ct2/show/NCT05991349
NCT05997615	AMX-500-001	Phase 1/Phase 2	Recruiting	NSW, VIC	11/08/2023		AMX-500	unknown_drug_class	AMX-500	unknown_drug_class	U1111-1287-6968; AMX-500-001	A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Hormone-refractory Prostate Cancer	2010 - New South Wales - Investigational Site Number: 101; 3000 - Victoria - Investigational Site Number: 100	https://clinicaltrials.gov/ct2/show/NCT05997615
NCT06003621	MoST-TAP	Phase 2	Recruiting	NSW	15/08/2023		Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody		A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.	Solid Tumor, Adult	2640 - Albury - Border Medical Oncology Research Unit; 2640 - Albury - Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital	https://clinicaltrials.gov/ct2/show/NCT06003621
NCT06007482	NCT06007482	Phase 1	Recruiting	NSW, VIC	21/08/2023		ES009	anti-LILRB2_monoclonal_antibody	ES009	anti-LILRB2_monoclonal_antibody		An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	Frankston - Peninsula and South Eastern Oncology and Haematology Group; Kogarah - St George Private Hospital - (Not yet recruiting); Randwick - Scientia Clinical Research; Sunshine Coast - Sunshine Coast University Private Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06007482
NCT06016738	OPERA-01	Phase 3	Recruiting	VIC, NSW, SA, WA	29/08/2023		Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Exemestane; Fulvestrant; Letrozole; Palazestrant	aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	Anastrozole + Exemestane + Fulvestrant + Letrozole; Palazestrant; Anastrozole + Exemestane + Fulvestrant + Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist; aromatase_inhibitor + selective_estrogen_receptor_degrader	OPERA-01	A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma	2145 - Westmead - Clinical Trial Site; 2250 - Gosford - Clinical Trial Site; 3168 - Clayton - Clinical Trial Site; 3355 - Ballarat Central - Clinical Trial Site; 3630 - Shepparton - Clinical Trial Site; 5000 - Adelaide - Clinical Trial Site; 6009 - Nedlands - Clinical Trial Site	https://clinicaltrials.gov/ct2/show/NCT06016738
NCT06018337	CTR20233708	Phase 3	Recruiting	QLD	25/08/2023		Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Nab-paclitaxel; Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	CTR20233708	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Metastatic Breast Cancer	South Brisbane - Master Hospital Brisbane	https://clinicaltrials.gov/ct2/show/NCT06018337
NCT06024174	2023-505070-15	Phase 1/Phase 2	Recruiting	NSW, SA	29/08/2023		Adagrasib; BMS-986466; Cetuximab	SHP2_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib; BMS-986466; Cetuximab	KRAS_G12C_inhibitor; SHP2_inhibitor; anti-EGFR_monoclonal_antibody	2023-505070-15	Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors	Advanced Solid Tumors	2145 - Westmead - Local Institution - 0053; 5112 - Elizabeth Vale - Local Institution - 0078 - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06024174
NCT06031441	2023-509266-38-00	Phase 1	Recruiting	NSW, VIC	04/09/2023		Atezolizumab; Atezolizumab + RO7566802; RO7566802	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7566802; Atezolizumab + RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	2023-509266-38-00	A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumors; Recurrent Solid Tumors; Metastatic Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06031441
NCT06036836	MK-4280A-010	Phase 2	Recruiting	NSW, VIC, QLD, WA	07/09/2023		Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-4280A-010; 2023-505022-34	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)	Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer	2010 - Darlinghurst - St Vincent's Hospital-The Kinghorn Cancer Centre ( Site 0005); 2065 - St Leonards - Royal North Shore Hospital ( Site 0008); 2148 - Blacktown - Blacktown Hospital ( Site 0003); 3004 - Melbourne - The Alfred Hospital ( Site 0004); 4029 - Brisbane - Royal Brisbane and Women's Hospital ( Site 0002); 6150 - Murdock - Fiona Stanley Hospital ( Site 0006)	https://clinicaltrials.gov/ct2/show/NCT06036836
NCT06058793	2023-504522-19-00	Phase 3	Recruiting	QLD, VIC, WA	22/09/2023		Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	2023-504522-19-00	Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma	Liposarcoma, Dedifferentiated	3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06058793
NCT06063681	NCT06063681	Phase 1	Recruiting	NSW, VIC	23/09/2023		SR-8541A	ENPP1_inhibitor	SR-8541A	ENPP1_inhibitor		Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors	Advanced / Metastatic Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 3168 - Clayton - Monash Health - (Not yet recruiting); 3199 - Frankston - Peninsula &amp; South Eastern Haematology &amp; Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06063681
NCT06064877	FIERCE-HN	Phase 3	Recruiting	NSW	26/09/2023		Cetuximab; Cetuximab + Ficlatuzumab; Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody; placebo; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-HGF_monoclonal_antibody	Cetuximab + Ficlatuzumab; Cetuximab + Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo		A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)	Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma	Sydney - St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT06064877
NCT06065748	2022-502980-39-00	Phase 3	Recruiting	QLD, VIC, NSW, NZ	26/09/2023		Abemaciclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; Fulvestrant; Giredestrant; LHRH Agonist; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; LHRH_agonist; selective_estrogen_receptor_degrader	Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; LHRH Agonist	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist	2022-502980-39-00	A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	2060 - North Sydney - Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research; 2086 - Frenchs Forest - Northern Beaches Hospital; 2747 - Kingswood - Nepean Hospital; Nepean Cancer Care Centre; 3021 - St Albans - Sunshine Hospital; 3220 - Geelong - Barwon Health; 3280 - Warrnambool - South West Healthcare; 4101 - South Brisbane - Mater Misericordiae Limited; 4442 - Palmerston North - Palmerston North Hospital; Regional Cancer Treatment Service; 4556 - Sippy Downs - University of the Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT06065748
NCT06072781	RAMP-301	Phase 3	Recruiting	SA, QLD	02/10/2023		Anastrozole; Avutometinib; Avutometinib + Defactinib; Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	aromatase_inhibitor; FAK_inhibitor; RAF/MEK_clamp; FAK_inhibitor + RAF/MEK_clamp; anthracycline; topoisomerase_inhibitor; taxane	Avutometinib + Defactinib; Anastrozole; Avutometinib + Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	FAK_inhibitor + RAF/MEK_clamp; FAK_inhibitor + RAF/MEK_clamp; anthracycline; aromatase_inhibitor; taxane; topoisomerase_inhibitor	GOG-3097; ENGOT-ov81	A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)	Low Grade Serous Ovarian Cancer	4066 - Auchenflower - Icon Cancer Centre Wesley; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT06072781
NCT06074497	NCT06074497	Phase 1	Not yet recruiting	QLD, VIC	03/10/2023		KGX101	IL-12_Fc-fusion_protein	KGX101	IL-12_Fc-fusion_protein		A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Administered as a Monotherapy to Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 4575 - Birtinya - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06074497
NCT06074588	2023-503539-16	Phase 3	Recruiting	VIC, NSW	03/10/2023		Dexamethasone; Dexamethasone + MK-2870; Docetaxel; Docetaxel + Pemetrexed; MK-2870; Pemetrexed	anti-Trop2_antibody-drug_conjugate; glucocorticoid; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane; taxane; antimetabolite	Dexamethasone + MK-2870; Docetaxel + Pemetrexed; Dexamethasone + MK-2870; Docetaxel + Pemetrexed	anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane	2023-503539-16	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 3000); 3021 - Melbourne - Western Health-Sunshine &amp; Footscray Hospitals-Cancer Services-Cancer Research ( Site 3003); 3168 - Clayton - Monash Health-Oncology Research ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06074588
NCT06082960	NCT06082960	Phase 1	Recruiting	VIC	09/10/2023		GS-9911; GS-9911 + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody	GS-9911; GS-9911 + Zimberelimab; GS-9911 + Zimberelimab	DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody		A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06082960
NCT06092580	NCT06092580	Phase 1	Recruiting	SA, QLD, VIC	18/10/2023		AWT020	anti-PD1-IL2_fusion_protein	AWT020	anti-PD1-IL2_fusion_protein		A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer	Advanced Cancer	4101 - South Brisbane - ICON Cancer Center South Brisbane; 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); Melbourne - Alfred Health - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06092580
NCT06097728	eVOLVE-Meso	Phase 3	Recruiting	WA, VIC, QLD	18/10/2023		Carboplatin; Carboplatin + Pemetrexed; Cisplatin; Ipilimumab; Ipilimumab + Nivolumab + Pemetrexed; MEDI5752; Nivolumab; Pemetrexed	bispecific_PD-L1/CTLA-4_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody	Carboplatin + Pemetrexed; Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed; Cisplatin; Ipilimumab + Nivolumab + Pemetrexed; MEDI5752	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody	2023-000067-32	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Unresectable Pleural Mesothelioma	3168 - Clayton - Research Site - (Not yet recruiting); 4032 - Chermside - Research Site - (Not yet recruiting); 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06097728
NCT06099782	MK-3475A-F11	Phase 2	Recruiting	NSW, VIC	19/10/2023		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2023-506017-22; U1111-1293-0814; MK-3475A-F11; jRCT2051230147	A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma	2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 1001); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 1007)	https://clinicaltrials.gov/ct2/show/NCT06099782
NCT06103864	NCT06103864	Phase 3	Recruiting	WA, VIC, NSW	23/10/2023		Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Durvalumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab	gemcitabine; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; antimetabolite	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Durvalumab; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-Trop2_antibody-drug_conjugate; gemcitabine		A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Breast Cancer	2298 - Waratah - Research Site; 3000 - Melbourne - Research Site - (Not yet recruiting); 3065 - Melbourne - Research Site; 3084 - Heidelberg - Research Site - (Not yet recruiting); 6009 - Perth - Research Site	https://clinicaltrials.gov/ct2/show/NCT06103864
NCT06105632	2023-506487-13-00	Phase 3	Recruiting	QLD	24/10/2023		Everolimus; Exemestane; Fulvestrant; Fulvestrant + PF-07220060; PF-07220060	aromatase_inhibitor; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; mTORC1_inhibitor; CDK4_selective_inhibitor	Fulvestrant + PF-07220060; Everolimus; Exemestane; Fulvestrant + PF-07220060	CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor	2023-506487-13-00	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY	Advanced or Metastatic Breast Cancer	4812 - Townsville - Icon Cancer Centre Townsville	https://clinicaltrials.gov/ct2/show/NCT06105632
NCT06112314	PRISM-MEL-301	Phase 3	Recruiting	QLD, NSW	31/10/2023		Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2023-505306-42-00	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301	Advanced Melanoma	Wollstonecraft - University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre; Woolloongabba - The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT06112314
NCT06119581	SUNRAY-01	Phase 3	Recruiting	NSW, QLD, VIC, WA, SA	01/11/2023		Carboplatin; Carboplatin + Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; LY3537982; LY3537982 + Pembrolizumab; Pembrolizumab; Pemetrexed; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; placebo; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; LY3537982 + Pembrolizumab; Pembrolizumab; Carboplatin + Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; LY3537982 + Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	J3M-MC-JZQB; U1111-1288-0565; 2023-503412-33-00	SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	2250 - Gosford - Gosford Hospital - (Not yet recruiting); 3065 - Melbourne - St Vincent's Hospital - (Not yet recruiting); 3350 - Ballarat Central - Ballarat Health Services - (Not yet recruiting); 3630 - Shepparton - Goulburn Valley Health - (Not yet recruiting); 4066 - Auchenflower - Icon Cancer Centre Wesley - (Not yet recruiting); 4215 - Southport - Gold Coast University Hospital - (Not yet recruiting); 4575 - Birtinya - Sunshine Coast University Hospital - (Not yet recruiting); 4740 - Mackay - Mackay Base Hospital - (Not yet recruiting); 4814 - Townsville - The Townsville Hospital - (Not yet recruiting); 5000 - Adelaide - Royal Adelaide Hospital - (Not yet recruiting); 6009 - Perth - Sir Charles Gairdner Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06119581
NCT06120283	2023-506888-34-00	Phase 1	Recruiting	VIC, NSW	01/11/2023		BGB-43395; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; Fulvestrant; Letrozole	aromatase_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4_selective_inhibitor	BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader	2023-506888-34-00	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer	2109 - North Ryde - Macquarie University; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06120283
NCT06120491	EvoPAR-PR01	Phase 3	Recruiting	NSW, VIC, QLD, SA	06/11/2023		AZD5305; AZD5305 + Abiraterone + Darolutamide + Enzalutamide; Abiraterone; Abiraterone + Darolutamide + Enzalutamide; Darolutamide; Enzalutamide; Placebo	CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; placebo; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	AZD5305 + Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide; AZD5305 + Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide; Placebo	CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	2023-504214-30-00	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Metastatic Castration-Sensitive Prostate Cancer	2010 - Darlinghurst - Research Site; 2031 - Randwick - Research Site - (Not yet recruiting); 3000 - Melbourne - Research Site; 4032 - Chermside - Research Site; 4101 - South Brisbane - Research Site; 4812 - Hyde Park - Research Site; 5037 - Kurralta Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT06120491
NCT06130553	PRIMROSE	Phase 1/Phase 2	Recruiting	VIC	08/11/2023		Pemetrexed	antimetabolite	Pemetrexed	antimetabolite	165618	PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	Advanced Solid Tumours That Are MTAP Deficient	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06130553
NCT06132438	NCT06132438	Phase 1	Not yet recruiting		09/11/2023		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent		Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)	Glioblastoma		https://clinicaltrials.gov/ct2/show/NCT06132438
NCT06132958	U1111-1288-7581	Phase 3	Recruiting	NSW, VIC	10/11/2023		Dexamethasone; Dexamethasone + MK-2870; Doxorubicin; Doxorubicin + Paclitaxel; MK-2870; Paclitaxel	anti-Trop2_antibody-drug_conjugate; anthracycline + taxane; glucocorticoid; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin; anthracycline; taxane	Dexamethasone + MK-2870; Doxorubicin + Paclitaxel; Dexamethasone + MK-2870; Doxorubicin + Paclitaxel	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin	2023-504816-14; U1111-1288-7581	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Endometrial Cancer	2065 - St Leonards - GenesisCare North Shore ( Site 1103); 3002 - East Melbourne - Epworth Freemasons ( Site 1104); 3199 - Frankston - Frankston Hospital ( Site 1105)	https://clinicaltrials.gov/ct2/show/NCT06132958
NCT06136624	MK-5684-003	Phase 3	Recruiting	NSW	13/11/2023		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Enzalutamide; Prednisone	glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	2023-504899-25; MK-5684-003	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Prostate Cancer Metastatic	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0234)	https://clinicaltrials.gov/ct2/show/NCT06136624
NCT06136650	MK-5684-004	Phase 3	Recruiting	NSW	13/11/2023		Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Enzalutamide; Prednisone	glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	MK-5684-004	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)	Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0214)	https://clinicaltrials.gov/ct2/show/NCT06136650
NCT06151574	2023-504308-27-00	Phase 3	Recruiting	NSW	22/11/2023		Carboplatin; Cisplatin; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed; Zongertinib	anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,second_generation; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Pembrolizumab + Pemetrexed; Zongertinib; Carboplatin; Cisplatin; Pembrolizumab + Pemetrexed	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; platinum-based_antineoplastic_agent	2023-504308-27-00	Beamion LUNG-2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered BI 1810631 Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations	Lung Cancer, Non-squamous, Non-small Cell	2065 - St Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT06151574
NCT06157541	TCaP	Phase 1/Phase 2	Not yet recruiting	VIC, QLD	26/11/2023		Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody; alkylating_agent	Ifosfamide; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody		Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme	Glioblastoma Multiforme; Astrocytoma, Grade IV	3084 - Heidelberg - Austin Hospital; 4006 - Bowen Hills - Newro Foundation; 4006 - Herston - Royal Brisbane and Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT06157541
NCT06158971	NCT06158971	N/A	Recruiting	VIC	28/11/2023							Feasibility Study of the Microwave Ablation System for Lung Tissue Ablation	Lung Neoplasm	3050 - Melbourne - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT06158971
NCT06170190	NCT06170190	Phase 1/Phase 2	Recruiting	NSW	06/12/2023		IBI133	anti-ERBB3_monoclonal_antibody	IBI133	anti-ERBB3_monoclonal_antibody		A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours	Locally Advanced Unresectable or Metastatic Solid Tumors	2170 - Liverpool - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT06170190
NCT06170788	MK-2870-007	Phase 3	Recruiting	VIC, NSW	06/12/2023		Dexamethasone; Dexamethasone + MK-2870 + Pembrolizumab; MK-2870; Pembrolizumab	glucocorticoid; anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	Dexamethasone + MK-2870 + Pembrolizumab; Pembrolizumab; Dexamethasone + MK-2870 + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	MK-2870-007; 2023-503376-24-00	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 3000); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002); 3076 - Epping - Northern Hospital ( Site 3003); 3350 - Ballarat Central - Grampians Health-Medical Oncology ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06170788
NCT06174987	2023-506330-73-00	Phase 3	Not yet recruiting	VIC, SA	08/12/2023		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2023-506330-73-00	A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Advanced Cancer; Metastatic Cancer	3168 - Clayton VIC - Monash Medical Center; 5042 - Bedford Park SA - Flinders Medical Center	https://clinicaltrials.gov/ct2/show/NCT06174987
NCT06179160	2023-507091-47-00	Phase 1	Recruiting	WA, NSW, VIC	20/12/2023		Cetuximab; INCB161734; Retifanlimab	anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12D_inhibitor	INCB161734; Cetuximab; Retifanlimab	KRAS_G12D_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2023-507091-47-00	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Solid Tumors	02010 - Darlinghurst - St. Vincent'S Hospital Sydney - (Not yet recruiting); 02050 - Camperdown - Chris Obrien Lifehouse - (Not yet recruiting); 03004 - Melbourne - The Alfred Hospital; 06009 - Nedlands - Linear Clinical Research; 3051 - North Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06179160
NCT06179511	NCT06179511	Phase 1/Phase 2	Recruiting	VIC	19/12/2023		AZD9829	anti-CD123_antibody-drug_conjugate	AZD9829	anti-CD123_antibody-drug_conjugate		A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies	Hematological Malignancies	VIC 3000 - Melbourne - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06179511
NCT06184035	Tumorad	Phase 1/Phase 2	Recruiting	SA, VIC	14/12/2023						2023-505224-64	A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors	Solid Tumor; Metastatic Cancer; Unresectable Solid Tumor; Recurrent Solid Tumor; Locally Advanced Solid Tumor; Refractory Cancer	3065 - Melbourne - St Vincent Hospital Melbourne - (Not yet recruiting); 5000 - Adelaide - Cancer Research South Adelaide	https://clinicaltrials.gov/ct2/show/NCT06184035
NCT06188520	CYCAD-1	Phase 1/Phase 2	Recruiting	VIC	18/12/2023		AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; Abemaciclib; Camizestrant; Palbociclib; Ribociclib	CDK4/6_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor; selective_estrogen_receptor_degrader	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader		A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06188520
NCT06198426	NCT06198426	Phase 1/Phase 2	Not yet recruiting	NSW	08/01/2024		IBI3004	unknown_drug_class	IBI3004	unknown_drug_class		A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2770 - Randwick - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06198426
NCT06199908	NCT06199908	Phase 1	Not yet recruiting	NSW, VIC, SA	08/01/2024		AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562	anti-ERBB3_antibody-drug_conjugate		First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Malvern - Cabrini Malvern Hospital; North Ryde - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT06199908
NCT06208657	NCT06208657	Phase 1/Phase 2	Not yet recruiting	VIC, QLD, NSW, SA, WA	05/01/2024		Irinotecan; Irinotecan + Paxalisib + Temozolomide; Paxalisib; Pimasertib; Temozolomide	alkylating_agent; MEK_inhibitor; topoisomerase_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; dual_PI3K/mTOR_inhibitor	Irinotecan + Paxalisib + Temozolomide; Pimasertib; Irinotecan + Paxalisib + Temozolomide	MEK_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor		Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer	Adelaide - Women's and Children's Hospital; Brisbane - Queensland Children's Hospital; Melbourne - Monash Children's Hospital; Melbourne - Royal Children's Hospital; Newcastle - John Hunter Children's Hospital; Perth - Perth Children's Hospital; Sydney - Sydney Children's Hospital, Randwick; Sydney - The Children's Hospital at Westmead	https://clinicaltrials.gov/ct2/show/NCT06208657
NCT06212700	NCT06212700	N/A	Not yet recruiting	NSW	08/01/2024		Leucovorin; Radiotherapy	radiotherapy; folinic_acid	Radiotherapy; Leucovorin	radiotherapy; folinic_acid		Virtual Multimodal Hub for Patients Undergoing Major Gastrointestinal Cancer Surgery - PRIORITY-CONNECT 2 Pilot Randomised Type I Hybrid Effectiveness-Implementation Trial	Liver Cancer; Pancreas Cancer; Oesophageal Cancer; Gastric Cancer; Colorectal Cancer	2050 - Sydney - Chris O'Brien Lifehouse; 2050 - Sydney - Royal Prince Alfred Hospital, Surgical Outcomes Research Centre (SOuRCe)	https://clinicaltrials.gov/ct2/show/NCT06212700
NCT06219941	NCT06219941	Phase 2	Recruiting	NSW, VIC	12/01/2024		Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	gemcitabine; fluoropyrimidine; folinic_acid; Fluorouracil; topoisomerase_inhibitor; antimetabolite	Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	Fluorouracil; antimetabolite; fluoropyrimidine; folinic_acid; gemcitabine; topoisomerase_inhibitor		A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	Gastric Cancer; Gastroesophageal Junction Cancer; Pancreatic Adenocarcinoma	2031 - Randwick - Research Site - (Not yet recruiting); 3000 - Melbourne - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06219941
NCT06226766	NCT06226766	Phase 1/Phase 2	Not yet recruiting	NSW	18/01/2024		Envafolimab; JSKN003	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Envafolimab; JSKN003	anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody		Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06226766
NCT06256588	JADE	Phase 3	Not yet recruiting	QLD, VIC, NSW	05/02/2024		Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	2023-508613-17-00	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	2148 - Blacktown - GSK Investigational Site; 3004 - Melbourne - GSK Investigational Site; 3220 - Geelong - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 4029 - Herston - GSK Investigational Site; 4814 - Douglas - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06256588
NCT06257264	NCT06257264	Phase 1	Recruiting	NSW	05/02/2024		Fulvestrant	selective_estrogen_receptor_degrader	Fulvestrant	selective_estrogen_receptor_degrader		A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer	2065 - St Leonards - Genesiscare North Shore; 2148 - Blacktown - Blacktown Cancer and Haematology Centre	https://clinicaltrials.gov/ct2/show/NCT06257264
NCT06267729	APOLLO	Phase 1/Phase 2	Recruiting	VIC	19/02/2024							A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO	Metastatic Prostate Cancer	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06267729
NCT06302426	NCT06302426	Phase 1	Not yet recruiting	NSW, VIC	04/03/2024		Atezolizumab; Avelumab; Cemiplimab; Durvalumab; Nivolumab; Pembrolizumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Atezolizumab; Avelumab; Cemiplimab; Durvalumab; Nivolumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody		An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours	Advanced Solid Tumor	2640 - Albury - The Border Cancer Hospital; 3144 - Malvern - Cabrini Hospital	https://clinicaltrials.gov/ct2/show/NCT06302426
NCT06305962	NCT06305962	Early Phase 1	Recruiting	QLD, WA	07/03/2024							Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Non-small Cell Lung Cancer	PDL1 Gene Mutation; Non Small Cell Lung Cancer	4102 - Woolloongabba - Princess Alexandra Hospital; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06305962
NCT06307015	DE-RADIATE	N/A	Not yet recruiting	NSW	06/03/2024		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy		De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging as Non-Invasive Biomarkers of Hypoxia (DE-RADIATE)	HPV Positive Oropharyngeal Squamous Cell Carcinoma	2065 - Saint Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT06307015
NCT06326411	NST-628	Phase 1	Recruiting	SA, NSW	21/03/2024		NST-628	pan-RAF/MEK_glue	NST-628	pan-RAF/MEK_glue		A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation	2031 - Rand - Scientia Clinical Research, Ltd; 5042 - Adelaide - Southern Oncology Research Unit - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT06326411
